



US012392001B2

(12) **United States Patent**
Peters et al.

(10) **Patent No.:** US 12,392,001 B2
(45) **Date of Patent:** *Aug. 19, 2025

(54) **COMPOSITIONS AND METHODS FOR DETECTING AN RNA VIRUS**(71) Applicant: **ENVIROLOGIX INC.**, Portland, ME (US)(72) Inventors: **Lars Peters**, Portland, ME (US); **Stephen A. Judice**, Portland, ME (US); **Daniel Shaffer**, Portland, ME (US); **Breck Parker**, Portland, ME (US)(73) Assignee: **Envirologix Inc.**, Portland, ME (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 489 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **16/991,216**(22) Filed: **Aug. 12, 2020**(65) **Prior Publication Data**

US 2021/0025016 A1 Jan. 28, 2021

Related U.S. Application Data

(63) Continuation of application No. 15/520,328, filed as application No. PCT/US2015/056491 on Oct. 20, 2015, now Pat. No. 10,793,922.

(60) Provisional application No. 62/104,008, filed on Jan. 15, 2015, provisional application No. 62/066,277, filed on Oct. 20, 2014.

(51) **Int. Cl.**

C12Q 1/70	(2006.01)
C12Q 1/68	(2018.01)
C12Q 1/6865	(2018.01)

(52) **U.S. Cl.**

CPC	C12Q 1/701 (2013.01); C12Q 1/6865 (2013.01); C12Q 2600/158 (2013.01); Y02A 50/30 (2018.01)
-----------	--

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,455,166 A	10/1995	Walker
5,629,179 A	5/1997	Mierendorf et al.
5,952,202 A	9/1999	Aoyagi et al.
6,063,604 A	5/2000	Wick et al.
6,130,038 A	10/2000	Becker et al.
6,355,421 B1	3/2002	Coull et al.
6,617,137 B2	9/2003	Dean et al.
6,794,142 B2	9/2004	Laird et al.
6,977,148 B2	12/2005	Dean et al.
7,056,671 B2	6/2006	Enoki et al.
7,074,600 B2	7/2006	Dean et al.
7,094,539 B2	8/2006	Gu et al.
7,112,423 B2	9/2006	Van Ness et al.
7,282,328 B2	10/2007	Kong et al.

7,662,594 B2 * 2/2010 Kong C12P 19/34 435/183

8,574,847 B2 11/2013 Becker et al.

9,096,897 B2 8/2015 Shaffer et al.

9,322,053 B2 4/2016 Shaffer et al.

9,631,231 B2 4/2017 Shaffer et al.

9,845,510 B2 12/2017 Peters et al.

10,077,467 B2 9/2018 Shaffer et al.

10,100,370 B2 10/2018 Parker et al.

10,584,376 B2 3/2020 Shaffer et al.

10,793,922 B2 10/2020 Peters et al.

11,208,687 B2 12/2021 Shaffer et al.

2003/0060431 A1 3/2003 Simmonds et al.

2003/0082590 A1 5/2003 Van Ness et al.

2003/0211483 A1 11/2003 Schroeder et al.

2005/0059003 A1 3/2005 Enoki et al.

2006/0115838 A1 6/2006 Bazar et al.

2006/0216796 A1 9/2006 Hashiguchi et al.

2007/0054296 A1 3/2007 Piepenburg et al.

2007/0082011 A1 4/2007 Lehrer et al.

2008/0254458 A1 10/2008 Chou

2008/0274458 A1 11/2008 Latham et al.

2009/0017452 A1 1/2009 Ratain et al.

2009/0017453 A1 1/2009 Maples et al.

2009/0048439 A1 2/2009 Weisburg et al.

2009/0081670 A1 * 3/2009 Maples C12Q 1/6844 435/6.12

2009/0197254 A1 8/2009 Lee

2010/0092957 A1 4/2010 Zhao et al.

2010/0099149 A1 4/2010 Birnboim et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1633505 A 6/2005

CN 101952459 A 1/2011

(Continued)

OTHER PUBLICATIONS

Vallone, P.M. and Butler, J.M., 2004. AutoDimer: a screening tool for primer-dimer and hairpin structures. *Biotechniques*, 37(2), pp. 226-231. (Year: 2004).*Thornton B. and Basu, C., 2011. Real-time PCR (qPCR) primer design using free online software. *Biochemistry and molecular biology education*, 39(2), pp. 145-154. (Year: 2011).*Rychlik, W., 1995. Selection of primers for polymerase chain reaction, *Molecular biotechnology*, 3, pp. 129-134. (Year: 1995).*Borah, P., 2011. Primer designing for PCR. *Science Vision*, 11(3), pp. 134-136. (Year: 2011).*

Office Action issued in corresponding Mexican Patent Application No. MX/a/2017/005159, dated Dec. 2, 2020 (7 pages).

(Continued)

Primary Examiner — Stephanie E Mummert*Assistant Examiner* — Olayinka A Oyeyemi(74) *Attorney, Agent, or Firm* — Greenberg Traurig, LLP; Melissa Hunter-Ensor; Nicholas R. Ballor(57) **ABSTRACT**

The present invention provides methods for rapidly identifying an RNA viral infection using an isothermal nucleic acid amplification reaction that can be carried out extracted RNA in the context of a crude biological sample.

15 Claims, 50 Drawing Sheets**Specification includes a Sequence Listing.**

(56)

References Cited**U.S. PATENT DOCUMENTS**

2010/0255546 A1*	10/2010	Uematsu	C12Q 1/6844 435/91.2
2011/0081685 A1	4/2011	Makarov et al.	
2011/0151467 A1	6/2011	Usui et al.	
2012/0021461 A1	1/2012	Millar et al.	
2013/0217071 A1	8/2013	Montesclaros et al.	
2013/0280706 A1	10/2013	Judice	
2014/0093883 A1*	4/2014	Maples	C07H 21/04 435/6.12
2017/0044628 A1	2/2017	Peters et al.	
2017/0166960 A1	6/2017	Shaffer et al.	
2017/0327911 A1	11/2017	Peters et al.	
2018/0363046 A1	12/2018	Shaffer et al.	
2020/0239947 A1	7/2020	Shaffer et al.	
2022/0243262 A1	8/2022	Shaffer et al.	

FOREIGN PATENT DOCUMENTS

EP	1201768 A2	5/2002
EP	1420069 A1	5/2004
EP	2836609 A1	2/2015
JP	2002291490 A	10/2002
JP	2004532615 A	10/2004
JP	2008526228 A	7/2008
JP	2010505396 A	2/2010
JP	2010533494 A	10/2010
JP	2011521624 A	7/2011
JP	2014082936 A	5/2014
KR	20040028991 A	4/2004
WO	2002057479 A2	7/2002
WO	2003008622 A2	1/2003
WO	2003016569 A1	2/2003
WO	2006074162 A2	7/2006
WO	2008002920 A2	1/2008
WO	2008040126 A1	4/2008
WO	2009012246 A2	1/2009
WO	2009135093 A2	11/2009
WO	2010107946 A2	9/2010
WO	2012021493 A2	2/2012
WO	2012022755 A1	2/2012
WO	2013040491 A2	3/2013
WO	2013155056 A1	10/2013
WO	WO-2013155056 A9 *	10/2013
		C12Q 1/68
WO	2014004852 A2	1/2014
WO	2015168134 A1	11/2015
WO	2016064894 A2	4/2016
WO	2016069345 A1	5/2016
WO	2016122698 A1	8/2016

OTHER PUBLICATIONS

English explanation of the Office Action issued in corresponding Mexican Patent Application No. MX/a/2017/005159, dated Dec. 2, 2020 (6 pages).

Office Action dated Jan. 26, 2022 in corresponding Mexican Patent Application No. MX/a/2017/005159 (5 pages).

English translation of the Office Action dated Jan. 26, 2022 in corresponding Mexican Patent Application No. MX/a/2017/005159 (4 pages).

Ahern, Holly, "Biochemical, Reagent Kits Offer Scientists Good Return on Investment," *The Scientist*, Jul. 24, 1995, vol. 9, No. 15, pp. 1-5.

Armitage et al., "Hairpin-Forming Peptide Nucleic Acid Oligomers," *Biochemistry*, 1998, vol. 37, pp. 9417-9425.

Craw et al., "Isothermal nucleic acid amplification technologies for point-of-care diagnostics: a critical review," *Lab Chip*, 2012, vol. 12, No. 14, pp. 2469-2486.

Dames et al., "Characterization of Aberrant Melting Peaks in Unlabeled Probe Assays," *Journal of Molecular Diagnostics*, Jul. 2007, vol. 9, No. 3, pp. 290-296.

Dirks et al., "Triggered amplification by hybridization chain reaction," *Proceedings of the National Academy of Sciences of the United States of America*, Oct. 26, 2004, vol. 101, No. 43, pp. 15275-15278.

Holland et al., "Detection of specific polymerase chain reaction product by utilizing the 5'-3' exonuclease activity of *Thermus aquaticus* DNA polymerase," *Proceedings of the National Academy of Sciences of the United States of America*, Aug. 1991, vol. 88, pp. 7276-7280.

IDT "The Polymerase Chain Reaction," *Integrated DNA Technologies*, 2011, pp. 1-21.

ITO, et al., "Synthesis, thermal stability and resistance to enzymatic hydrolysis of the oligonucleotides containing 5-(N-aminoxyethyl)carbamoyl-2'-O-methyluridines," *Nucleic Acids Research*, 2003, vol. 31, No. 10, pp. 2514-2523.

Krishnan et al., "Nucleic Acid Based Molecular Devices," *Angewandte Chemie International Edition*, 2011, vol. 50, pp. 3124-3156.

Li et al., "Enzymatic signal amplification of molecular beacons for sensitive DNA detection," *Nucleic Acids Research*, 2008, vol. 36, No. 6, e36, pp. 1-17.

Mann et al., "A thermodynamic approach to PCR primer design," *Nucleic Acids Research*, 2009, vol. 37, No. 13, e95, pp. 1-9.

Markham et al., "UNAFold: Software for Nucleic Acid Folding and Hybridization," *Bioinformatics*, vol. II: Structure, Function and Applications, Sep. 2, 2008, vol. 453, pp. 1-33.

Notomi et al., "Loop-mediated isothermal amplification of DNA," *Nucleic Acids Research*, 2000, vol. 28, No. 12, e63, pp. i-vii.

Owczarzy et al., "IDT SciTools: a suite for analysis and design of nucleic acid oligomers," *Nucleic Acids Research*, 2008, vol. 36, pp. W163-W169.

Paulasova et al., "The peptide nucleic acids (PNAs): a new generation of probes for genetic and cytogenetic analyses," *Annales de Génétique*, 2004, vol. 47, pp. 349-358.

"PCR Primer Design Guidelines," Premier Biosoft, www.premierbiosoft.com/tech_notes/PCR_Primer_Design.html.

Prediger, Ellen, "Designing PCR Primers and Probes," *Decoded*, Oct. 2013, vol. 3, No. 4, pp. 2-3.

"Primer Dimer," Wikipedia, the free encyclopedia, retrieved from the Internet Feb. 14, 2020 https://en.wikipedia.org/wiki/Primer_dimer.

Santalucia, Jr et al., "The Thermodynamics of DNA Structural Motifs," *Annual Review of Biophysics and Biomolecular Structure*, 2004, vol. 33, pp. 415-440.

Santangelo et al., "Dual FRET molecular beacons for mRNA detection in living cells," *Nucleic Acids Research*, 2004, vol. 32, No. 6, e57, pp. 1-9.

Stofer et al., "Free Energy Calculations of Watson-Crick Base Pairing in Aqueous Solution," *Journal of the American Chemical Society*, 1999, vol. 121, No. 41, pp. 9503-9508.

Stratagene Catalog, "Gene Characterization Kits," *Stratagene Catalog*, 1988, p. 39.

Thornton et al., "Real-time PCR (qPCR) Primer Design Using Free Online Software," *Biochemistry and Molecular Biology Education*, 2011, vol. 39, No. 2, pp. 145-154.

Tyagi et al., "Molecular Beacons: Probes that Fluoresce upon Hybridization," *Nature Biotechnology*, Mar. 1996, vol. 14, pp. 303-308.

Untergasser et al., "Primer3—new capabilities and interfaces," *Nucleic Acids Research*, 2012, vol. 40, No. 15, e115, pp. 1-12.

Examination and Search Report dated Sep. 9, 2021 in corresponding ARIPO Patent Application No. AP/P/2017/009907 (4 pages).

Office Action dated Apr. 30, 2021 in corresponding Chinese Patent Application No. 201580069867.5 (12 pages).

English translation of the Office Action dated Apr. 30, 2021 in corresponding Chinese Patent Application No. 201580069867.5 (16 pages).

Office Action dated Jul. 27, 2021 in corresponding Mexican Patent Application No. MX/a/2017/005159 (9 pages).

English translation of the Office Action dated Jul. 27, 2021 in corresponding Mexican Patent Application No. MX/a/2017/005159 (9 pages).

Office Action dated Nov. 24, 2021 in corresponding Chinese Patent Application No. 201580069867.5 (14 pages).

English translation of the Office Action dated Nov. 24, 2021 in corresponding Chinese Patent Application No. 201580069867.5 (3 pages).

(56)

References Cited**OTHER PUBLICATIONS**

- Office Action dated Nov. 24, 2021 in corresponding Canadian Patent Application No. 2965137 (5 pages).
- Office Action dated Nov. 30, 2021 in corresponding Japanese Patent Application No. JP 2020-189107 (5 pages).
- English translation of the Office Action dated Nov. 30, 2021 in corresponding Japanese Patent Application No. JP 2020-189107 (5 pages).
- Examination Report issued in corresponding Australian Patent Application No. 2015336086, dated Nov. 12, 2020 (3 pages).
- Ehres et al., "Optimization and design of oligonucleotide setup for strand displacement amplification," *Journal of Biochemical and Biophysical Methods*, Jun. 30, 2005, vol. 63, Iss. 3, pp. 170-186.
- Yan et al., "Isothermal amplified detection of DNA and RNA," *Molecular BioSystems*, 2014, vol. 10, No. 5, pp. 970-1003; <http://dx.doi.org/10.1039/c3mb70304e>.
- Examination Report in corresponding Australian Patent Application 2015336086, dated Nov. 20, 2019 (6 pages).
- Extended Search Report in corresponding European Patent Application No. 15852795.2, dated Mar. 22, 2018 (9 pages).
- International Search and Examination Report issued in corresponding ARIPO Patent Application No. AP/P/2017/009907, dated May 25, 2020 (5 pages).
- International Search Report and Written Opinion, for corresponding PCT/US2015/056491, dated Apr. 11, 2016 (27 pages).
- Office Action in corresponding Brazilian Patent Application No. BR 112017008082-6, dated Dec. 9, 2019 (4 pages).
- English explanation of the Office Action in corresponding Brazilian Patent Application No. BR 112017008082-6, dated Dec. 9, 2019 (2 pages).
- Office Action in corresponding Chinese Patent Application No. 201580069867.5, dated Jun. 3, 2020 (15 pages).
- English translation of the Office Action in corresponding Chinese Patent Application No. 201580069867.5, dated Jun. 3, 2020 (21 pages).
- Office Action in corresponding European Patent Application No. 15852795.2, dated Nov. 5, 2019 (6 pages).
- Office Action in corresponding Japanese Patent Application No. 2017-521095, dated Nov. 5, 2019 (8 pages).
- English translation of the Office Action in corresponding Japanese Patent Application No. 2017-521095, dated Nov. 5, 2019 (8 pages).
- Examination Report dated Sep. 14, 2022 in corresponding Australian Patent Application No. 2021201378 (4 pages).
- Examination and Search Report issued in corresponding ARIPO Patent Application No. AP/P/2017/009907, dated Mar. 2, 2021 (4 pages).
- First Examination Report issued in corresponding Indian Patent Application No. 201747017620, dated Mar. 1, 2021 (9 pages).
- Office Action issued in corresponding European Patent Application No. 15852795.2, dated Jul. 20, 2020 (4 pages).
- Chu, Y.L., "Fundamental Concepts of Bioinformatics for Medical Use," Shaanxi Science and Technology Press, Oct. 31, 2005, p. 222.
- Office Action dated Apr. 2, 2022 in corresponding Chinese Patent Application No. 201580069867.5 (8 pages).
- English translation of the Office Action dated Apr. 2, 2022 in corresponding Chinese Patent Application No. 201580069867.5 (16 pages).
- Office Action dated Jul. 25, 2022 in corresponding Mexican Patent Application No. MX/a/2017/005159 (5 pages).
- English translation of the Office Action dated Jul. 25, 2022 in corresponding Mexican Patent Application No. MX/a/2017/005159 (5 pages).
- Office Action dated Nov. 1, 2022 in corresponding Canadian Patent Application No. 2,965,137 (6 pages).
- Notice of Opposition dated Jun. 14, 2023 in corresponding European Patent Application No. 15852795.2.
- Comparison between granted Claim 1 of European Patent No. 3209802 and Claim 1 of European Patent Application No. 22187762.4 filed on Sep. 26, 2022.
- Nie et al., "Evaluation of Alere i influenza A&B for Rapid Detection of Influenza Viruses A and B," *Journal of Clinical Microbiology*, Sep. 2014, vol. 52, No. 9, pp. 3339-3344.
- Niemz et al., "Point-of-care nucleic acid testing for infectious diseases," *Trends in Biotechnology*, May 2011, vol. 29, No. 5, pp. 240-250.
- Sambrook et al., "Extraction, Purification, and Analysis of mRNA from Eukaryotic Cells," Chapter 7, Protocol 1, *Molecular Cloning*, 2001.
- Screenshots of the User Manual on Viral RNA and DNA isolation, NucleoSpin 8 Virus manual from Sep. 1, 2013.
- Affidavit of Professor John SantaLucia submitted Sep. 29, 2021 in the opposition proceedings of corresponding European Patent Application No. 15783300.5 (21 pages).
- Curriculum vitae of Professor John SantaLucia submitted Sep. 29, 2021 in the opposition proceedings of corresponding European Patent Application No. 15783300.5 (23 pages).
- European Search Report and Search Opinion issued on divisional application (EPA 22187762.4) and Claims 1-15 of EPA 22187762.4 filed on Sep. 26, 2022.
- Lodish et al., "Glossary," 4th edition, *Molecular Cell Biology*, NCBI Bookshelf, 2000. New York W. H. Freeman, pp. 1-46.
- Van Ness et al., "Isothermal reactions for the amplification of oligonucleotides," *Proceedings of the National Academy of Sciences*, 2003, vol. 100, No. 8, 4504-4509.
- Walker et al., "Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system," *Proceedings of the National Academy of Sciences*, 1992, vol. 89, pp. 392-396.
- Walker et al., "Strand displacement amplification—an isothermal, in vitro DNA amplification technique" *Nucleic Acids Research*, 1992, vol. 2, No. 7, pp. 1691-1696.
- Summons to attend oral proceedings dated Oct. 12, 2020, in the opposition proceedings of corresponding European Patent Application No. 13775206.9 (1 page).
- Notice of Opposition dated Mar. 3, 2021 in corresponding European Patent Application No. 15783300.5 (36 pages).
- Written submission from patentee dated Jul. 9, 2021, in preparation to/during oral proceedings in the opposition proceedings of corresponding European Patent Application No. 13775206.9 (2 pages).
- Written submission from opponent dated Jul. 22, 2021, in preparation to/during oral proceedings in the opposition proceedings of corresponding European Patent Application No. 13775206.9 (13 pages).
- Written submission from patentee dated Aug. 20, 2021, in preparation to/during oral proceedings in the opposition proceedings of corresponding European Patent Application No. 13775206.9 (4 pages).
- Minutes of the oral proceedings taking place on Sep. 22, 2021, in the opposition proceedings of corresponding European Patent Application No. 13775206.9. Document dated Nov. 5, 2021 (2 pages).
- Interlocutor decision and grounds for decision dated Nov. 8, 2021 in the opposition proceedings of corresponding European Patent Application No. 13775206.9 (13 pages).
- Notice of Appeal dated Jan. 17, 2022, against decision in the opposition proceedings of corresponding European Patent Application No. 13775206.9 (2 pages).
- Summons to attend postponed oral proceedings dated Oct. 10, 2022 in the opposition proceedings of corresponding European Patent Application No. 157833005 (1 page).
- Summons to attend postponed oral proceedings dated Oct. 21, 2022 in the opposition proceedings of corresponding European Patent Application No. 157833005 (1 page).
- Written submission from patentee dated Mar. 13, 2023 in preparation to/during oral proceedings in the opposition proceedings of corresponding European Patent Application No. 15783300.5 (2 pages).
- Written submission from opponent dated Mar. 16, 2023 in preparation to/during oral proceedings in the opposition proceedings of corresponding European Patent Application No. 15783300.5 (23 pages).
- Notice of Opposition dated Jul. 6, 2023 in corresponding European Patent Application No. 15852795.2 (13 pages).

(56)

References Cited

OTHER PUBLICATIONS

Interlocutor decision and grounds for decision dated Aug. 31, 2023, in the opposition proceedings of corresponding European Patent Application No. 15783300.5 (17 pages).

Notice to Appeal dated Nov. 9, 2023, against decision in the opposition proceedings of corresponding European Patent Application No. 15783300.5 (2 pages).

Statement of Grounds of Appeal Dated Jan. 10, 2024, against decision in the opposition proceedings of corresponding European Patent Application No. 15783300.5 (47 pages).

Reply to Appeal dated May 16, 2024 against decision in the opposition proceedings of corresponding European Patent Application No. 15783300.5 (29 pages).

Reply to Notice of Opposition dated Jul. 20, 2020 in corresponding European Patent Application No. 13775206.9 (33 pages).

Reply to Notice of Opposition dated Sep. 29, 2021 in corresponding European Patent Application No. 15783300.5 (15 pages).

Provisional and Non-binding opinion of the Opposition Division dated Oct. 10, 2022 in corresponding European Application No. 15783300.5 (8 pages).

Provisional and Non-binding opinion of the Opposition Division dated Oct. 12, 2022 in corresponding European Application No. 13775206.9 (8 pages).

Office Action received Apr. 25, 2025 in corresponding Canadian Application No. 2,965,137 (5 pages).

* cited by examiner

FIG. 1

Candidate Assays




FIG. 2

Screened Assays

Top Beacon	Screened Assays	
Zeb.Probe.T	gctaccACGACTTTYGCTGAAGgtacg	
Zeb.Probe.B	gctaccCTTCAGCRAAAGTCGgtacg	
Zeb.P1F7	GACTCGGATATCGAGTCGGCTTCCACWGTTATCTWXXYW	W mA
Zeb.P1F8	GACTCGGATATCGAGTCGCTTCCAXAGTTATCZMXXX	X mC
Zeb.P1F2	GACTCGGATATCGAGTCACAGTTAZCTACCGAYWWX	Y mG
Zeb.P1R1	GACTCGGATATCGAGTCAAATGCACWGCACWXXXZ	Z mT
Zeb.P1R2	GACTCGGATATCGAGTCGAAATGCWAGGAXWXXZ	
Zeb.P1R3	GACTCGGATATCGAGTCAGAAATGXAACGWXX	
Zeb.P2F2	GACTCGGGCGGAGTCACAGTTAZCTACCGAYWWX	
Zeb.P2F3	GACTCGGGCGGAGTCGCCACAGTTCTACCGWYYWW	
Zeb.P2F4	GACTCGGGCGGAGTCAGTZATCTACCYWYYW	
Zeb.P2R1	GACTCGGGCGGAGTCAAATGCACWGCACWXXZ	
Zeb.P2R2	GACTCGGGCGGAGTCAGAAATGCWAGGAXWXXZ	
Zeb.P2R3	GACTCGGGCGGAGTCAAATGXAACGWXX	
Zeb.gBlock	CCACAGTTATCTACCGAGGAACCGACTTTTCGCTGAAGGGTGTG	

FIG. 3A
10k Copies gBlock in 18 ng Human cDNA
Assay 1




FIG. 3B


5k Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3C


2.5K Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3D


1.25k Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3E


625 Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3F


312 Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3G


156 Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3H


78 Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3I


39 Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3J


19.5 Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3K


9.8 Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3L


0 Copies gBlock in 18 ng Human cDNA
Assay 1

FIG. 3M


10K Copies gBlock in 18 ng Human cDNA
Assay 2

FIG. 3N


5K Copies gBlock in 18 ng Human cDNA
Assay 2

FIG. 30


2.5K Copies gBlock in 18 ng Human cDNA
Assay 2

FIG. 3P


1.25K Copies gBlock in 18 ng Human cDNA
Assay 2

FIG. 3Q


625 Copies gBlock in 18 ng Human cDNA
Assay 2

FIG. 3R


312 Copies gBlock in 18 ng Human cDNA
Assay 2

FIG. 3S


156 Copies gBlock in 18 ng Human cDNA
Assay 2

FIG. 3T


78 Copies gBlock in 18 ng Human cDNA
Assay 2

FIG. 3U


39 Copies gBlock in 18 ng Human cDNA
Assay 2

FIG. 3V


19.5 Copies gBlock in 18 ng Human cDNA
Assay 2

FIG. 3W


9.8 Copies gBlock in 18 ng Human cDNA
Assay 2

FIG. 3X


0 Copies gBlock in 18 ng Human cDNA
Assay 2

FIG. 4





FIG. 5

Example One-Step RNAble Using a Synthetic RNA in an Excess Background of Total Human RNA



ZEB titration starting at 1×10^6 copies per reaction (—), 1×10^4 per reaction (----), 1×10^2 per reaction (····); and 1×10^0 per reaction (—), synthetic RNA in a background of a 1ug human RNA. Target specific first strand RT (Maxima) in a homogeneous reaction

FIG. 6A




FIG. 6B

Sample Preparation 2

Capillary-based collection of blood.

FTA elute punch in well, load blood, dry wash, load assay, run with the punch in tube.

Collect data on Amplifire or similar instrument





FIG. 6C

Lyophilized Assay Procedure 8-well Strip (or single tube)








FIG. 7A

Sample Preparation 3

ClaremontBio[®] Solutions

Protocol for Rapid RNA Isolation

Visual Protocol



*Includes optional DNase 1 step for DNA-free RNA

FIG. 8
Fluorescence History




FIG. 9

Fluorescence History




FIG. 10

Fluorescence History




FIG. 11A

A. Two-Step RNA^{ble}® Reaction with cDNA
GENE ID: 85495 RPPH1 (RNase P RNA component)

Fluorescence History




FIG. 11B

B. One-Step RNAble® RPPH1 Detection with Purified Human RNA




FIG. 12

Zaire Ebola One-Step RNABlue® Reaction in a Crude Blood Prep #4

Crude Blood Prep Method #4

To 20 μ L whole blood, add:
20 μ L 0.5% SDS in H₂O.
Mix.
Incubate for 3 minutes at room
temperature.
Add 20 μ L 2% BSA in H₂O.
Mix.
Incubate for 1 minute at room
temperature.
Add 1 μ L of crude blood prep. to a
10 μ L reaction with 1000 copies
synthetic RNA target. Run reaction
in triplicate at 56° C on LC480.




FIG. 13

Zaire Ebolavirus Mayinga vs. Sudan Ebolavirus Boniface Specificity Example
One-Step RNAble®






FIG. 14

Instrument Comparison Zaire Ebolavirus Mayinga
Roche LightCycler 480 II


Fluorescence History



Quadruplicates





Axxin



Minutes



Example Amplification Curves Representing Serially Diluted One-Step RNAAble®
Zaire Ebolavirus Mayinga RNA

FIG. 15 A



25 Copies 10 Technical Replicates Each

FIG. 15 B



12 Copies

164

HIV One-step RNA₁
Candidate assay
gag protein target

F2/R1 Amplicon Map

Digitized by

Reverse
Probe T

External primer

5' TGACTAGCTGAGGCCCTAGAAGGAGAGATGGGTGCGAGAGCCGTCAATAATTAAAGAGGGAAAAATTAGATGC
5' TGACTAGCTGAGGCCCTAGAAGGAGAGATGGGTGCGAGAGCCGTCAATA

卷之三

ANDREW

*Note: bold bases indicate non-tilde sequence variations

Награди се


Primer	Sequence
Hgag.F2a	GACTCGATA TCGAGTCTGACTAGmCGGGmCmTmAmGmAmG
Hgag.F2b	GACTCGATA TCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmG
Hgag.R1a	GACTCGATA TCGAGTCTATTGACmGCTCmTmCmGmCmAmC
Hgag.R1b	GACTCGATA TCGAGTCTACTTGACmGC1CmTmCmGmCmAmC
Hgag.rt3.subC*	GCATCTAA TTTTCGCC (ecterma)
Hgag.probe.T	cgcaaqGGAGAGAGATGGGTGcttgcg

primers: mN indicates methoxy base

Probe sequence: lowercase = stems, uppercase = recognition


*External primer sequence is specific to HIV subtype C (for the purified RNA sample used)

FIG. 16B



EIGEN

Dengue 4 One-step RNA₁ Candidate assay 3' UTR target



Primer	Sequence
Den4_F2	GACTCGATAATCGAGTCCAAAAACmAGGATATTmGmAAGmGmC
Den4_R1a	GACTCGATAATCGAGTCAGACAGCmAGGATCmTmGmG
Den4_R1b	GACTCGATAATCGAGTCAGACAGCmAGGATCmTmGmG
Den4_extRT1	TCTGTGCCCTGGATTGAT (exterior primer)
Den4_probe.B	cggatCTGGTCTTTCCCAAGCqatccg

Primers: mN indicates methoxy base
 Probe sequence: lowercase = stems, uppercase = recognition

FIG. 17B





FIG. 18A

Influenza B One-step RNABle
Candidate assay
Segment 7 target


Amplicon Map



FluB (influenza B)

Primer	Sequence
FluB.F2a	GACTCGATAATCGAGTCAAATGCAmGATGGTCTCmAmGmCmTmA
FluB..F2b	GACTCGATAATCGAGTCAAATGCAmAAIGGTCmAmGmCmTmA
FluB..F2c	GACTCGATAATCGAGTCAAATGCAmGATGGTTTCTmAmGmCmTmA
FluB..R3a	GACTCGATAATCGAGTCCTCCCTTmTCCCATTCCTmCmAmTmT
FluB..R3b	GACTCGATAATCGAGTCCTCCCTTmTCCCATTCCTmCmAmTmT
FluB..R3c	GACTCGATAATCGAGTCCTCCCTTmCCCCATCCATTCCTmCmAmTmT
FluB.extRT1a	TTTGGACGTCCTCTCC
FluB.extRT1b	TTTGAACGTCCTCTCC
FluB.probe.T	gc当地GCTATGAACACAGCAAActggc

FIG. 18B



Cp values across 4 technical replicates (10 μ l reactions): Isolated total RNA from cell culture includes both viral and host cell RNA, total copy number is unknown. Samples 1 and 2 are different viral isolates.

FIG. 19A

BVDV1 One-step RNABle
Candidate assay
Polyprotein gene target





FIG. 19B



1

**COMPOSITIONS AND METHODS FOR
DETECTING AN RNA VIRUS**

**CROSS REFERENCE TO RELATED
APPLICATIONS**

This application is a continuation of U.S. patent application Ser. No. 15/520,328, filed on Apr. 19, 2017, now U.S. Pat. No. 10,793,922; which is the U.S. national phase application, pursuant to 35 U.S.C. § 371, of PCT International Application Serial No.: PCT/US2015/056491, filed Oct. 20, 2015, designating the United States and published in English, which claims priority to and the benefit of U.S. Provisional Patent Application Serial Nos. 62/066,277, filed Oct. 20, 2014, and 62/104,008, filed Jan. 15, 2015. The entire contents of each of these applications are hereby incorporated by reference herein.

SEQUENCE LISTING

This application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Aug. 7, 2020, is named 167665_010403.txt and is 48,985 bytes in size.

BACKGROUND OF THE INVENTION

The Ebola virus causes hemorrhagic fever with mortality rates reaching 50% to 90% of infected humans. Ebola virus (EBOV) includes four species, Zaire EBOV, Sudan EBOV, Ivory Coast EBOV, and Reston EBOV. Human infection with Ebola typically results from contact with contaminated blood, tissues, and/or excretions of animals or patients with an Ebola infection. Patients typically exhibit symptoms 4 to 10 days after Ebola infection. This long incubation period provides an opportunity for the virus to be carried to new areas before the carrier displays any signs of illness. Symptoms of Ebola include fever, chills, malaise, and myalgia. Because such symptoms are displayed in a variety of illnesses, there is a significant risk that Ebola infection may be misdiagnosed in the early stages, thereby facilitating spread of the disease. In later stages, Ebola-infected subjects typically develop vomiting, diarrhea, coughing, vascular symptoms, headache, confusion, coma, mucosal hemorrhages, bloody diarrhea and ultimately multiorgan failure, resulting in death. The bodily fluids of Ebola patients are highly infectious as are the dead bodies of Ebola patients.

Public health concerns about Ebola infection are mounting as Ebola infections in West Africa in late 2014 are predicted to rise to 10,000 people per week. Because of their exposure to the bodily fluids of Ebola patients, health care workers are at risk for catching Ebola from infected patients. The risk of infection increases as the extent and the frequency of contact increased. In a 1976 Sudan Ebola outbreak 81% of healthcare workers nursing Ebola patients were infected with the virus. In order for medical staff and health care workers to avoid unnecessary infections, early detection of Ebola is critical so that appropriate infection control measures are instituted and the risk of transmission is minimized.

To stop the spread of Ebola within West Africa and internationally, rapid diagnosis is essential so that infected subjects may be immediately quarantined and proper protective equipment used by health care workers caring for these subjects. High titers of infectious filovirus are present in the blood and tissues during early stages of illness.

2

Currently, Ebola is identified by virus isolation, reverse transcription-PCR (RT-PCR), including real-time quantitative RT-PCR, antigen-capture enzyme-linked immunosorbent assay (ELISA), antigen detection by immunostaining, and IgG- and IgM-ELISA using authentic virus antigens. Unfortunately, these tests are time-consuming because they can only be carried out on purified and isolated RNA and require access to laboratory equipment and trained technicians that are scarce in many areas where Ebola is endemic.

Accordingly, improved methods for rapidly identifying patients infected with Ebola virus are urgently required.

SUMMARY OF THE INVENTION

The present invention provides methods for rapidly identifying an Ebola infection using an isothermal nucleic acid amplification reaction that can be carried out on extracted RNA in the context of a crude biological sample.

In one aspect, the invention provides a method of detecting a specific target polynucleotide (e.g., RNA) in an isothermal amplification reaction coupled with reverse transcription, the method involving

(a) contacting a target polynucleotide molecule in a sample with a primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA;

(b) contacting the cDNA with forward and reverse primers each carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically bind the cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, a detectable oligonucleotide probe, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA; and

(c) detecting a signal specific for detectable oligonucleotide probe hybridization to the amplicon, where detection of the signal indicates the presence or quantity of the target polynucleotide present in the sample and failure to detect the signal indicates the absence of target polyribonucleotide in the sample.

In another aspect, the invention provides a method of detecting an RNA virus in a sample, the method involving

(a) contacting an RNA virus polynucleotide molecule in a biological sample with a primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA;

(b) contacting the cDNA with forward and reverse primers each carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically bind the cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, a detectable oligonucleotide probe, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA; and

(c) detecting a signal specific for detectable oligonucleotide probe hybridization to the amplicon, where detection of the signal indicates the presence or quantity of the RNA virus polynucleotide molecule present in the sample and failure to detect the amplicon indicates the absence of an RNA virus.

In a related aspect, the invention provides a method of detecting an Ebola virus in a sample, the method involving

(a) contacting an Ebola polynucleotide molecule in a biological sample with a primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA;

(b) contacting the cDNA with forward and reverse primers each carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically bind the cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, a detectable oligonucleotide probe, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA; and

(c) detecting a signal specific for detectable oligonucleotide probe hybridization to the amplicon, where detection of the signal indicates the presence or quantity of the Ebola polynucleotide present in the sample and failure to detect the signal indicates the absence of Ebola polynucleotide present in the sample.

In various embodiments of the above aspects or any other aspect of the invention delineated herein, the Ebola polynucleotide is obtained by contacting a biological sample with an agent capable of extracting an RNA molecule present in the sample and an agent capable of stabilizing an RNA molecule against degradation.

In yet another aspect, the invention provides a method of detecting an Ebola virus in a sample, the method involving

(a) contacting a biological sample with an agent capable of extracting a polynucleotide molecule present in the sample and an agent capable of stabilizing a polynucleotide molecule against degradation;

(b) contacting the extracted and stabilized Ebola RNA with a primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating an Ebola cDNA;

(c) contacting the Ebola cDNA with forward and reverse primers each carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically bind the Ebola cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA, thereby generating amplicons; and

(d) detecting the amplicons, where the presence of an Ebola amplicon detects an Ebola polynucleotide in the sample and failure to detect the amplicon indicates the absence of an Ebola polynucleotide in the sample.

In yet another aspect, the invention provides a kit for detecting an RNA virus polynucleotide molecule involving primers that specifically bind an RNA viral sequence, a detectable probe that specifically binds a viral (e.g., Ebola) amplicon, a reverse transcriptase enzyme, a nicking enzyme, and a strand-displacement polymerase. In one embodiment, the primers contain the following sequences:

Forward primer:

(SEQ ID NO: 1)
GACTCGATATCGAGTCGCTTCCA[MeOC]AGTTATC[MeOU][MeOA]

[MeOC][MeOC][MeOG]

Reverse Primer:

(SEQ ID NO: 2)
GACTCGATATCGAGTCGAAATGC[MeOA]ACGA[MeOC][MeOA]

[MeOC][MeOC][MeOU];

and the probe contains the following sequence: gcta-CACGACTTYGCTGAAGgtacg (SEQ ID NO: 3).

In another embodiment, the probe has a fluorescent dye at the 5' end, and a quencher at the 3' end or vice versa. In one embodiment, the probe is

(SEQ ID NO: 4)
5'-CALRed_{610 nm}-gctacACGACTTYGCTGAAGgtacg BHQ2-3'
or

(SEQ ID NO: 5)
5'-FAM or FITC-gctacACGACTTYGCTGAAGgtacg-BHQ1-3'.

In one embodiment, the 3' quencher is replaced by DABsyl.

In another aspect, the invention provides a kit for amplifying an Ebola polynucleotide molecule in a reverse transcriptase nicking amplification reaction, the kit containing the following primers:

Forward primer:

(SEQ ID NO: 1)
GACTCGATATCGAGTCGCTTCCA[MeOC]AGTTATC[MeOU][MeOA]
[MeOC][MeOC][MeOG]

Reverse Primer:

(SEQ ID NO: 2)
GACTCGATATCGAGTCGAAATGC[MeOA]ACGA[MeOC][MeOA]
[MeOC][MeOC][MeOU];

the following probe:

(SEQ ID NO: 3)
gctacACGACTTYGCTGAAGgtac;

a reverse transcriptase enzyme, a nicking enzyme, a strand-displacement polymerase, and directions for use of the aforementioned primers, probes and enzymes for detecting an Ebola polynucleotide molecule.

In one embodiment, the kit further contains a capillary tube that may or may not contain lyophilized lysis or RNA stabilization reagents for viral polynucleotide extraction. In another embodiment, the kit further contains one or more vessels containing a buffer suitable for carrying out a reverse transcriptase and/or amplification reaction. In another embodiment, the kit further contains vessels containing the reverse transcriptase enzyme, nicking enzyme, and strand-displacement polymerase in lyophilized form.

In yet another aspect, the invention provides a method of diagnosing a human or animal subject with an RNA virus, the method involving

(a) contacting a sample of the subject with an agent capable of extracting an RNA virus present in the sample and an agent capable of stabilizing the extracted polynucleotide molecule against degradation;

(b) contacting the polynucleotide molecule with a reverse transcriptase primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA copy of the polynucleotide molecule;

(c) contacting the cDNA with forward and reverse primers carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically bind the cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA, thereby generating amplicons; and

(d) detecting the amplicons, where the presence of an RNA viral amplicon diagnoses an RNA viral infection in the subject and failure to detect the amplicon diagnoses the absence of an RNA viral infection in the subject.

In various embodiments of any aspect delineated herein, no detectable signal is present in a control assay lacking a target polynucleotide at seven minutes, ten minutes, and/or fifteen minutes following initiation of the assay. In other embodiments of any aspect delineated herein, the primer used in step (a) has the same sequence or a different sequence than a primer used in step (b). In other embodiments of any of the above, steps (a)-(c) are carried out in a single reaction. In still other embodiments of the above aspects, the reverse transcriptase enzyme and the strand-displacement DNA polymerase are the same or different enzymes. In still other embodiments, the cDNA of step (a) is generated in a first reaction vessel, then transferred to a second reaction vessel where step (b) is carried out. In still other embodiments of any aspect delineated herein, the polynucleotide molecule is an Ebola polynucleotide. In still other embodiments of any aspect delineated herein, the sample is a bodily fluid (e.g., saliva, sweat, tears, fluids accumulating in a bodily cavity, urine, ejaculate, vaginal secretion, cerebrospinal fluid, lymph, feces, sputum, decomposition fluid, vomit, sweat, breast milk, blood, serum, and plasma). In still other embodiments of any aspect delineated herein, the bodily cavity is peritoneal cavity or pericardial cavity. In still other embodiments of any aspect delineated herein, the limit of detection is 10 or 20 copies per reaction. In still other embodiments of any aspect delineated herein, the method is carried out in about 5, 7, 10, 15, 20, 25 or thirty minutes. In still other embodiments of any aspect delineated herein, steps a-d are carried out in the context of the biological sample. In still other embodiments of any aspect delineated herein, Ebola or other viral RNA is not purified or isolated away from the biological sample (e.g., crude). In still other embodiments of any aspect delineated herein, the method is carried out at a point of care or diagnosis in a portable battery powered device. In still other embodiments of any aspect delineated herein, no separate reverse transcriptase primer is required, but the forward and/or reverse primers are used. In still other embodiments of any aspect delineated herein, the sample is a biological sample or an environmental sample. In still other embodiments of any aspect delineated herein, the biological sample is obtained from a subject, bat, bush meat, or a domestic animal. In still other embodiments of any aspect delineated herein, the biological sample is a swab of a mucosal membrane that is any one or more of buccal, nasal, eye, rectal, and vaginal or skin. In still other embodiments of any aspect delineated herein, the biological sample is a tissue sample obtained from a subject, necropsy, or culture media. In still other embodiments of any aspect delineated herein, the necropsy is of a human, primate, bat, or other mammal. In still other embodiments of any aspect delineated herein, the environmental sample is a material that may be contaminated with a biological fluid of a subject having or having a propensity to develop an Ebola viral infection. In still other embodiments of any aspect delineated herein, the environmental sample is bedding, a seat cushion, a rug, an air condition filter or other material. In still other embodiments of any aspect delineated herein, the polymerases are 5'-exo-derivatives of Bst DNA polymerase I, Gst DNA polymerase I, Gka DNA polymerase I, Gca DNA polymerase I, Gan DNA polymerase I, Gbo DNA polymerase I, Gsp70 DNA polymerase I, GspT3 DNA polymerase I, Gsp52 DNA polymerase I and/or fragments thereof. In still other embodiments of any aspect delineated herein, the nicking enzyme is one or more of Nt.BstNBI, Nt.BspD6I, Nt.BspQI, Nt.B-smAI, Nt.AlwI, N.Bst9I, or N.BstSEI. In still other embodiments of any aspect delineated herein, the reverse tran-

scriptase is M-MLV RT, AMV RT, RSV RT, and/or mutants/derivates thereof. In still other embodiments of any aspect delineated herein, the detectable probe contains a molecular beacon. In various embodiments of any aspect delineated herein, an amplification primer (e.g., forward and/or reverse primer) comprises one or more 2' modified nucleotides (e.g., 2'-O-methyl ribonucleotides) in the 3' terminal region or recognition region. In particular embodiments, the amplification primer comprises one or more 2'-O-methyl modified nucleotides at the 3' end, including for example 2'-O-methyl, 2'-methoxyethoxy, 2'-fluoro, 2'-hydroxyl, 2'-alkyl, 2'-allyl, 2'-O-[2-(methylamino)-2-oxoethyl], 4'-thio, 4'-CH₂-O-2'-bridge, 4'-(CH₂)₂-O-2'-bridge, 2'-LNA, and 2'-O-(N-methylcarbamate).

In still other embodiments of any aspect delineated herein, the forward and reverse primers for detection of Ebola virus contain the following sequences, respectively:

20 Forward primer:

(SEQ ID NO: 1)
GACTCGATATCGAGTCGCTTCCA[MeOC]AGTTATC[MeOU][MeOA]
[MeOC][MeOC][MeOG]

Reverse Primer:

(SEQ ID NO: 2)
GACTCGATATCGAGTCGAAATGC[MeOA]ACGA[MeOC][MeOA][MeOC]
[MeOC][MeOU]

In still other embodiments of any aspect delineated herein, amplification is detected using a probe having the following sequence: gctacACGACTTYGCTGAAGgtage (SEQ ID NO: 3). In still other embodiments of any aspect delineated herein, the probe has a fluorescent dye at 5' end, and a quencher at 3' end or vice versa. In still other embodiments of any aspect delineated herein, the probe is

(SEQ ID NO: 4)
5' -CALRed_{610 nm}-gctacACGACTTYGCTGAAGgtage BHQ2-3'
or

(SEQ ID NO: 5)
5' -FAM or FITC-gctacACGACTTYGCTGAAGgtage-BHQ1-3"

In still other embodiments of any aspect delineated herein, the 3' quencher is replaced by DABsyl.

In still other embodiments of any aspect delineated herein, the forward and reverse primers for detection of HIV virus contain one or more of the following sequences, respectively:

Forward primer:

(SEQ ID NO: 6)
GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmAmG;

(SEQ ID NO: 7)
GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmAmG;
and

Reverse Primer:

(SEQ ID NO: 8)
GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmCmAmC,

(SEQ ID NO: 9)
GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC.

In still other embodiments of any aspect delineated herein, amplification is detected using a probe having the following sequence: cgcaagGGAGAGAGATGGGTGcttgcg (SEQ ID NO: 10).

In still other embodiments of any aspect delineated herein, the forward and reverse primers for detection of Dengue virus contain one or more of the following sequences, respectively:

Forward primer:

(SEQ ID NO: 11)

GACTCGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC;
and

Reverse Primer:

(SEQ ID NO: 12)

GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG,

(SEQ ID NO: 13)

GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG.

In still other embodiments of any aspect delineated herein, amplification is detected using a probe having the following sequence: cgcacTGTTCTTCCCAGCgtgcg (SEQ ID NO: 14).

In still other embodiments of any aspect delineated herein, the forward and reverse primers for detection of influenza B virus contain one or more of the following sequences, respectively:

Forward primer:

(SEQ ID NO: 15)

GACTCGATATCGAGTCAAATGCAmGATGGTCTCmAmGmCmTmA,

(SEQ ID NO: 16)

GACTCGATATCGAGTCAAATGCAmAATGGTCTCmAmGmCmTmA,

(SEQ ID NO: 17)

GACTCGATATCGAGTCAAATGCAmGATGGTTTCmAmGmCmTmA;
and

Reverse Primer:

(SEQ ID NO: 18)

GACTCGATATCGAGTCCTCCTTmTCCCATTCCATmTmCmAmTmT,

(SEQ ID NO: 19)

GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT,

(SEQ ID NO: 20)

GACTCGATATCGAGTCCTCCTTmTCCCATTCCATmTmCmAmTmT.

In still other embodiments of any aspect delineated herein, amplification is detected using a probe having the following sequence: gccaaGCTATGAACACAGCAAActggc (SEQ ID NO: 21).

In still other embodiments of any aspect delineated herein, the forward and reverse primers for detection of BVDV1 virus contain one or more of the following sequences, respectively:

Forward primer:

(SEQ ID NO: 22)

GACTCGATATCGAGTCGGCCACmTGTATTGCTmAmCmGmAmAmA;
and

Reverse Primer:

(SEQ ID NO: 24)

GACTCGATATCGAGTCTGTGATCmAACTCCmAmTmGmTmGmCmC.

In still other embodiments of any aspect delineated herein, amplification is detected using a probe having the following sequence: cgctacATCTCTGCTGTACATGgtgcg (SEQ ID NO: 25). In still other embodiments of any aspect delineated herein, the probe has a fluorescent dye at the 5' end and a quencher at the 3' end, or a fluorescent dye at the 3' end and a quencher at the 5' end. In particular embodiments, the fluorescent dye is CALRed_{610nm}, and the quencher is BHQ2 or DABsyl. In certain embodiments, the fluorescent dye is FAM or FITC and the quencher is BHQ1 or DABsyl.

In still other embodiments of any aspect delineated herein, the RNA virus is an Ebola virus, human immunodeficiency virus (HIV), Dengue virus, influenza virus (e.g., influenza B), Bovine Viral Diarrhea virus (e.g., BVDV Genotype 1), Yellow Fever virus, West Nile virus, Hepatitis C, Lassa virus, Flavivirus, Arenavirus, or single-stranded RNA virus. In still other embodiments of any aspect delineated herein, the agent capable of extracting the virus is one of or a combination of sodium dodecyl sulfate, sodium lauryl sulfate, Guanidinium thiocyanate, and/or guanidine hydrochloride. In various embodiments, the Guanidinium thiocyanate or other agent capable of extracting the virus is used at a concentration of about 0.1, 0.5, 1.0, 2.5, 5.0, 7.5, 10, 15, 20, 25, 50, 100, 250, 500 mM or more. In still other embodiments of any aspect delineated herein, the method is used for daily screening of health care workers. In still other embodiments of any aspect delineated herein, the samples are pooled and the screening is carried out on a human or animal population.

Definitions

By "Ebola virus (EBOV)" is meant a Filoviridae virus having at least about 85% amino acid sequence identity to an Ebola virus. Exemplary Ebola viruses include, but are not limited to, Ebola-Zaire virus, Ebola-Sudan virus, Ebola-Ivory Coast virus, and Ebola-Bundibugyo, which cause disease in humans, or Ebola-Reston virus, which affects non-human primates.

The sequence of an exemplary Ebola Zaire genome is provided at NCBI Accession No. KC242800.1 (SEQ ID NO: 26), which is reproduced below:

```

1  cggacacaca aaaagaaaaga agaattttta ggatttttt tggcgata actatgagga
61  agattaataa ttttcctctc attgaaattt atatcgaaat ttaatttggaa attgttactg
121 taatcacacc tggtttgtt cagaggcaca tcacaaagat agagaacacgc ctaggtctcc
181 gaagggaaaca agggcaccag tggctcaagt tgaaaatccc ttgtcaacat ctaggtctta
241 tcacatcaca agttccacct cagactctgc agggtgatcc aacaacccta atagaaaaat
301 tattgttaac ggacagcatt agttcacagt caaacaagca agattgagaa ttaacccgttga
361 ttttgaactt caaacacctt aggattggag attcaacaac cctaaaactt gggtaaaac
421 attggaaata gttgaaagac aaattgctcg gaatcacaaa attccgagta tggattctcg

```

-continued

```

481 tcctcagaaa gtctggatga cgccgagtct tactgaatct gacatggatt accacaagat
541 cttgacagca ggtctgtccg ttcaacaggg gattgttcgg caaagagtca tcccagtgtta
601 tcaagtaaac aatcttgagg aaatttgcac acttatcata caggccttg aagcagggtgt
661 tgatttcaa gagagtgcgg acagttcct tctcatgctt tgcttcatc atgcgtacca
721 aggagateac aaactttctt tgaaaaagtgg tgcaagtcaag tatttggaaag ggcacgggtt
781 ccgtttgaa gtcaagaaac gtgtatgggt gaagcgccctt gaggaaattgc tgccagcagt
841 atcttagtgaa aaaaacatta agagaacact tgctgccatg ccggaagagg agacgactga
901 agctaattgc ggtcaagttc tctctttgc aagtcttattc ctccgaaat tggttagg
961 agaaaaggct tgocttgaga aagtcaaaag gcaaattcaa gtacatgcag agcaaggact
1021 gatacaaat ccaacagctt ggcaatcagt aggacacatg atggtgattt tccgtttgat
1081 gcgaacaaat ttttgatca aatttcttcc aatacaccaa gggatgcaca tggttgcgg
1141 gcatgatgcc aacgatgctg tgatttcaaa ttcaatggctt caagctcgat tttcagggtt
1201 attgattgtc aaaacagtc ttgatcatat cctacaaaag acagaacgag gagtttgtct
1261 ccatccttcc gcaaggactt ccaaggtaaa aaatgagggtg aactccctta aggctgcact
1321 cagccccctg gccaagcatg gagagtatgc tccttcgcg ccacttttga accttctgg
1381 agtaaataat cttagcatg gtctttccc tcaactatcg gcaattgcac tcggagtcgc
1441 cacagcacac gggagcaccc tcgcaggagt aaatgttggaa gaacagtatc aacagctcag
1501 agaggctgcc actgaagctt agaagcaact ccaacaatat gcagaatctc gcaacttga
1561 ccatcttggaa cttagatgatc agggaaagaa aattctttagt aacttccatc agaaaaagaa
1621 cgaaatcagc ttccagcaaa caaacgctat ggtaactcta agaaaagagc gcctggccaa
1681 gctgacagaa gctatcactg ctgcactact gccaaaaca agtggacctt acgatgatga
1741 tgacgacatt cccttcacg gaccatcaa tgatgacgac aatcctggcc atcaagatga
1801 tgatccgact gactcacagg atacgaccat tcctcgatgtg gtgggtgatc ccgatgatgg
1861 aagctacggc gaataccaga gttactcgga aaacggcatg aatgcaccag atgacttgg
1921 cctattcgat ctagacgagg acgacgagga cactaagcca gtccttaaca gattgaccaa
1981 gggtgacaa cagaaaaaca gtcaaaaggg ccagcatata gagggcagac agacacaatc
2041 caggccaact caaaatgtcc cagggcctcg cagaacaatc caccacgcca gtgcctccact
2101 cacggacaac gacagaggaa atgaaccctc cgctcaacc agccctcgca tgctgacacc
2161 aattaacgaa gaggcagacc cactggacga tgccgacgac gagacgtcta gtctccgc
2221 ctggaggta gacgatgaa aacaggacag ggacgaaact tccaaccgca caccactgt
2281 cgccccaccc gtcggatcatc acagagatca ctctgaaaag aaagaactcc cgcaagatga
2341 gcagcaagat caggaccata ctcaagaggc caggaaccag gagagtgaca acacccagcc
2401 agaacactct tttgaggaga tgtatgcacca cattctaaga tcacaggacat catttgc
2461 tggtttgtat tatcatatgaa tgaaggatga gcctgttagtt ttcaatgtacta gtgtggca
2521 agagtacacg tatccggact cccttgcaga ggaatataccca ccatggctca ctgaaaaaga
2581 ggccatgaaat gaagagaata gatttgcac attggatggt caacaattttt attggccggt
2641 aatgaatcac aagaataat tcatggcaat cctgcacat catcagtgaa tgagaatgg
2701 ataatggat gatttaaccg acaaatacg aacattaaat agtcaagaaa cgcaaacagg
2761 aagaatttttt gatgtctaaat gtgtgaattt ttatcacaat aaaaatgttattt cttat
2821 aatttaaagc tagcttattt ttactagccg ttttcaag ttcaatttgc gtcttaatgc

```

-Continued

2881 aaataggegt taagccacag ttataggccat aattgttaact caatatctta gctagegatt
 2941 tatctaaatt aaattacatt atgttttat aacttaccta ctgcctgcc caacattac
 3001 acgatcggt tataattaag aaaaactaa tgatgaagat taaaacccctt atcatcctta
 3061 cgtcaattga attctctagc actcgaagct tattgtcttc aatgtaaaag aaaagctgg
 3121 ccaacaagat gacaactaga acaaaggca gggccatac tgtggccacg actcaaaacg
 3181 acagaatgcc aggccttagt cttcggct ggatctccga gcagctaattt accggaagaa
 3241 ttcctgttaag cgacatcttc tgtatattt agaacaatcc aggattatgt tacgcattcc
 3301 aaatgcaca aacaaagcca aaccgaaaga tgcgcaacag tcaaacccaa acggacccaa
 3361 tttgcaatca tagtttgag gaggtgtac aaacattggc ttcattggct actgttgtgc
 3421 aacaacaaac tatcgcatca gaatcattt aacaacgtat tacgagtctt gagaatggc
 3481 taaagccagt ttatgtatgc gaaaaacaa tccttcattt gaacagggtt tgtgctgaga
 3541 tggttgcaaa atatgtatctt ctgggtatga caaccggctg ggcaacagca accactgcgg
 3601 caactgaggc ttatgggctt gaacatggc aaccaccacc tggaccatca ctttatgaag
 3661 aaagtgcattt tcggggttaag attgtatctt gagatgagac cgtccctcaa agtgttaggg
 3721 aggcattca caatctagac agtaccactt cactaactga gggaaatttt gggaaacctg
 3781 acatttcagc aaaggattt agaaacattt tttatgtatca cttgcctgg tttggactg
 3841 cttccacca attagtacaa gtgattgtt aattggggaa agatagcaac tcattggata
 3901 tcattcatgc tgagttccag gccagcctgg ctgaaggaga ctctcctcaa tttggccctaa
 3961 ttcaatttac aaaaaggtt ccaatcttcc aagatgctgc tccacctgtc atccacatcc
 4021 gctctcgagg tgacattccc cgagcttgcc agaaaagctt gctccctgac ccgccccatcac
 4081 ccaagattga tcgaggttgg gtatgtttt tccagcttca agatggtaaa acacttggac
 4141 tcaaaatttgc agccaatctc cttccctcc gaaagaggcg accaatagca gaggcttcaa
 4201 ctgctgaact acagggtacg ttacatataat gatacacttgc tgagtatcg cccttagataa
 4261 tataagtcaa taaaacgacc aagccaaaat tttatgtatcc cggcttagcgtt cttaaaatat
 4321 aatgtaaaataa ggagctatctt ctgtacatgtt attataatca attgttattt agtaacccaa
 4381 accaaaaatgtt atgaagatattt agaaaaacccctt acctcgactg agagagtgtt tttccattaa
 4441 cttccatctt gtaaacgttgc agccaaaattt ttacatataat gaggcgggtt atattgtctt
 4501 ctgctccctcc tgaatataatg gaggccatataat accctgtcgtt gtcatttca acaattgtca
 4561 ggggtggcaaa caacaataca ggttcccttga caccggatgc agtcaatggaa gacactccat
 4621 cgaatccactt caggccattt gtcgtatgaca ccatcgacca tgctagccac acaccaggca
 4681 gtgtgtcattt agcatttcattt ctttgcgttgc tggtgtatgtt catatcgccgc cccaaagtgc
 4741 taatgtttttt aattttttttt tggcttcctt taggtgtcgtt tgatcaaaag acctacagct
 4801 ttgactcaac tacggccgc accatgttttgc ttctatataac tttatccatccat ttcggccatgg
 4861 caaccaatcc accgttgcaga gtcaatcgcc tgggtccctgg aatcccgat caccctctca
 4921 gggtccctgcg aatttggaaac caggcccttcc tccaggagtt cgttcccttcc ccaatgttca
 4981 tacccctgtt tttcacctttt gatttgacatgc cactcaactt gatcacccttcc ccaatgttca
 5041 ctgcaacatgtt gaccgtatgc acttcaacatgc gatcaatggt agtgcgttgcgtt ccagggattt
 5101 cgtttcatcc aaaacttcgc cccattttt taccttacaa aagtggaaag aagggaaaca
 5161 gtgtccatctt aacatcttca gaaaaatcc accgttcaat gatcttcactt caggacttta
 5221 agatgtttcc aattgtatcca accaaaaataa tcatgggtat cgaatgttca gaaactctgg
 5281 tccacaagctt gaccggtaag aaggtgactt cttttttttt acaaccaatcc accctgttcc

-continued

5341 ttttgcacaa gtacattggg ttggaccgg tggtccagg agacctcacc atggtaatca
 5401 cacaggattg tgacacgtgt catttcctg caagtcttcc agctgtgatt gagaagtaat
 5461 tgcaataatt gactcagatc cagttttaca gaatcttctc agggatagtg ataacatcta
 5521 ttttagtaatc cgtctattag aggagatact tttaattgt caatatacta aagggtgttt
 5581 acaccattgt ctttttctc tcctaaatgt agaacttaac aaaagactca caatataactt
 5641 gtcttaaaga gattgattga tgaagatca tgactataaa cattacaat aatcctacta
 5701 taatcaatac ggtgattcaa atattaatct ttcttaattgc acatactotc tgcccctatc
 5761 ctcaattgc ctacatgcct acatctgagg atagccagtg tgacttggat tggagatgt
 5821 gggaaagaaat cgaaacccat ctccaggttg ttccacaatcc aagcacagac atcgcccttc
 5881 taatcaaaga aaaatcgccg atgaagatgg agccgacagt gagcgcatac ttcatctctc
 5941 tttagattatt tgtttccag agtaggggtc atcaggcctt ttccaaatcat ataacaaaa
 6001 taaacctcac tagaaggata ttgtgaggca acaaacaat gggtattaca ggaatattgc
 6061 agttacctcg tgatcgattc aagaggacat catttttctt ttggtaatt atcctttcc
 6121 aaagaacatt ttccatcccc cttggagtca tccacaatag cacattacaat gtttgtatg
 6181 tcgacaaact agttgtcgt gacaaactgt catccacaaa tcaattgaga tcagttggac
 6241 tgaatctcg agggaaatggg gtggcaactg acgtgccatc tgcaactaaa agatggggct
 6301 tcaggtccgg tgtccctcca aaggtggtca attatgaagc tggtaatgg gctgaaaact
 6361 gctacaatct tgaatcaaa aaacctgacg ggagtggatg tctaccagca ggcgcacacg
 6421 ggattcgggg cttccccccg tgccggatgt tgccacaaatg atcaggaacg ggaccgtgt
 6481 ccggagactt tgccttccac aaagaggggtg ctttttctt gtatgatcg cttgcttcca
 6541 cagttatcta ccgaggaacg actttcgctg aaggtgtcgt tgcatcttctg atactgcccc
 6601 aagtaagaa ggacttcc tcgatcgatcc ccttgagaga gccggtaat gcaacggagg
 6661 acccggtccag tggctactat tctaccacaa ttagatatca ggctaccggg tttggAACCA
 6721 atgagacggg gtacttggtc gaggttgaca atttgacca cgtccaaactt gaatcaagat
 6781 tcacgcccaca gttttgttc cagttgtatg agacaatata tgcaagtggg aaaaggagca
 6841 acaccacggg aaaactaatt tggaaaggta accccgaaat tgatacaaca atcggggatg
 6901 gggccctctg ggaaactaaa aaaacctcac tagaaaaatt cgcaatgtcaag agttgtctt
 6961 cacagctgta tcaaaccggag ccaaagacat cagttggatc agtccggcgc gaaacttctc
 7021 cgaccacggg acctacacaa caactgaaga ccacaaaatc atggcttcgt aaaattccctc
 7081 tgcaatgggtt caagtgcaca atcaaggaag ggaagctgca gtgtcgatc tgataaccct
 7141 tgccacaatc tccacggatc ctcaatcccc tacaacccaa ccaggtcagg acaacagcac
 7201 ccataatata cccgtgtata aacttgacat ctctgaggca actcaagttg aacaacatca
 7261 tcgcagaaca gacaacgaca gcacagccctc cgacactccc cccgcccacg cccgagccgg
 7321 acccccaaaa gcagagaaca tcaacacggg caagagcgct gactccctgg acccccggcac
 7381 cacgacaagt ccccaaaaact acagcgagac cgctggcaac aacaacactc atccaaga
 7441 taccggagaa gagagtgcgg gcagcgggaa gctgggctt attgccaata ctattgtgg
 7501 agtcgcagggt ctgatcagac gggggagaag aacttcgatca gaagcaattt tcaatgtca
 7561 accccaaatgc aacccttacatc tacattactg gactactcg gatgaaggtt ctgcatacg
 7621 attggcctgg ataccatatt tcggccacg agccgaggaa atttacacag aggggctaat
 7681 gcacaatcaa gatggttaa tctgtggatt gaggcagctg gccaatgaga cgactcaacg

-Continued

7741 tcttcaactg ttccctgagag ccacaactga gctacgcacc tttcaatcc tcaaccgtaa
 7801 ggcaattgat ttcttgctc agcgatgggg cggcacatgc cacatttgg gaccggactg
 7861 ctgtatcgaa ccacatgatt ggaccaagaa catacagac aaaattgatc agattattca
 7921 tgattttgtt gataaaaacc ttccggacca gggggacaat gacaatttgt ggactggatg
 7981 gagacaatgg ataccggcag gtattggagt tacaggcgtt ataattgcag ttattgttt
 8041 attctgtata tgcaaatttgc tcttttagtt ttttcaga ttgcttcatg gcaaagctca
 8101 gcctcaaatc aatgagatta ggatthaatt atatggatca cttgaatcta agattacttg
 8161 acaaattgata atataataca ctggagctt aaatatagcc aatgtgattc taactcctt
 8221 aaactcaca aataatcataa acaaggttt acatcaatct agttatctt ttgagaatga
 8281 taaaacttgat gaagattaag aaaaaggtaa tctttcgatt atcttttagtc ttcatcctt
 8341 attctacaat catgacatgt gtcttttagt acaaggaaaaa gaaggccttt tagtaagttt
 8401 taataatcag atctgcgaac cggttagatgat taattgcaac ctaacacacaca taaagcattt
 8461 gtcaaaaagt caatagaat taaaacagtg agtggagaca actttcaaat ggaagctcca
 8521 tacgagagag gacgcccccg agctgccaga cagcattca gggatggaca cgaccatcat
 8581 gttcgagcac gatcatcatc cagagagaat tatcgaggtg agtaccgtca atcaaggagc
 8641 gcctcacaag tgccgcgttcc tactgtatccataagagga gagttgaacc attaacagtt
 8701 cctccagcac ctaaaagacat atgtccgacc ttgaaaaaaag gatTTTGTG tgacagtagt
 8761 ttttgcaaaa aagatcacca gttggaaagt ttaactgata gggaaattact cctactaattc
 8821 gcccgttcaaga cttgtggatc agttagaacaa caattaaata taactgcacc caaggactcg
 8881 cgcttagcaa atccaaacggc tgatgatttc cagcaagagg aagggtccaaa aattacctt
 8941 ttgacactga tcaagacggc agaacaactgg gcgagacaag acatcaggac cacagaggat
 9001 tc当地atcagcattgtt gactctatgt gctgtatgatc cgaggaaatt ct当地atcc
 9061 cagctgatgc ttttatgtga gacacacctg aggcgcgagg ggcttggca agatcaggca
 9121 gaaccgcgttcc tcaacgtata tcaacgatta cacagtataa aaggaggcag ttgc当地atc
 9181 gcactatggc aacaatgggatc tgcacaatcc ctaattatgt ttatcactgc attcttgaat
 9241 atcgctctcc agttaccgtg tgaaaggatc gctgtcgatc ttccagggtt aagaacattt
 9301 gttccctcaat cagataatgatc ggaaggatc accaaccggc ggacatgcctc atggctgtat
 9361 gatggtaccc ctttataagg ctgactaaaa cactatataa ctttctactt gatcacaata
 9421 ctccgtatac ctatcatcat atattcaatc aagacggat cttttaaaac ttattcagta
 9481 ctataatcac tctcgatcc aattaataag atatgcataa ttgctttaat atatgaagag
 9541 gtatgataca accctaaacag tgatcaaaga aaatcataat ctcttgcgc tcgtatata
 9601 acctgccaag ctttcttgc gacaaaggatc attcttgcac acaaataatg ttttactctt
 9661 caggaggtag caacgatcc tcccatcaaa aaataaggat tttatgactt actaatgatc
 9721 tctttaaaata ttaagaaaaa ctgacggac accaattctt tctgcttca gttgtggagg
 9781 aggtctttgg tattggatc ttttatattttaa caatcataa caagcttgc aaaaatttgt
 9841 tcttgcgttca agaggtagat ttttgcgttca aacgctaaac taatgatgaa gattaatgc
 9901 gaggtctgtatc aagaataaaac ctttatttc agattaggcc ccaagaggca ttcttcatct
 9961 ctttttagca aagtactatt tcagggtatc ccaatttagtgc acacgtctt tagctgtata
 10021 tcagtcgttcc ctgagatacg ccacaaaatg gtttgcgttca aaaaaggatc ttatcata
 10081 tcatacatttgc tattttggc aataatatct aattgatcattt agccgtttaa aatttagtgc
 10141 ataaacctgg gtttgcgttca ccaggtaac tccattggatc gaaaagaagc ccacctacaa

-continued

10201 cgaacatcac tttgagcgcc cttacaatta aaaaatagga acgtcggtcc aacaatttgag
 10261 cgcaaggttt caaggttcaa ctgagagtgc ctaaacacca aaatatcgat aattcagaca
 10321 ccaagcaaga cctgagaagg aaccatggct aaagctacgg gacgatacaa tctaataatcg
 10381 cccaaaaagg acctggaaagg aggggttgc ttaagcgacc tctgttaactt cctagttatgt
 10441 caaactattc aagggtggaa ggtctattgg gctggatttgc agtttgcgtt gactcaca
 10501 ggaatggccc tattgcatacg actgaaaact aatgcatttgc cccctgcatacg gtcaatgaca
 10561 aggaatctat ttocctcattt atttcaaaat ccgaattcca caatttgatgc accactgtgg
 10621 gcattgagag tcatccttcgc agcagggtta caggaccgc tgattgacca gtctttgatt
 10681 gaacccttag caggageccct tggctgtatc tctgatttgc tgctaaacaac caacactaac
 10741 catttcaaca tgcgaaacaca acgtgttaag gacaattga gcctaaaaat gctgtcggtt
 10801 attcgatcca atattctcaa gtttattaac caattggatgc ctctacatgt cgtgaactac
 10861 aacgggttgt tgagcgtat tgaaatttgc actcaaaatc atacaatcat tataactcg
 10921 actaacatgg gtttctgggt ggagctccaa gaaccgcaca aatcgcaat gaaccgcag
 10981 aagcctgggc cggcggaaatt ttccctccctt catgagtcatac cactgaaagc atttacacaa
 11041 gggtcctcga cacgaatgca aagtttgcattt ctgttatcatac tgctatctt
 11101 ttaagatggaa atacttcata ttgagctaac tcataatgc tgactcaata gttatcttga
 11161 catctctgtt ttcataatca gatataataag cataataatc aaataactcat atttcttgc
 11221 aatttgcattt accacagata aatcctactt gtaagccagc ttccaaatggc acacccttac
 11281 aaaaaccagg actcagaatc cctcaaataa gagattccaa gacaacatca tagaattgct
 11341 ttattatatg aataagcatg ttatcaccatc aaatccaata tactaaatag ttaattgtaa
 11401 ctgaacccgc aggtcacgtg tggtaggttt cacagattat atatattact aactccatac
 11461 ccgtatcaa cattagataa gtagattaag aaaaacgtt gggaaatggatt aagaaaaact
 11521 gcttatttggg tcttcgtt gtttagatgc agcagttgcatttcttcc ttgatattaa
 11581 atggctacac aacataccca atacccagac gccagggtt catcacaat tggatggac
 11641 caatgtgacc tagtcacttag agcttgcggg ttatattcat catactccct taatccgca
 11701 ctacgcaact gtaaactccccca gaaacatatac taccgtttaa aatatgtatgt aactgttacc
 11761 aagttcttaa gtgatgtacc agtggcgaca ttgccaatag atttcataatgtt cccaaatttctt
 11821 ctcaaggcac tgtcaggcaa tgggttctgt cctgttgac cgcgggtgtca acagtttta
 11881 gatgaaatca ttaagtgac aatgcaagat gctctcttcc tggaaatattttt tctcaaaaat
 11941 gtgggtgtc aaggaggactg tggtagtgc cactttcaag agaaaatctt atcttcattt
 12001 cagggcaatg aatttttaca tcaaatttttgc ttctggatgc acctggctat ttgtactcg
 12061 aggggtatg taaatcgagg aaactctaga tcaacatggt ttgttcatga tgatattata
 12121 gacatcttag gctatggggc ctatgtttt tggaaatgc caatttcaat gttacccttgc
 12181 aacacacaag gaatccccca tgctgctatg gattggatgc aggcacatgtt attcaaaagaa
 12241 gcggttcaag ggcatacaca catttttttgc ttcttactgc ccgacgttcc gataatgtgc
 12301 aaagatttaa ttacatgtcg attcaacaca actctaatctt caaaatgttgc agaggttgc
 12361 gatccagttt gttctgatcc tcccgatattt aagattgtgtt ctatgttccatcc ccagagcg
 12421 gattacttac tctccatattt agggctgtat gggataaaa ttatattttt cctcgaaacca
 12481 ttgtgcttgg cccaaatttca attatgttca aagttacaccg agaggttgc agggatcc
 12541 acacaaatgc atttagtgcgtt aatcacaccctt ctgaaagaaa ttacagaaat gctgtgcacta

-Continued

12601 aagecttcac aggatcaaaa gatccgtgaa ttccatagaa cattgataag gctggagatg
 12661 acgeccacaac aactttgtga gctatttcc attcaaaaac actggggca tcctgtgcta
 12721 catagtgaaa cagcaatcca aaaagttaaa aaacatgcc cggtgctaa agcattacgc
 12781 cctatagtga tttcgagac atattgtgtt tttaaatata gtattgcaaa acattatTTT
 12841 gatagtcaag gatctggta cagtgtaact tcagatagga atttaacgcc aggtctaat
 12901 tcttatatca aaagaaaatca attccccccg ttgccaatga ttaaagaact actatggaa
 12961 tttaccacc ttgaccatcc tccactttc tcaaccaaaa ttattagtga cttaagtatt
 13021 ttataaaag acagagtcg cgcaggaa aggacatgtt gggatgcagt attcgagcct
 13081 aatgttctag gatataatcc acctcacaaa ttcatgtacta aacgtgtacc agaacaattt
 13141 ttagagcaag aaaactttc tattgagaat gttttttc acgcgcacaaa actcgagtat
 13201 ctactaccac aataccggaa tttttttc tcattgaaag agaaagagtt gaatgttaggt
 13261 agaactttcg gaaaatttgc ttatccgact cgcaatgttc aaacactttg tgaagctctg
 13321 tttagctgtatgt gtcttgcata agcatttcc agcaatatga tggtagtac agagcgtgag
 13381 caaaaagaaa gcttattgca tcaagcatca tggcaccaca caagtgtatga ttttggtag
 13441 catgccacag ttagaggag tagcttgcata actgatTTT agaaatacaa tcttgcattt
 13501 agatatgagt ttacagcacc tttatagaa tattgttaacc gttgctatgg tgtaagaat
 13561 gtttttaattt ggatgcatta tacaatcccc cagtttata tgcatgtcag tgattattat
 13621 aatccaccgc ataacctcac tctggaaaat cgagacaacc cccccgaagg gcccagttca
 13681 tacagaggc atatggggg gattgaagga ctgcaacaaa aactctggac aagtattca
 13741 tgtgctcaaa ttcttttagt tgaataaaag actgggtttt agttacgctc agctgtgatg
 13801 ggtgacaatc agtgcattac cgttttatca gtcttccct tagagactga cgcagacgag
 13861 caggaacaga gcgcgaaga caatgcagcg agggtggccg ccagcctagc aaaagttaca
 13921 agtgccctgtg gaatttttt aaaaactgtat gaaacatttgc tacattcagg ttttatctat
 13981 ttggaaaaaa aacaatattt gaatggggc caattgcctc agtccctaa aacggctaca
 14041 agaatggcac cattgtctga tgcaatTTT gatgtcttc aaggggccct ggctgtata
 14101 ggcactgctt ttgaacgatc catctctgag acacgacata tctttccttg caggataacc
 14161 gcagcttcc atacgTTTT ttccgtgaga atcttgcaac atcatcacct cgggttcaat
 14221 aagggtttt accttggaca gttgacactt ggcaaacctc tggatttcgg aacaatatca
 14281 ttggcaactag cggtaaccgc ggtgcttggaa gggttatcct tcttgaatcc tgagaaatgt
 14341 ttctaccggaa atttaggaga tccagttacc tcaggctt tccagttaaa aacttatctc
 14401 cgaatgattt agatggatgat tttattctt cctttaattt cgaagaaccc tgggaactgc
 14461 actgcatttgc acttggatc aaatcttagc ggattaaatg tccccgggc gcaagactta
 14521 acttcatttc tgccgcagat tggcgatgg actatcaccc taagtgcgaa aaacaaactt
 14581 attaataactt tatttcatgc gtcagctgac ttcaagacg aaatggttt taaatggctaa
 14641 ttatcatcaa ctccgtttt gagtcgtttt gcggccgata tctttcacg cacgccttgc
 14701 gggaaacgt tgcaatttctt aggatacctg gaaggaacac gcacattt accctctaag
 14761 atcatcaaca ataatacaga aacaccgggtt ttggacagac tgaggaaaat aacattgcaaa
 14821 aggtggagtc tatggtttag ttatcttgcata cattgtgata atatcctggc agaggcttta
 14881 accaaataaa cttgcacagt tgatTTTgcata cagatcctgaa gggaaatattc atgggcacat
 14941 atttaggagg ggagacctct tattggagcc acacttccat gtatgattga gcaattcaaa
 15001 gtggtttggc tgaaaccctt cgaacaatgtt ccgcagttt gcaatgcaaa gcaaccctgg

-continued

-Continued

```

17461 cttaaagtct ttctaaagtga tactgagggt atgttatggc taaatgataa tttagccccg
17521 tttttgcctt ctgggttattt aattaagccca ataacgtcaa gtgctagatc tagtgagtgg
17581 tatcttgctc tgacgaacctt cttatcaact acacgtaaga tgccacacca aaaccatctc
17641 agttgtaaac aggtataact tacggcattt caactgcaaa ttcaacggag cccatactgg
17701 ctaagtcatcatt taactcgatc tgctgactgc gatttacatt taagttatat ccgccttgg
17761 tttccatcat tagagaaaatg actataaccac aggtataacc tcgtcgattt aaaaagaggt
17821 ccactagtct ctatcactca gcacttggca catcttagag cagagattcg agaatttgact
17881 aatgattata atcaacacgca acaaagtccg actcaaacat atcaactttt tcgtactgca
17941 aaaggacgaa tcacaaaact agtcaatgat tattttaaaat tcttttttat tgtgcaagca
18001 ttaaaacata atgggacatg gcaagctgag tttaagaaaat taccagagtt gatttagtgg
18061 tgcaataggt tctatcatat tagagattgc aattgtgaag aacggtttttt agttcaacc
18121 ttatatctac atagaatgca ggattctgaa gttaaagctt tcgaaaggct gacagggctt
18181 ctgagtttat tcccgatgg tctctacagg tttgattgaa ttaccgtgca tagtacccctg
18241 atacttgtga aggttgatc tcaacgtaca gattataaaa aactcacaaa ttgctctcat
18301 acatcatatt gatcgaattt caataaataa ctattnaaaat aacgaaagaa gtccttataat
18361 tatacactat atttagcctc tctccctgcg tgataatcaa aaaattcaca atgcagcatg
18421 tgtgacatatt tacttccgcg atgaatctaa cgcaacataaa taaaactctgc actctttata
18481 attaagctttt aacaaaaggct ctgggctcat attgttattt atataataat gttgtatcaa
18541 tatacgttca gatgaaatg tgttttgggtt gataacacgaa ctttttttttt caaaaattgtat
18601 cttaaagattt aagtttttta taattatcat tacttttattt tgtcgatttta aaaatgggtga
18661 tagccttaat ctttgtttaa aataagagat taggtgtat aacttttacaa ttttggcttag
18721 taagctacta tttcatacag aatgataaaaa tttaaaaagaaa aggcatgact gtaaaatcag
18781 aaatacccttc tttaataat agcagactag ataataatct tcgtgttaat gataatgg
18841 acattgacca cgctcatcag gaggtcgcc aggataaagg ttgcaaaaag gattccctgg
18901 aaaatggtcg cacacaaaaa tttaaaaata aatcttatttcc ttcttttttgg tttgttcc

```

The invention further provides polynucleotides having at least about 85, 90, 95, 96, 97, 98, 99, or 100% identity to this sequence. Other Ebola Zaire genomes are known in the art and described, for example, by Baize et al., N Engl J Med 2014; 371:1418-25, which is incorporated herein by reference.

By "Ribonuclease P RNA component H1 (RPPH1) is meant the RNA component of the RNase P ribonucleoprotein, an endoribonuclease that cleaves tRNA precursor molecules to form the mature 5-prime termini of their tRNA sequences. An exemplary nucleic acid sequence is provided at NCBI Accession No. NR_002312 (SEQ ID NO: 27).

By "amplicon" is meant a polynucleotide generated during the amplification of a polynucleotide of interest. In one example, an amplicon is generated during a polymerase chain reaction.

By "amplification rate modifiers" is meant an agent capable of affecting the rate of polymerase extension.

By "base substitution" is meant a substituent of a nucleobase polymer that does not cause significant disruption of the hybridization between complementary nucleotide strands.

In this disclosure, "comprises," "comprising," "containing" and "having" and the like can have the meaning ascribed to them in U.S. Patent law and can mean

```

1 atagggcgga gggaaagctca tcagtggggc caegagctga gtgcgtctg tcactccact
61 cccatgtccc ttggaaagggt ctgagactag ggcacagggc ggccttaaca gggctctccc
121 tgagcttcgg ggaggtgagt tcccagagaaa cggggctccg cgccagggtca gactgggcag
181 gagatgccgt ggaccccgcc ctteggggag gggccggcgt gatgccttct ttgcccggac
241 ttggaaacaga ctcacggcca gcaagtgag ttcaatggct gaggtgaggt accccgcagg
301 ggacacctata acccaattca gactactctc ctccggccat t

```

"includes," "including," and the like; "consisting essentially of" or "consists essentially" likewise has the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.

By "complementary" or "complementarity" is meant that a nucleic acid can form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or Hoogsteen base pairing. Complementary base pairing includes not only G-C and A-T base pairing, but also includes base pairing involving universal bases, such as inosine. A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, or 10 nucleotides out of a total of 10 nucleotides in the first oligonucleotide being based paired to a second nucleic acid sequence having 10 nucleotides represents 50%, 60%, 70%, 80%, 90%, and 100% complementary respectively). To determine that a percent complementarity is of at least a certain percentage, the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence is calculated and rounded to the nearest whole number (e.g., 12, 13, 14, 15, 16, or 17 nucleotides out of a total of 23 nucleotides in the first oligonucleotide being based paired to a second nucleic acid sequence having 23 nucleotides represents 52%, 57%, 61%, 65%, 70%, and 74%, respectively; and has at least 50%, 50%, 60%, 60%, 70%, and 70% complementarity, respectively). As used herein, "substantially complementary" refers to complementarity between the strands such that they are capable of hybridizing under biological conditions. Substantially complementary sequences have 60%, 70%, 80%, 90%, 95%, or even 100% complementarity. Additionally, techniques to determine if two strands are capable of hybridizing under biological conditions by examining their nucleotide sequences are well known in the art.

As used herein, "duplex" refers to a double helical structure formed by the interaction of two single stranded nucleic acids. A duplex is typically formed by the pairwise hydrogen bonding of bases, i.e., "base pairing", between two single stranded nucleic acids which are oriented antiparallel with respect to each other. Base pairing in duplexes generally occurs by Watson-Crick base pairing, e.g., guanine (G) forms a base pair with cytosine (C) in DNA and RNA, adenine (A) forms a base pair with thymine (T) in DNA, and adenine (A) forms a base pair with uracil (U) in RNA. Conditions under which base pairs can form include physiological or biologically relevant conditions (e.g., intracellular: pH 7.2, 140 mM potassium ion; extracellular pH 7.4, 145 mM sodium ion). Furthermore, duplexes are stabilized by stacking interactions between adjacent nucleotides. As used herein, a duplex may be established or maintained by base pairing or by stacking interactions. A duplex is formed by two complementary nucleic acid strands, which may be substantially complementary or fully complementary. Single-stranded nucleic acids that base pair over a number of bases are said to "hybridize."

"Detect" refers to identifying the presence, absence or amount of the analyte to be detected. In one embodiment, the analyte is an Ebola polynucleotide or other RNA viral polynucleotide.

By "detectable moiety" is meant a composition that when linked to a molecule of interest renders the latter detectable,

via spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, or haptens.

By "fragment" is meant a portion of a nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides. In one embodiment, the fragment comprises at least about 50, 75, 80, 85, 89, 90, or 100 nucleotides of an Ebola polynucleotide or other RNA viral polynucleotide.

By "free energy (ΔG)" is meant the net exchange of energy between the system and its environment at a constant temperature and pressure described by the formula: $\Delta G = \Delta H - T\Delta S$. Free energy represents how thermodynamically stable a structure is, with formation of structures having a negative ΔG (e.g., expressed in kcal/mole) being thermodynamically stable (i.e., a structure having a lower ΔG is more stable than one having a higher ΔG). The thermodynamic potential is minimized when a system reaches equilibrium at constant pressure and temperature.

By "hybridize" is meant to form a double-stranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) *Methods Enzymol.* 152:399; Kimmel, A. R. (1987) *Methods Enzymol.* 152:507). Hybridization occurs by hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases. For example, adenine and thymine are complementary nucleobases that pair through the formation of hydrogen bonds.

By "isolated polynucleotide" is meant a nucleic acid (e.g., a DNA, RNA) that is free of the genes which, in the naturally-occurring genome of the organism from which the nucleic acid molecule of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. In addition, the term includes an RNA molecule that is transcribed from a DNA molecule, as well as a recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequence.

The terms "isolated," "purified," or "biologically pure" refer to material that is free to varying degrees from components which normally accompany it as found in its native state. "Isolate" denotes a degree of separation from original source or surroundings. "Purify" denotes a degree of separation that is higher than isolation. A "purified" or "biologically pure" protein is sufficiently free of other materials such that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, a nucleic acid or peptide of this invention is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, for example, polyacrylamide gel electrophoresis or high

performance liquid chromatography. The term "purified" can denote that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For a protein that can be subjected to modifications, for example, phosphorylation or glycosylation, different modifications may give rise to different isolated proteins, which can be separately purified.

By "melting temperature (Tm)" is meant the temperature of a system in equilibrium where 50% of the molecular population is in one state and 50% of the population is in another state. With regard to the nucleic acids of the invention, Tm is the temperature at which 50% of the population is single-stranded and 50% is double-stranded (e.g., intramolecularly or intermolecularly).

By "monitoring a reaction" is meant detecting the progress of a reaction. In one embodiment, monitoring reaction progression involves detecting polymerase extension and/or detecting the completion of an amplification reaction.

As used herein, "obtaining" as in "obtaining an agent" includes synthesizing, purchasing, or otherwise acquiring the agent.

As used herein, the term "nucleic acid" refers to deoxyribonucleotides, ribonucleotides, or modified nucleotides, and polymers thereof in single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, 2' modified nucleotides (e.g., 2'-O-methyl ribonucleotides, 2'-F nucleotides).

As used herein, "modified nucleotide" refers to a nucleotide that has one or more modifications to the nucleoside, the nucleobase, pentose ring, or phosphate group. For example, modified nucleotides exclude ribonucleotides containing adenosine monophosphate, guanosine monophosphate, uridine monophosphate, and cytidine monophosphate and deoxyribonucleotides containing deoxyadenosine monophosphate, deoxyguanosine monophosphate, deoxythymidine monophosphate, and deoxycytidine monophosphate. Modifications include those naturally occurring that result from modification by enzymes that modify nucleotides, such as methyltransferases. Modified nucleotides also include synthetic or non-naturally occurring nucleotides. Synthetic or non-naturally occurring modifications in nucleotides include those with 2' modifications, e.g., 2'-O-methyl, 2'-methoxyethoxy, 2'-fluoro, 2'-hydroxyl (RNA), 2'-allyl, 2'-O-[2-(methylamino)-2-oxoethyl], 4'-thio, 4'-CH₂—O-2'-bridge, 4'-(CH₂)₂—O-2'-bridge, and 2'-O—(N-methylcarbamate) or those comprising base analogs.

By "nucleotide adduct" is meant a moiety that is bound covalently or otherwise fixed to a standard nucleotide base.

By "nicking agent" is meant a chemical entity capable of recognizing and binding to a specific structure in double stranded nucleic acid molecules and breaking a phosphodiester bond between adjoining nucleotides on a single strand upon binding to its recognized specific structure, thereby creating a free 3'-hydroxyl group on the terminal nucleotide preceding the nick site. In preferred embodiments, the 3' end can be extended by an exonuclease deficient polymerase. Exemplary nicking agents include nicking enzymes, RNAAzymes, DNAzymes, and transition metal chelators.

By "palindromic" is meant nucleic acid sequences that are identical or substantially identical when read from 5' to 3' on one strand or 5' to 3' on the complementary strand. A perfect palindrome refers to a sequence having two adjacent sub-

sequences, such that when one subsequence is read from the 5' to 3' direction, it is identical to the other subsequence read from the 3' to 5' direction.

By "polymerase-arresting molecule" is meant a moiety associated with a polynucleotide template/primer that prevents or significantly reduces the progression of a polymerase on the polynucleotide template. Preferably, the moiety is incorporated into the polynucleotide. In one preferred embodiment, the moiety prevents the polymerase from progressing on the template.

By "polymerase extension" is meant the forward progression of a polymerase that matches incoming monomers to their binding partners on a template polynucleotide.

As used herein, "primer-dimer" is meant a dimer of two monomer oligonucleotide primers. In the oligonucleotide primers of the invention, the 5' tail regions of monomer primers dimerize.

By "semi-quantitative" is meant providing an estimate of relative quantity based on an internal control.

By "specific product" is meant a polynucleotide product resulting from the hybridization of primer oligonucleotides to a complementary target sequence and subsequent polymerase mediated extension of the target sequence.

By "substantially isothermal condition" is meant at a single temperature or within a narrow range of temperatures that does not vary significantly. In one embodiment, a reaction carried out under substantially isothermal conditions is carried out at a temperature that varies by only about 1-5° C. (e.g., varying by 1, 2, 3, 4, or 5 degrees). In another embodiment, the reaction is carried out at a single temperature within the operating parameters of the instrument utilized.

By "quantity threshold method" is meant providing an estimate of quantity based on either exceeding or not exceeding in quantity a comparative standard.

By "reference" is meant a standard or control condition. As is apparent to one skilled in the art, an appropriate reference is where an element is changed in order to determine the effect of the element.

By "reverse transcriptase" is meant an enzyme that replicates a primed single-stranded RNA template strand into a complementary DNA strand in the presence of deoxyribonucleotides and permissive reaction medium comprising, but not limited to, a buffer (pH 7.0-9.0), sodium and/or potassium ions and magnesium ions. As is apparent to one skilled in the art, concentration and pH ranges of a permissive reaction media may vary in regard to a particular reverse transcriptase enzyme. Examples of suitable "reverse transcriptases" well known in the art, but not limited to, are MmLV reverse transcriptase and its commercial derivatives "Superscript I, II and III" (Life Technologies), "MaxiScript" (Fermentas), RSV reverse transcriptase and its commercial derivative "OmniScript" (Qiagen), AMV reverse transcriptase and its commercial derivative "Thermoscript" (Sigma-Aldrich).

By "subject" is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline.

By "target nucleic acid molecule" is meant a polynucleotide to be analyzed. Such polynucleotide may be a sense or antisense strand of the target sequence. The term "target nucleic acid molecule" also refers to amplicons of the original target sequence.

Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3,

4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.

Unless specifically stated or obvious from context, as used herein, the term "or" is understood to be inclusive. Unless specifically stated or obvious from context, as used herein, the terms "a", "an", and "the" are understood to be singular or plural.

Unless specifically stated or obvious from context, as used herein, the term "about" is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.

The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic diagram illustrating the design of candidate assays for Ebola virus (EBOV). Assays 1 and 2 were tested for their ability to detect an EBOV polynucleotide (SEQ ID NO: 51).

FIG. 2 shows the various probes and primers tested (SEQ ID NOS: 52-65, respectively, in order of appearance), as well as the Ebola gBlock sequence used in assay development (SEQ ID NO: 66). A gBlock is a synthetic, double-stranded fragment of DNA ranging in size from 100 bp to 1000 bp that is entirely assembled in-vitro from synthetic single-stranded oligonucleotides and which represents a sequence-verified synthetic block of genomic DNA. Unless specifically stated or obvious from context, as used herein, the "gBlock®" is used as a synthetic target nucleic acid whenever a native target sequence or target genome is not available and/or not useful. Sequence-verified blocks of genomic DNA for any target sequence can be procured as a custom-order service from IDT Technologies Inc. (1710 Commercial Park, Coralville, Iowa 52241, USA) and the term "gBlock®" is a registered trademark of that company.

FIG. 3A-3X show amplification results obtained with Assay 1 and Assay 2.

FIG. 4 shows detection of Ebola virus in a background of total human RNA in a one-step assay.

FIG. 5 shows detection of synthetic Ebola virus RNA in a background of total human RNA in a one-step assay.

FIGS. 6A-6C provide flow charts illustrating sample processing for use in an amplification and detection instrument, including, for example, a hand-held device. FIG. 6A indicates that a stabilization/lysis reagent (e.g., Guanidine isothiocyanate (GITC)) is lyophilized onto the inside of the capillary tube. FIG. 6B illustrates use of a paper impregnated with lyophilized GITC and buffer (e.g., Whatman™ FTATM Elute Cards). FIG. 6C depicts a lyophilized assay procedure in multiplex (e.g., an 8-well strip) or single tube.

FIGS. 7A and 7B show sample preparation methods. FIG. 7A depicts sample preparation from swab samples. FIG. 7B depicts sample preparation from a blood sample.

FIG. 8 is a graph showing results obtained in a one-step reaction process where the reverse transcriptase and polymerase are included in a single reaction.

FIG. 9 is a graph showing results obtained in a two-step reaction process where the reverse transcriptase reaction is carried out at room temp or 56° C. and the cDNA is transferred to a second tube where the amplification reaction is carried out at 56° C.

FIG. 10 is a graph showing RT at 56° C., DNAble at 56° C. on 1×10^4 copies.

FIGS. 11A and 11B show the detection of a target RNA in a sample containing total cellular RNA. FIG. 11A is a graph showing detection of RPPH1 (RNase P RNA Component) in a 2-step reaction. FIG. 11B is a graph showing detection of RPPH1 in a 1-step reaction.

FIG. 12 is a graph showing the detection of Zaire Ebola in a crude blood preparation in a 1-step reaction.

FIG. 13 is a graph depicting that the Zaire Ebola assay specifically detects Zaire Ebola Mayinga but not Sudan Ebola Boniface.

FIG. 14 are graphs depicting instrument comparison for the detection of various dilutions of Zaire Ebolavirus Mayinga.

FIGS. 15A-15D depict the limit of detection of the Ebola virus assay. FIG. 15A is a graph depicting detection in samples containing 100 copies of Ebola virus target RNA. FIG. 15B is a graph depicting detection in samples containing 50 copies of Ebola virus target RNA. FIG. 15C is a graph depicting detection in samples containing 25 copies of Ebola virus target RNA. FIG. 15D is a graph depicting detection in samples containing 12 copies of Ebola virus target RNA.

FIGS. 16A and 16B show detection of human immunodeficiency virus (HIV) in a one-step assay. FIG. 16A is an amplicon map showing sequences used in the design of assay primers and probes (SEQ ID NOS: 67-68, respectively, in order of appearance). Population sequence variations in forward and reverse primers are indicated (SEQ ID NOS: 6-9, 43 and 10, respectively, in order of appearance). External primer sequence is specific to HIV subtype C (for the purified RNA sample used). FIG. 16B shows real-time target specific amplification of HIV in a one-step assay. Cp values are shown across 5 technical replicates for each copy number (10 μL reactions). Copies of purified HIV RNA (subtype C) (SeraCare) are indicated, as quantified by COBAS TaqMan HIV-1 v2.0 test FIGS. 17A and 17B show detection of dengue virus type 4 (DENV-4) in a one-step assay. FIG. 17A is an amplicon map showing sequences used in the design of assay primers and probes (SEQ ID NOS: 69-70, respectively, in order of appearance). Population sequence variations in reverse primers are indicated (SEQ ID NOS: 11-13, 44 and 14, respectively, in order of appearance). FIG. 17B shows real-time target specific amplification of DENV-4 in a one-step assay. Cp values are shown across 4 technical replicates (10 μL reactions). Isolated total RNA (20 pg) from cell culture included both viral and host cell RNA and total copy number of viral RNA was unknown.

FIGS. 18A and 18B show detection of influenza B in a one-step assay. FIG. 18A is an amplicon map showing sequences used in the design of assay primers and probes (SEQ ID NOS: 71-73, respectively, in order of appearance). Population sequence variations in forward and reverse primers and external primers are indicated (SEQ ID NOS: 15-20, 45, 46 and 21, respectively, in order of appearance). FIG. 18B shows real-time target specific amplification of influenza B in a one-step assay. Cp values are shown across 4 technical replicates (10 μL reactions). Isolated total RNA (20 pg) from cell culture included both viral and host cell RNA

and total copy number of viral RNA was unknown. Samples 1 and 2 are different viral isolates.

FIGS. 19A and 19B show detection of Bovine Viral Diarrhea Virus Genotype 1 (BVDV1) in a one-step assay. FIG. 19A is an amplicon map showing sequences used in the design of assay primers and probes (SEQ ID NOS: 74-75, respectively, in order of appearance). Population sequence variations in forward primers are indicated (SEQ ID NOS: 22-24, 47 and 25, respectively, in order of appearance). FIG. 19B shows real-time target specific amplification of Bovine Viral Diarrhea Virus Genotype 1 (BVDV1) in a one-step assay. Technical replicates (10 µL reactions) are shown. Isolated total RNA (20 pg) from cell culture included both viral and host cell RNA and total copy number of viral RNA was unknown. Cell culture crude lysate was used undiluted and at 1:100 dilution.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods for rapidly identifying an RNA viral infection (e.g., Ebola virus) using an isothermal nucleic acid amplification reaction that can be carried out on extracted RNA in the context of a crude biological sample.

Ebola is clinically difficult to diagnose and to distinguish. A rapid and reliable laboratory diagnosis is required in suspected cases of Ebola. The present invention provides such an assay. The invention is based, at least in part, on the discovery that an Ebola viral polynucleotide (e.g., RNA) can be detected in a one-step or two-step real-time reverse transcription-isothermal amplification assay for an Ebola viral polynucleotide.

Ebola Virus

The Ebola viruses are filamentous viruses with a negative-sense RNA genome. Virions are cylindrical/tubular containing a viral envelope, matrix, and nucleocapsid components, approximately 80 nm in diameter and 800-1000 nm in length. Ebola is classified as a biosafety level 4 agent. The period of incubation for the Ebola virus hemorrhagic fever is usually 5-18 days, but may extend from 2-21 days depending on the viral strain contracted and the condition of the infected individual. The Ebola virus acts quickly. Initial symptoms of Ebola resemble symptoms of malaria, influenza, or various bacterial infections. Therefore, days or weeks may pass before Ebola is diagnosed. Secondary symptoms include diarrhea, red eyes, vomiting blood, bleeding from the nose, mouth or rectum, and even bleeding in the brain. About 50%-90% of those infected with the virus go on to systemic multi-organ failure and death.

Patient Diagnosis and Monitoring

The condition of a patient as having or not having Ebola can be diagnosed by detecting an Ebola viral polynucleotide in a biological sample and correlating this detection with the existence of an Ebola infection. In one embodiment, a disease state of a patient having Ebola virus can be detected using the methods and compositions of the invention to detect Ebola virus in a biological sample of the patient. Exemplary biological samples include body fluids (e.g., saliva, sweat, tears, fluids accumulating in a bodily cavity, urine, ejaculate, vaginal secretion, cerebrospinal fluid, lymph, feces, sputum, decomposition fluid, vomit, sweat, breast milk, blood, serum, and plasma), tissue extracts, culture media (e.g., a liquid in which a cell, such as a pathogen cell, has been grown), or environmental samples obtained, for example, from a material that may be contaminated with a biological fluid of a subject.

In one embodiment, the invention provides a method of amplifying a target polynucleotide in a reverse transcriptase and nicking amplification reaction involving:

(a) contacting a target RNA molecule (e.g., Ebola virus genome) with a reverse transcriptase (RT) primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA; and

(b) contacting the cDNA with forward and reverse primers carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically bind the cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA, thereby generating amplicons.

In one particular embodiment, the invention provides a method of detecting an Ebola virus in a biological sample involving:

(a) contacting a sample with an agent capable of extracting an Ebola RNA present in the sample (e.g., SDS, sodium lauryl sulfate, guanidium isothio-cyanate, guanidium hydrochloride) and an agent capable of stabilizing Ebola RNA against degradation (e.g., SDS, RNAase inhibitors, antibodies against RNase, competitive RNase inhibitor, or an agent capable of reversibly chemically modifying RNA in situ (e.g., acetic anhydride);

(b) contacting the Ebola RNA with a RT primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA copy of the Ebola RNA;

(c) contacting the Ebola cDNA with forward and reverse primers carrying at least one nicking enzyme recognition sequence within their respective 5'-terminal regions which specifically binds the Ebola cDNA with their respective 3'-terminal regions in the presence of a nicking enzyme, dNTPs, and a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA, thereby generating amplicons; and

(d) detecting the amplicons, wherein the presence of an Ebola virus amplicon detects an Ebola virus infection in the sample and failure to detect the amplicon indicates the absence of an Ebola virus infection.

In one embodiment, the methods of the invention described herein provide results in no longer than 5, 7, 10, 15, 20, 25 or 30 minutes. Advantageously, the methods of the invention can be applied to RNAs extracted—but not purified or isolated from—a crude biological sample (e.g., saliva, sweat, tears, fluids accumulating in a bodily cavity, urine, ejaculate, vaginal secretion, cerebrospinal fluid, lymph, feces, sputum, decomposition fluid, vomit, sweat, breast milk, blood, serum, and plasma). Because the test is carried out on-site (e.g., in a hospital, clinic, physician's office, urgent care center, home, community center, airport, ship (e.g., cruise ship or other vessel used for transporting humans or animals), train or train station, or point of entry into a nation (e.g., border crossing). Advantageously, in one embodiment, the testing is carried out in a portable battery powered device (e.g., Amplifire).

In one embodiment, the RNA is extracted from the biological sample using a chaotropic salt (e.g., GITC, GHCL) or a detergent (e.g., SDS, Tween and triton). If desired, an RNase inhibitor is added before, during, or after the extraction step.

In another embodiment, the reverse transcriptase enzyme and the strand-displacement DNA polymerase are one and the same.

33

In another embodiment, no separate primer is required or the RT primer same as forward and/or reverse primers.

In another embodiment, the invention provides for detection of an EBOV or other viral amplicon using a Dual FRET molecular beacon for mRNA detection (e.g., as described by Santagelo, Nucleic Acids Res. 2004; 32(6): e57), turbidity release of pyrophosphate from DNTPs and precipitation with magnesium or calcium.

In another embodiment, the invention provides for detection of an Ebola viral amplicon using a lateral flow device where the Ebola virus amplicon comprises one member of a pair of binding partners (e.g., biotin and streptavidin) and the lateral flow device comprises the other member of the pair, and provides a means of detection (e.g., colorimetric) for the amplicon.

Reverse transcriptases used in the methods of the invention include, but are not limited to, a Maloney murine leukemia virus reverse transcriptase enzyme (MMLV RT) and derivatives or variants thereof comprising a mutation relative to wild-type MMLV RT; avian myeloblastosis virus (AMV RT) and derivatives or variants thereof comprising a mutation relative to that render them thermostable, Rous sarcoma virus (RSV) RT (e.g., Omniscript, Qiagen) and derivatives or variants thereof, and a pyroreverse transcriptase (e.g., Pyroscript luceigen) and derivatives or variants thereof, an RT described in U.S. Pat. No. 7,094,539, which is incorporated herein by reference in its entirety, or a commercially available High-fidelity Thermostable Reverse Transcriptase for RT PCR and Transcriptome analysis (e.g., Lucigen).

In one embodiment, at 56 degrees the primer and RNA or amplicon forms a stable complex. In one embodiment, more than 50% of primer sequence must be complementary to the target nucleic acid molecule. In one embodiment, the rT primer is about 18 bases in length. In one embodiment, the reverse transcriptase (RT) primer is a random primer (e.g., in each sequence position any one of four bases is possible, any of these primers hybridize with the target). In one embodiment, the rT primer is a hexamer, heptamer, octamer, or nonamer.

In one embodiment, the RT is derived from *Geobacillus stearothermophilus*, is M-MLV RT (i.e. Superscript/LifeTech, Maxima/Thermo-Fisher) and/or mutants/derivatives thereof, AMV RT (i.e. Thermoscript/LifeTech) and/or mutants/derivatives thereof, RSV RT (i.e. OmniScript/Qia-

gen) and/or mutants/derivatives thereof.

Methods of the invention provide a high degree of sensitivity. In one embodiment, EBOV is detected at 1×10^3 , 1×10^4 , 1×10^5 , 1×10^6 , 1×10^7 , or 1×10^8 copies of EBOV RNA per ml in blood. In another embodiment, the invention provides for the detection of between about 1-10 (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) copies of RNA per reaction.

EBOV (or other virus) is detected by obtaining a sample (e.g., biological sample) from a subject having or suspected of having an EBOV infection or by obtaining an environmental sample from a home, hospital room, means of transportation that is or is suspected of being contaminated with an Ebola virus or EBOV-containing biological fluid.

In one embodiment, a biological sample is obtained by obtaining a blood sample, mucous sample, feces, or by swabbing an affected tissue. Swabs can be taken from the nose, throat, eyes, or other mucosal membrane. At necropsy, samples can be collected from blood or tissues of the deceased.

Advantageously, the diagnostic methods of the invention are suitable for use in virtually any setting. EBOV is endemic in much of west Africa including Liberia, Nigeria,

34

Guinea, and Sierra Leone. Many areas within west Africa lack access to basic medical facilities and diagnostic laboratories. The present invention can be used in a battery powered hand held device that is well-suited to testing of biological samples in areas where access to electricity is non-existent. Moreover, the present methods are simple enough that they can easily be carried out by health workers who have limited training in the use of diagnostic technologies.

The present invention provides methods for rapidly identifying an EBOV or other viral infection using an isothermal nucleic acid amplification reaction that can be carried out on extracted RNA in the context of a crude biological sample.

Early in the disease process, only low levels of virus are present in a biological sample of the subject, such as a blood sample. If desired, the virions present in the sample are enriched using methods known in the art, for example, by precipitating the virions from the sample by adding PEG and NaCl then filtering virions out of the sample using a nanopore filter, thereby providing for early detection of a viral polynucleotide.

The disease state or treatment of a subject that may have been exposed to Ebola virus (or other virus) can be monitored using the methods and compositions of the invention.

In one embodiment, the detection of an Ebola virus polynucleotide (or other virus polynucleotide) is present in a bodily fluid, such as saliva, sweat, tears, fluids accumulating in a bodily cavity, urine, ejaculate, vaginal secretion, cerebrospinal fluid, lymph, feces, sputum, decomposition fluid, vomit, sweat, breast milk, blood, serum, and plasma, is monitored. Such monitoring may be useful, for example, in diagnosing the subject as having Ebola (or other virus), or determining the efficacy of a particular drug in a subject or in assessing disease progression.

35 Nucleic Acid Amplification Methods

Nucleic acid amplification technologies have provided a means of understanding complex biological processes, detection, identification, and quantification of pathogenic organisms, such as EBOV or other RNA viruses. The present invention provides for the detection of an EBOV negative-sense RNA genome in a biological sample by using reverse transcriptase to synthesize an EBOV DNA molecule from the RNA genome and then amplifying the DNA in an isothermal nicking amplification reaction.

The polymerase chain reaction (PCR) is a common thermal cycling dependent nucleic acid amplification technology used to amplify DNA consisting of cycles of repeated heating and cooling of the reaction for DNA melting and enzymatic replication of the DNA using a DNA polymerase.

Real-Time quantitative PCR (qPCR) is a technique used to quantify the number of copies of a given nucleic acid sequence in a biological sample. Currently, qPCR utilizes the detection of reaction products in real-time throughout the reaction and compares the amplification profile to the amplification of controls which contain a known quantity of nucleic acids at the beginning of each reaction (or a known relative ratio of nucleic acids to the unknown tested nucleic acid). The results of the controls are used to construct standard curves, typically based on the logarithmic portion of the standard reaction amplification curves. These values are used to interpolate the quantity of the unknowns based on where their amplification curves compared to the standard control quantities.

In addition to PCR, non-thermal cycling dependent amplification systems or isothermal nucleic acid amplification technologies exist including, without limitation: Nicking Amplification Reaction, Rolling Circle Amplification

(RCA), Helicase-Dependent Amplification (HDA), Loop-Mediated Amplification (LAMP), Strand Displacement Amplification (SDA), Transcription-Mediated Amplification (TMA), Self-Sustained Sequence Replication (3SR), Nucleic Acid Sequence Based Amplification (NASBA), Single Primer Isothermal Amplification (SPIA), Q- β Replicase System, and Recombinase Polymerase Amplification (RPA).

Isothermal nicking amplification reactions have similarities to PCR thermocycling. Like PCR, nicking amplification reactions employ oligonucleotide sequences which are complementary to a target sequences referred to as primers. In addition, nicking amplification reactions of target sequences results in a logarithmic increase in the target sequence, just as it does in standard PCR. Unlike standard PCR, the nicking amplification reactions progress isothermally. In standard PCR, the temperature is increased to allow the two strands of DNA to separate. In nicking amplification reactions, the target nucleic acid sequence is nicked at specific nicking sites present in a test sample. The polymerase infiltrates the nick site and begins complementary strand synthesis of the nicked target nucleotide sequence (the added exogenous DNA) along with displacement of the existing complimentary DNA strand. The strand displacement replication process obviates the need for increased temperature. At this point, primer molecules anneal to the displaced complementary sequence from the added exogenous DNA. The polymerase now extends from the 3' end of the template, creating a complementary strand to the previously displaced strand. The second oligonucleotide primer then anneals to the newly synthesized complementary strand and extends making a duplex of DNA which includes the nicking enzyme recognition sequence. This strand is then liable to be nicked with subsequent strand displacement extension by the polymerase, which leads to the production of a duplex of DNA which has nick sites on either side of the original target DNA. Once this is synthesized, the molecule continues to be amplified exponentially through replication of the displaced strands with new template molecules. In addition, amplification also proceeds linearly from each product molecule through the repeated action of the nick translation synthesis at the template introduced nick sites. The result is a very rapid increase in target signal amplification; much more rapid than PCR thermocycling, with amplification results in less than ten minutes.

Nicking Amplification Assays

The invention provides for the detection of EBOV target nucleic acid molecules amplified in an isothermal nicking amplification assay.

Polymerases useful in the methods described herein are capable of catalyzing the incorporation of nucleotides to extend a 3' hydroxyl terminus of an oligonucleotide (e.g., a primer) bound to a target nucleic acid molecule and/or a 3' hydroxyl terminus at a nick site in a double-stranded DNA

molecule in conjunction with strand displacement activity. Such polymerases also lack or have substantially reduced 5'-3' exonuclease activity and may include those that are thermophilic. DNA polymerases useful in methods involving primers having 2'-modified nucleotides in the primer region comprising the six 3'-terminal nucleotides include derivatives and variants of the DNA polymerase I isolated from *Bacillus stearothermophilus*, also classified as *Geobacillus stearothermophilus*, and from closely related bacterial strains, isolates and species comprising the genus *Geobacillus*, which lack or have substantially reduced 5'-3' exonuclease activity and have strand-displacement activity. Exemplary polymerases include, but are not limited to, the large fragments of Bst DNA polymerase I, Gst DNA polymerase I, and Gka DNA polymerase I.

A nicking agent useful in methods described herein is a chemical entity capable of recognizing and binding to a specific structure in double stranded nucleic acid molecules and breaking a phosphodiester bond between adjoining nucleotides on the top strand with a substantially higher rate than breaking the phosphodiester bond between adjoining nucleotides on the bottom strand upon binding to its recognized specific structure, thereby creating a free 3'-hydroxyl group on the terminal nucleotide preceding the nick site that can be extended by a 5'-3'-exonuclease deficient strand displacement polymerase. In a preferred embodiment of the methods disclosed herein, the top strand phosphodiester bond cleavage rate of the "nicking agent" approaches 100%, while the cleavage rate of the bottom strand phosphodiester bond approaches 0%. Nicking agents useful in methods described herein, can either be enzymes, i.e. self-regenerating catalysts turning over multiple substrate molecules, or non-regenerating catalysts turning over just a single substrate molecule at an equimolar ratio fashion.

A nicking enzyme binds double-stranded DNA and cleaves one strand of a double-stranded duplex. In the methods of the invention, the nicking enzyme cleaves the top stand (the strand comprising the 5'-3' sequence of the nicking agent recognition site). In a particular embodiment of the invention disclosed herein, the nicking enzyme cleaves the top strand only and 3' downstream of the recognition site. In exemplary embodiments, the reaction comprises the use of a nicking enzyme that cleaves or nicks downstream of the binding site such that the product sequence does not contain the nicking site. Using an enzyme that cleaves downstream of the binding site allows the polymerase to more easily extend without having to displace the nicking enzyme. Ideally, the nicking enzyme is functional under the same reaction conditions as the polymerase. Exemplary nicking enzymes include, but are not limited to, N.Bst9I, N.BstSEI, Nb.BbvCI(NEB), Nb.Bpu10I(Fermentas), Nb.BsmI(NEB), Nb.BsrDI(NEB), Nb.BtsI(NEB), Nt.Alwi(NEB), Nt.BbvCI(NEB), Nt.Bpu10I(Fermentas), Nt.BsmAI, Nt.BspD6I, Nt.BspQI(NEB), Nt.BstNBI(NEB), and Nt.CviPII(NEB). Sequences of nicking enzyme recognition sites are provided at Table 1.

TABLE 1

Nicking enzyme recognition sequences	
N.Bst9I	5' -GAGTCNNNNNN↓NN-3' (SEQ ID NO: 28) 3' -CTCAGNNNNNN·NN-5'
N.BstSEI	5' -GAGTCNNNNNN↓NN-3' (SEQ ID NO: 28) 3' -CTCAGNNNNNN·NN-5'

TABLE 1-continued

Nicking enzyme recognition sequences	
Nb.BbvCI (NEB)	5' - CCTCA·GC-3' 3' - GGAGT [↑] CG-5'
Nb.Bpu10I (Fermentas)	5' - CCTNA·GC-3' 3' - GGANT [↑] CG-5'
Nb.BsmI (NEB)	5' - GAATG·CN-3' 3' - CTTAC [↑] GN-5'
Nb.BsrDI (NEB)	5' - GCAATG·NN-3' 3' - CGTTAC [↑] NN-5'
Nb.BtsI (NEB)	5' - GCAGTG·NN-3' 3' - CGTCAC [↑] NN-5'
Nt.AlwI (NEB)	5' - GGATCNNNN↓N-3' (SEQ ID NO: 29) 3' - CCTAGNNNN·N-5'
Nt.BbvCI (NEB)	5' - CC [↓] TCAGC-3' 3' - GG·AGTCG-5'
Nt.Bpu10I (Fermentas)	5' - CC [↓] TNAGC-3' 3' - GG·ANTCG-5'
Nt.BsmAI	5' - GTCTCN↓N-3' 3' - CAGAGN·N-5'
Nt.BspD6I	5' - GAGTCNNNN↓N-3' (SEQ ID NO: 30) 3' - CTCAGNNNN·N-5'
Nt.BspQI (NEB)	5' - GCTCTTCN↓-3' 3' - CGAGAAGN-5'
Nt.BstNBI (NEB)	5' - GAGTCNNNN↓N-3' (SEQ ID NO: 30) 3' - CTCAGNNNN·N-5'
Nt.CviPII (NEB)	5' - ↓CCD-3' 3' - GGH-5'

Nicking enzymes also include engineered nicking enzymes created by modifying the cleavage activity of restriction endonucleases (NEB expressions July 2006, vol 1.2). When restriction endonucleases bind to their recognition sequences in DNA, two catalytic sites within each enzyme for hydrolyzing each strand drive two independent hydrolytic reactions which proceed in parallel. Altered restriction enzymes can be engineered that hydrolyze only one strand of the duplex, to produce DNA molecules that are "nicked" (3'-hydroxyl, 5'-phosphate), rather than cleaved. Nicking enzymes may also include modified CRISPR/Cas proteins, Transcription activator-like effector nucleases (TALENs), and Zinc-finger nucleases having nickase activity.

A nicking amplification reaction typically comprises nucleotides, such as, for example, dideoxyribonucleoside triphosphates (dNTPs). The reaction may also be carried out in the presence of dNTPs that comprise a detectable moiety including but not limited to a radiolabel (e.g., ³²P, ³³P, ¹²⁵I, ³⁵S) an enzyme (e.g., alkaline phosphatase), a fluorescent

label (e.g., fluorescein isothiocyanate (FITC)), biotin, avidin, digoxigenin, antigens, haptens, or fluorochromes. The reaction further comprises certain salts and buffers that provide for the activity of the nicking enzyme and polymerase.

Advantageously, the nicking amplification reaction is carried out under substantially isothermal conditions where the temperature of the reaction is more or less constant during the course of the amplification reaction. Because the temperature does not need to be cycled between an upper temperature and a lower temperature, the nicking amplification reaction can be carried out under conditions where it would be difficult to carry out conventional PCR. Typically, the reaction is carried out at about between 35 C and 90 C (e.g., about 35, 37, 42, 55, 60, 65, 70, 75, 80, or 85° C.). Advantageously, it is not essential that the temperature be maintained with a great degree of precision. Some variability in temperature is acceptable.

Sets of primers for amplification reactions are selected as having ΔΔG's≤-15, -16, 17, -18, -19, -20, -25, -30

kcal/mole or more. The performance characteristics of amplification reactions may be altered by increasing the concentration of one or more oligonucleotides (e.g., one or more primers and/or probes) and/or their ratios. High concentrations of primers also favor primer-dimer formation. In various embodiments, concentration of a primers is 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 nM or more. Melt temperature (Tm) and reaction rate modifiers may also be used to lower the melting temperature of the oligonucleotides, such as (but not limited to) ethylene glycol and glycerol. In addition, DNA polymerase reaction rate modifiers (such as dNTP and magnesium concentration) may be used to alter the reaction rate to lead to a greater quantification precision. In particular embodiments, the 5' tail sequences of the forward and reverse primers have the same nucleic acid sequence.

This invention provides methods of monitoring a nicking amplification reaction in real time, including for example utilizing the amplification strategy as described herein. In one embodiment, quantitative nucleic acid amplification utilizes target nucleic acids amplification alongside a control amplification of known quantity. The amount of target nucleic acid can be calculated as an absolute quantification or a relative quantification (semi-quantitative) based on the source of the control (exogenous or endogenous control).

Quantification of the unknown nucleotide sequence can be achieved either through comparison of logarithmic threshold amplification of the unknown to a series of known target sequences in either a separate set of reactions or in the same reaction; or as an internal endogenous or exogenous co-amplification product, which produces a threshold value, indicative of either a positive result (if the unknown exceeds the threshold) or negative result (if the unknown does not exceed the threshold).

The invention also provides a method of designing a nicking agent-dependent isothermal strand-displacement amplification assay without experimental screening of a multitude of combinations of candidate forward primers and/or candidate reverse primers. A 35 to 70 bp long region within the target sequence is identified having a 12 to 20 bp sequence in the central portion with a Tm \geq the assay temperature (e.g., ~55° C.). Adjacent sequences 12 bp to 20 bp long immediately downstream and upstream of the 15 to 20 bp long central region are identified, according to the above criteria. The Tm of the chosen double stranded downstream and upstream adjacent sequences deviate from each other by less than $\pm 3^\circ$ C. A target-specific pair of forward and reverse primers are created by attaching a 5'-tail region for a stable dimer-forming primer to the 5'-terminus of the 12-20 base upstream adjacent sequence and to the 5'-terminus of the complementary strand of the 12-20 base downstream adjacent sequence. When combining the forward primer, reverse primer, and a probe, the primer driving the synthesis of the strand complementary to the probe is in excess over the other primer at a molar ratio of about 1.1:1 to 10:1. The combined concentration of a primer in the assay is no higher than 1000 nM. The assay design method can also be used to convert a pre-validated PCR assay for an amplicon \leq 70 bp to a nicking agent-dependent isothermal strand-displacement amplification assay.

Primer Design

Conventional methods for primer design have focused on primer melting temperature, primer annealing temperature, GC (guanine and cytosine) content, primer length, and minimizing interactions of the primer with all but the target nucleic acid (see e.g., [premierbiosoft.com](http://www.premierbiosoft.com)). Contrary to these methods, it has been found that primers that form

stable primer/dimers, expressed in terms of free energy of formation (ΔG), function predictably in nucleic acid amplification reactions. While Free Energy (ΔG) and Melting Temperature (Tm) share primary components Enthalpy (ΔH) and Entropy (ΔS), ΔG and Tm values are derived differently and have no correlative relationship, and the only way to relate a given ΔG with a given Tm value is to explicitly know the value of ΔH and ΔS from which they are derived (Manthey, "mFold, Delta G, and Melting Temperature" ©2005 and 2011 Integrated DNA Technologies). FIGS. 1-11 relate to the design of optimal primers.

The free energy of formation (ΔG) for intermolecular primer structures may be calculated using formulas known in the art. A number of programs are available for determining the formation of various intramolecular and intermolecular primer structures and calculating their ΔG 's, including for example mfold and UNAFold prediction algorithms (see e.g., Markham and Zuker. UNAFold: Software for Nucleic Acid Folding and Hybridization. Bioinformatics: Volume 2, Chapter 1, pp 3-31, Humana Press Inc., 2008; Zuker et al. Algorithms and Thermodynamics for RNA Secondary Structure Prediction: A Practical Guide In RNA Biochemistry and Biotechnology, 11-43, NATO ASI Series, Kluwer Academic Publishers, 1999; M. Zuker. Prediction of RNA Secondary Structure by Energy Minimization. Methods in Molecular Biology, 267-294, 1994; Jaeger et al. Predicting Optimal and Suboptimal Secondary Structure for RNA. In Molecular Evolution: Computer Analysis of Protein and Nucleic Acid Sequences, Methods in Enzymology 183, 281-306, 1990; Zuker. On Finding All Suboptimal Foldings of an RNA Molecule. Science 244, 48-52, 1989). OligoAnalyzer 3.1 is one such implementation of mfold for primer design (idtdna.com). For example, with reference to OligoAnalyzer 3.1, ΔG calculations may be performed using the following parameters: Target Type: DNA; Oligo Concentration 0.25 μ M; Na⁺ Concentration: 60 mM; Mg⁺⁺ Concentration: 15 mM; and dNTPs Concentration: 0.3 mM. 3' Recognition Region

The invention provides a primer having a 3' recognition sequence whose primer-target formation is stable ($\Delta G \leq$ about -20 kcal/mol or more) and has the potential to enhance nucleic acid amplification reaction performance. The 3' recognition region specifically binds to the nucleic acid molecule, for example a complementary sequence of the nucleic acid molecule. In certain embodiments, the 3' recognition region has a sequence that is complementary to 12, 13, 14, 15, 16, 17, 18, 19, or 20 bases or more of a nucleic acid sequence. In particular embodiments, the 3' recognition region comprises one or more inosine bases. In specific embodiments, the 3' recognition region comprises no more than 2/12 inosines. In various embodiments, the primer-target melting temperature is equal to or greater than 8° or 6° C. below the reaction or extension temperature of the assay (Tm \geq assay temperature-8°). In particular embodiments, the 3' recognition sequence comprises 12-20, 12-17, or 12-14 bases. In particular embodiments, the primer-target formation is more stable than self dimer formation (e.g., $\Delta \Delta G \leq$ about -15, -16, -17, -18, -19, -20 kcal/mol or more). Preferably, the 3' recognition sequence does not contain self-complementary sequences, short inverted repeats (e.g., >4 bases/repeat), or sequences that otherwise promote intramolecular interactions, which have the potential to interfere with primer-target annealing.

In one embodiment, a primer is designed having a Tm of 56° C. with 4 sequence specific bases at the end of the primer that may not contribute to annealing. In one embodiment, the primer is a 16, 17, 18, 19, 20 or 21-mer.

41

In particular, a primer of the invention having a 3' recognition sequence is useful in nicking amplification assays. Additionally, the EBOV or other viral target specific 3' recognition region comprises one or more 2' modified nucleotides (e.g., 2'-O-methyl, 2'-methoxyethoxy, 2'-fluoro, 2'-alkyl, 2'-allyl, 2'-O-[2-(methylamino)-2-oxoethyl], 2'-hydroxyl (RNA), 4'-thio, 4'-CH₂-O-2'-bridge, 4'-(CH₂)₂-O-2'-bridge, and 2'-O-(N-methylcarbamate)). Without being bound to theory, it is hypothesized that incorporating one or more 2' modified nucleotides in the recognition regions reduces or eliminates intermolecular and/or intramolecular interactions of primers/templates (e.g., primer-dimer formation), and, thereby, reduces or eliminates the background signal in isothermal amplification. The 2' modified nucleotide preferably has a base that base pairs with the target sequence. In particular embodiments, two or more 2' modified nucleotides (e.g., 2, 3, 4, 5 or more 2' modified nucleotides) in the EBOV or other viral target specific recognition region are contiguous (e.g., a block of modified nucleotides). In some embodiments, the block of 2' modified nucleotides is positioned at the 3' end of the target specific recognition region. In other embodiments, the block of 2' modified nucleotides is positioned at the 5' end of the EBOV or other viral target specific recognition region. When the block of 2' modified nucleotides is positioned at the 5' end of the target specific recognition region, the 2' modified nucleotides may be separated from the nick site by one or more non-modified nucleotides (e.g., 2, 3, 4, 5 or more 2' unmodified nucleotides). Applicants have found that positioning of one or more 2' modified nucleotides or of a block of 2' modified nucleotides alters the kinetics of amplification. When the one or more 2' modified nucleotides or block of 2' modified nucleotides are positioned at or near the 5' end of the recognition region or proximal to the nick site, real-time amplification reactions showed decreased time to detection. Additionally, the signal curve is contracted and the slope of the curve shifted.

In a related embodiment, ratios of a primer having one or more 2' modified nucleotides can be used to alter the time-to-detection and/or the efficiency of the reaction for the 'tuning' of reactions, resulting in a predictable control over reaction kinetics. Increasing the ratio of primer having one or more 2' modified nucleotides at the 3' end of the recognition sequence to primer having one or more 2' modified nucleotides at the 5' end of the recognition sequence contracted the signal curve and shifted the slope of the curve. It is advantageous to be able to "tune" a reaction providing a means to manipulate both the time-to-detection as well as the efficiency of the reaction. Relative quantification using an internal control requires that two important conditions be met. First, it is beneficial to be able to modify a reaction's time-to-detection creating a non-competitive reaction condition. Thus, by affecting the control reaction to be detectable at a later time-point (relative to the target of interest) the control reaction does not out-compete the specific target of interest even when the target of interest is in low initial abundance. Second, to ensure a true relative abundance calculation, it is required that the control and specific target reactions have matched efficiencies. By controlling the efficiency of each reaction using a "tuning" condition enables reactions to be matched allowing for satisfactory relative quantification calculations. Tuning the reactions can be used to match efficiencies of target nucleic acid amplification and reference nucleic amplification (e.g., internal standard) in quantitative PCR (qPCR). Additionally, amplification curves of the target nucleic acid and the internal standard may be altered so time of detection of their amplification products

42

are separated, while providing the same efficiency for target nucleic acid amplification and internal standard amplification. Through the use of specific combinations and ratios of oligonucleotide structures within a reaction it is possible to create conditions which enable tuned reaction performance.

5 Tail Dimerization Region

The invention provides a primer having a 5' tail region capable of self-dimerization that enhances EBOV or other viral nucleic acid amplification reaction performance. Without being bound to theory, in a nucleic acid amplification reaction the primer anneals to the target nucleic acid as a primer-dimer. For example, nicking amplification primers have a nicking agent recognition site present at the 5' end that is unrelated to the binding specificity of the primer for the target recognition sequence. Non-specific background products from non-specific primer interactions have the potential to sequester reaction components that would otherwise have been utilized for the amplification of the specific product. In various embodiments, homodimer formation is stable (e.g., $\Delta G \leq$ about -30, -35, -40, -45, -50, -55, -60 kcal/mol or more). In various embodiments, the homodimer has a melting temperature higher than the extension reaction temperature. In particular embodiments, the 5' tail region has a sequence that is a palindrome. In further embodiments, the 5' tail region is at least 12 bases (e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 bases) in length. In additional embodiments, the 5' tail region has a GC content of 80-90%. In certain embodiments, homodimer formation is more stable than formation of other less stable primer dimer conformations formation (e.g., $\Delta G \leq$ about -12, -13, -14, -15, -16, -17, -18, -19, -20, -25, -30, -35, -40 kcal/mol or more).

In particular, a primer of the invention having a 5' tail sequence is useful in nicking amplification reactions. For use in nicking amplification reactions, the 5' tail region comprises one or more nicking agent recognition sites and the 5' tail region has a symmetrically inverted sequence. In particular embodiments, the 5' tail region contains an even number of nucleotides (e.g., 22, 24 nucleotides). The nick site is designed to be positioned between the nucleotide at the 3' end of the 5' tail region and the nucleotide at the 5' end of the 3' recognition region. Without being bound to theory, the nicking enzyme does not cleave at the nick site when the 3' recognition is single-stranded. However, cleavage at the nick site occurs when the 3' recognition region is double stranded (e.g., when the primer is incorporated into a double-stranded target nucleic acid molecule during the course of the nucleic acid amplification reaction).

In various embodiments, the 5' tail sequence comprises from 5' to 3' an inverted nicking enzyme recognition sequence that is operatively linked to a palindromic sequence (or self-complementary sequence) that is operatively linked to a nicking enzyme recognition sequence. In certain embodiments, the spacer region is an even number of nucleotides (e.g., 2, 4, 6, etc.). Exemplary 5' tails based on the Nt.BstNBI nicking enzyme recognition sequence (5'-GAGTC-3') having a 2, 4, and 6 nucleotide spacers comprise a nucleic acid sequences according to the formula below:

(SEQ ID NO: 31)

5' - GACTCN₁N₁, GAGTC - 3'

(SEQ ID NO: 32)

5' - GACTCN₂N₁N₁, N₂, GAGTC - 3'

(SEQ ID NO: 33)

5' - GACTCN₃N₂N₁N₁, N₂, N₃, GAGTC - 3'

where "N" is any nucleotide (e.g., having an adenine (A), thymine (T), cytosine (C), or guanine (G) nucleobase), and N₁ is complementary to N₁, N₂ is complementary to N₂, and N₃ is complementary to N₃, etc.

Exemplary 5' tail region sequences 24 nucleotides in length having a Nt.BstNBI recognition sequence can be generated based on the following template 5'-NNNNNGACTCBBBBBNGAGTCNNNN-3' (SEQ ID NO: 34). Based on this template, there are 537,824 5' tail sequences having the following properties: ΔG=-48 Kcal/mole to -62 kcal/mole; ΔΔG<-40 kcal/mole; and GC content 68% to 84%. Of these, 1050 selected sequences are provided, representing 0.2% of the entire sequence space (248,832). Exemplary 5' tail region sequences 22 nucleotides in length having a Nt.BstNBI recognition sequence and based on the following template 5'-NNNNNGACTCBBBBB-GAGTCNNNN-3' (SEQ ID NO: 35). Based on this template, there are 248,832 5' tail sequences having the following properties: ΔG=-47 Kcal/mole to -55 kcal/mole; ΔΔG<-40 kcal/mole; and GC content 72% to 82%. Of these, 200 selected sequences are provided, representing 0.08% of the entire sequence space (248,832).

Target Nucleic Acid Molecules

Methods and compositions of the invention are useful for the amplification and/or identification of an EBOV or other viral nucleic acid molecule in a test sample. The target sequences are amplified from virtually any samples that comprises a viral nucleic acid molecule, including a EBOV nucleic acid molecule. In particular, the methods and compositions of the invention are useful for the amplification and/or identification of RNA viruses. In addition to EBOV, exemplary RNA viruses that can be detected using the methods and compositions of the invention include, without limitation, Human Immunodeficiency Virus (HIV), Dengue virus, influenza virus (e.g., influenza B), Bovine Viral Diarrhea virus (e.g., BVDV Genotype 1), Yellow Fever virus, West Nile Virus, Hepatitis C, Lassa virus, Flaviviridae, Arenaviridae, and single-stranded RNA viruses.

Exemplary test samples include body fluids (e.g. saliva, sweat, tears, fluids accumulating in a bodily cavity, urine, ejaculate, vaginal secretion, cerebrospinal fluid, lymph, feces, sputum, decomposition fluid, vomit, sweat, breast milk, blood, serum, and plasma), tissue extracts, culture media (e.g., a liquid in which a cell, such as a pathogen cell, has been grown), environmental samples, agricultural products or other foodstuffs, and their extracts, and DNA identification tags. If desired, the sample is purified prior to inclusion in a nicking amplification reaction using any standard method typically used for isolating a nucleic acid molecule from a biological sample.

In one embodiment, primers amplify a target nucleic acid of a pathogen to detect the presence of EBOV or other virus in a sample. For environmental applications, test samples may include water, liquid extracts of building materials (e.g., drywall, ceiling tiles, wall board, fabrics, wall paper, and floor coverings) that may have been exposed to a subject infected with EBOV, environmental swabs, or any other sample.

Methods of the invention provide for the detection of 1×10³, 1×10⁴, 1×10⁵, 1×10⁶, 1×10⁷, or 1×10⁸ copies of EBOV RNA per ml in blood.

Applications

Target nucleic acid amplification using primers of the invention have characteristics useful for rapid detection of viral (e.g., EBOV) nucleic acid molecules. Compositions and methods of the invention are useful in human diagnostics, where a rapid diagnostic answer is desired (e.g., detect-

able amplification in under 20, 15, 10, 9, 8, 7, 6, 5 minutes or less). In particular embodiments, the invention provides for the use of an EBOV nicking amplification reaction assay in human or veterinary diagnostics in clinical settings or in the field. In other embodiments, the invention provides for the use of nicking amplification reaction assays in diagnostic field work, where access to thermocycling equipment is unavailable or would be prohibitively expensive. In still other embodiments, the invention provides for the use of nicking amplification reaction assays in a clinical setting where rapid quantitative answers are desired.

Detectable Oligonucleotide Probes

The present invention provides for the detection of target nucleic acid molecules or amplicons thereof in a nicking amplification reaction using non-amplifiable detectable polynucleotide probes comprising at least one polymerase-arresting molecule (e.g., nucleotide modification or other moiety that renders the oligonucleotide capable of binding a target nucleic acid molecule, but incapable of supporting polymerase extension utilizing the detectable oligonucleotide probe as a target). Without wishing to be bound by theory, the presence of one or more moieties which does not allow polymerase progression likely causes polymerase arrest in non-nucleic acid backbone additions to the oligonucleotide or through stalling of a replicative polymerase (i.e. C3-spacer, damaged DNA bases, other spacer moiety, O-2-Me bases). These constructs thus prevent or reduce illegitimate amplification of the probe during the course of a nicking amplification reaction. This distinguishes them from conventional detection probes, which must be added at the end of the nicking amplification reaction to prevent their amplification.

Conventional detection probes have proven impractical for detecting a nicking amplification reaction in real time. If conventional detection probes are incorporated into the nicking amplification reaction, these conventional detection probes are amplified concurrently with the target. The amplification of these detection molecules masks the detection of legitimate target amplicons due to the number of starting molecules of the detection probe at the start of the reaction.

The invention provides non-amplifiable detectable polynucleotide probe that comprise least one polymerase-arresting molecule. A polymerase-arresting molecule of the invention includes, but is not limited to, a nucleotide modification or other moiety that blocks extension by replicative DNA polymerases, thereby preventing the amplification of detection molecules; but can allow proper hybridization or nucleotide spacing to the target molecule or amplified copies of the target molecule. In one embodiment, a detectable oligonucleotide probe of the invention comprises a 3 carbon spacer (C3-spacer) that prevents or reduces the illegitimate amplification of a detection molecule.

In one embodiment, a detectable oligonucleotide probe comprises one or more modified nucleotide bases having enhanced binding affinity to a complementary nucleotide. Examples of modified bases include, but are not limited to 2' Fluoro amidites, and 2'OMe RNA amidites (also functioning as a polymerase arresting molecule). Detectable oligonucleotide probes of the invention can be synthesized with different colored fluorophores and may be designed to hybridize with virtually any target sequence. In view of their remarkable specificity, a non-amplifiable detectable polynucleotide probe of the invention is used to detect a single target nucleic acid molecule in a sample, or is used in combination with detectable oligonucleotide probes each of which binds a different target nucleic acid molecule. Accordingly, the non-amplifiable detectable polynucleotide probes

of the invention may be used to detect one or more target nucleic acid molecules in the same reaction, allowing these targets to be detected simultaneously. The present invention encompasses the use of such fluorophores in conjunction with the detectable oligonucleotide probes described herein. Implementation in Hardware and/or Software

The methods described herein can be implemented on general-purpose or specially programmed hardware or software. For example, the methods can be implemented by a computer readable medium. Accordingly, the present invention also provides a software and/or a computer program product configured to perform the algorithms and/or methods according to any embodiment of the present invention. It is well-known to a skilled person in the art how to configure software which can perform the algorithms and/or methods provided in the present invention. The computer-readable medium can be non-transitory and/or tangible. For example, the computer readable medium can be volatile memory (e.g., random access memory and the like) or non-volatile memory (e.g., read-only memory, hard disks, floppy discs, magnetic tape, optical discs, paper tape, punch cards, and the like). The computer executable instructions may be written in a suitable computer language or combination of several languages. Basic computational biology methods are described in, for example Setubal and Meidanis et al., *Introduction to Computational Biology Methods* (PWS Publishing Company, Boston, 1997); Salzberg, Searles, Kasif, (Ed.), *Computational Methods in Molecular Biology*, (Elsevier, Amsterdam, 1998); Rashidi and Buehler, *Bioinformatics Basics: Application in Biological Science and Medicine* (CRC Press, London, 2000) and Ouelette and Bzevanis *Bioinformatics: A Practical Guide for Analysis of Gene and Proteins* (Wiley & Sons, Inc., 2nd ed., 2001).

The present invention may also make use of various computer program products and software for a variety of purposes, such as probe design, management of data, analysis, and instrument operation. (See, U.S. Pat. Nos. 5,593,839, 5,795,716, 5,733,729, 5,974,164, 6,066,454, 6,090,555, 6,185,561, 6,188,783, 6,223,127, 6,229,911 and 6,308,170.) Additionally, the present invention may have preferred embodiments that include methods for providing genetic information over networks such as the Internet as shown in U.S. Ser. Nos. 10/197,621, 10/063,559 (US Pub No 20020183936), Ser. Nos. 10/065,856, 10/065,868, 10/328,818, 10/328,872, 10/423,403, and 60/482,389.

Kits

The invention also provides kits for the amplification of an EBOV or other RNA virus nucleic acid molecule. Such kits are useful for the detection or quantitation of an EBOV or other RNA nucleic acid in a biological sample obtained from a subject. Kits of the present invention may comprise, for example, one or more of reverse transcriptase, DNA polymerases, forward and reverse primers, and one or more nicking enzymes, as described herein, and a detectable probe. Where EBOV or other RNA is to be amplified, one or two nicking enzymes may be included in the kit. Where multiple pathogen sequences are to be amplified, and the templates designed for those target sequences comprise the nicking enzyme sites for the same nicking enzyme, then one or two nicking enzymes may be included. Where the templates are recognized by different nicking enzymes, more nicking enzymes may be included in the kit, such as, for example, 3 or more.

In one aspect, the invention provides a kit for nucleic acid amplification comprising a reverse transcriptase, DNA polymerase; a primary primer, a secondary primer, a nicking enzyme with specificity to a nicking enzyme binding site

within the primers, and deoxynucleotide triphosphates (dNTP's) (e.g., in a buffered solution containing components sufficient for amplification. In various embodiments, the primary primer and secondary primer, each have a 3'-end specific recognition region sequence complementary or substantially complementary to the target sequence, where the end specific recognition region comprises one or more 2' modified nucleotides; a 5'-end tail region containing a nicking enzyme binding site upstream of the 3'-end specific recognition region sequences that is able to dimerize with itself (e.g., self-complementary). In particular embodiments, one or more primers are in a primer-dimer configuration (e.g., produced by heating about Tm and slow cooling).

The kits of the present invention may also comprise one or more of the components in any number of separate containers, packets, tubes (e.g., <0.2 ml, 0.2 ml, 0.6 ml, 1.5 ml, 5.0 ml, >5.0 ml), vials, microtiter plates (e.g., <96-well, 96-well, 384-well, 1536-well, >1536-well), ArrayTape, and the like, or the components may be combined in various combinations in such containers. In various embodiments, the kit further comprises a pair of primers capable of binding to and amplifying a reference sequence. In particular embodiments, the kit comprises one or more primers in a primer-dimer configuration (e.g., produced by heating about Tm and slow cooling). In yet other embodiments, the kit comprises a sterile container which contains the primers; such containers can be boxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container form known in the art. Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding nucleic acids.

The components of the kit may, for example, be present in one or more containers, for example, all of the components may be in one container, or, for example, the enzymes may be in a separate container from the primers. The components may, for example, be dried (e.g., powder) or in a stable buffer (e.g., chemically stabilized, thermally stabilized). Dry components may, for example, be prepared by lyophilization, vacuum and centrifugal assisted drying and/or ambient drying. In various embodiments, the polymerase and nicking enzymes are in lyophilized form in a single container, and the primers are either lyophilized, freeze dried, or in buffer, in a different container. In some embodiments, the polymerase, nicking enzymes, and the primers are, in lyophilized form, in a single container. In other embodiments, the polymerase and the nicking enzyme may be separated into different containers.

Kits may further comprise, for example, dNTPs used in the reaction, or modified nucleotides, cuvettes or other containers used for the reaction, or a vial of water or buffer for rehydrating lyophilized components. The buffer used may, for example, be appropriate for both polymerase and nicking enzyme activity.

The kits of the present invention may also comprise instructions for performing one or more methods described herein and/or a description of one or more compositions or reagents described herein. Instructions and/or descriptions may be in printed form and may be included in a kit insert. A kit also may include a written description of an Internet location that provides such instructions or descriptions.

The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are well within the purview of the skilled artisan. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual", second edition (Sambrook,

1989); "Oligonucleotide Synthesis" (Gait, 1984); "Animal Cell Culture" (Freshney, 1987); "Methods in Enzymology" "Handbook of Experimental Immunology" (Weir, 1996); "Gene Transfer Vectors for Mammalian Cells" (Miller and Calos, 1987); "Current Protocols in Molecular Biology" (Ausubel, 1987); "PCR: The Polymerase Chain Reaction", (Mullis, 1994); "Current Protocols in Immunology" (Coligan, 1991). These techniques are applicable to the production of the polynucleotides and polypeptides of the invention, and, as such, may be considered in making and practicing the invention. Particularly useful techniques for particular embodiments will be discussed in the sections that follow.

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the assay, screening, and therapeutic methods of the invention, and are not intended to limit the scope of what the inventors regard as their invention.

EXAMPLES

Example 1. One-Step and Two-Step Real-Time Reverse Transcription-Isothermal Amplification Assays for EBOV

A one-step reaction refers to a reverse transcriptase (RT) reaction in which reverse transcription and amplification occur in a single reaction protocol. A two-step reaction refers to a reverse transcriptase reaction in which the reverse transcription is carried out first; followed by a transfer to a second amplification reaction.

Assays 1 and 2 were tested for their ability to detect an EBOV polynucleotide EBOV (FIG. 1). Primers for these assays are shown at FIG. 2.

FIGS. 3A-3X show amplification results obtained with Assay 1 and Assay 2. The assays were used to detect copies of EBOV gBlock in a background of human cDNA.

Reaction conditions are specified.

FIG. 4 shows detection of EBOV in a background of total human RNA in a one-step assay.

FIG. 5 shows detection of synthetic EBOV RNA in a background of total human RNA in a one-step assay.

FIGS. 6A-6C provide flow charts illustrating sample processing for use in an amplification and detection instrument.

FIGS. 7A and 7B show sample preparation methods from swabs and blood, respectively.

In one working example, Ebola virus was detected using the following primers and probe sequences:

In the sequences above, GAGTC is the nicking enzyme recognition site. Pyrimidine provides for degeneracy detection of Ebola strains including Zaire.

5 (SEQ ID NO: 37)
Synthetic DNA target:
AAGATGACTGCAGGAGTCAATGCGCAGTTGGTCCCGGCAGACCAGGCCAAC
ATTACCGAATTTACAAACAAGTCCCTTCATCCTACAAGGAGAACGGAG
10 AACATCCAGTGTGGGGAGAACCTTCATGGACATGGAGTGCTTCATGATTCTG
AACCCCAGTCAGCAGCTGGCAATTGCCGCTTGTCTCTCACACTGGGCACC
TTTCACAGTTCTGGAGAACCTGTGGTCTGTGTGTACCCACAGTTATCTAC
15 CGAGGAACGACTTCGCTGAAGGTGTCGTTGCATTCGATTCCCTCACTC
CCGCAGCCTCCGCTGCCGCCCTCTTACCACTTCATCATTAGCCTGGCCGT
GGCCGACCTCTGGGGAGTGTCACTTTGTCTACAGCTTGTGACTTCA
20 TGTGTTCCACCGCAAGGACAGCCCCAACGTCTTCTCTCAAATTGGGTGG
GGTCACCGCCTCTTCACGGCCTCTGTAGGCAGCCTCTTCC

(SEQ ID NO: 38)
Synthetic RNA target:
25 rGrArCrUrGrCrArGrGrArGrUrCrUrGrCrUrCrUrCrCrArCr
ArGrUrUrArUrCrUrArCrCrGrArGrGrArArCrGrArCrUrUrUrCrG
rCrUrGrArArGrGrUrGrUrCrGrUrUrGrCrArUrUrUrCrUrGrArUr
UrCrCrUrUrCrArCrUrCrCrG

Both 1-step and 2-step reactions contained a final concentration of 166.7 nM forward primer and a final concentration of 833.3 nM reverse primer with 200 nM concentration of Probe and 0.1×SYBR green (final concentration). In addition both 1 and 2 step reactions contained a final concentration of 1×Extract Buffer 2, comprising Tris pH 8.0, NH₄⁺, Na⁺, and Mg²⁺; dNTPs; 0.4 U/μl BST polymerase; and 0.3 U/μl Nt.BSTnb1 nicking enzyme. In addition to these components; the 1 step reactions contained 10 U/μl of Maxima Reverse Transcriptase enzyme; 1.0 U/μl of an RNase inhibitor (SUBERase IN by life technologies). Synthetic RNA had 1.0 U/μl of RNase inhibitor added as well to prevent degradation. All water used was purchased nucleic acid free.

45 Reactions were mixed on ice and kept cold until run on the Roche LC480. The Roche LC480 was run under a two color detection to detect the calfluor red 610 beacon signal (Abs 590 nm/Em 610 nm) and the SYBR green signal (Abs 495 nm/Em 520 nm). 1-Step reactions were carried out at 56° C. for 20 minutes. Results are shown at FIG. 8.

50 2-step reactions were carried out with the reverse transcriptase step at 56° C. for 5 minutes (in a heat block) or at

Forward	GACTCGATATCGAGTCGCTTCCA[MeOC]AGTTATC	SEQ ID NO: 1
Primer	[MeOU][MeOA][MeOC][MeOC][MeOG]	
Reverse	GACTCGATATCGAGTCGAAATGC[MeOA]ACGA[MeOC]	SEQ ID NO: 2
Primer	[MeOA][MeOC][MeOC][MeOU]	
Probe	gctac <u>ACGACTTTYGCTGAAGgtac</u>	SEQ ID NO: 3
External	CTTCTTAGCTGGGCAGTATCA	SEQ ID NO: 36
Primer		

Primers: [MeON] indicates methoxy base

Probe sequence: lowercase = stems, uppercase = recognition
1:5 1000 nM 0.3 U/μl nicking enzyme

room temperature for 5 minutes following the setup condition outlined by New England Biolabs (www.neb.com) (FIG. 9). Both these RT temperatures produced signal for 1×10^5 copies of target per reaction. The reverse transcriptase step was followed by an amplification step at 56° C. for 15 minutes on the LC480. Results of this assay are shown at FIG. 10. The copy number indicated per reaction was determined using the suppliers' calculations.

Example 2. Detection of a Target RNA in a Complex RNA Mixture

To determine whether the 1-step and 2-step reactions could detect a target RNA in complex mixtures of RNA molecules, assays were designed for the detection of RPPH1 (RNase P RNA Component) in total human RNA. In one working example, RPPH1 was detected using the following primers and probe sequences:

Forward RPPH1.Fc Primer	GACTCGATATCGAGTCCACGAGCmUG SEQ ID NO: 39 AGTGCmGmUmCmCmUmG
Reverse RPPH1.Rc Primer	GACTCGATATCGAGTCAGACCTTmCC SEQ ID NO: 40 CAAGGmGmAmCmAmU
Probe RPPH1.Probe.T Primer	CCACGCCCTGTCACTC- CACTCCGGCTGG SEQ ID NO: 41
External rpph1extprimR Primer	CCTCTGGCCCTAGTCTCAG SEQ ID NO: 42

Primers: mN indicates methoxy base

In a 2-step reaction, human RNA (10 ng) was converted to cDNA with random hexamer primer and RPPH1 was detected by amplification of a target specific sequence (FIG. 11A). In a 1-step reaction, human RNA (20 ng) was detected by amplification of a target specific sequence using specific reverse transcription primers (FIG. 11B).

Example 3: Detection of Ebola Virus in a Biological Sample

In another working example, a synthetic Ebola virus RNA target was detected when mixed with a crude blood preparation using the 1-step assay. The crude blood preparation was prepared by mixing whole blood (20 µl) and sodium dodecyl sulfate (0.5% SDS; 20 µl) and incubating the mixture at room temperature (3 min.). After incubation, bovine serum albumin was added (2% BSA; 20 µl) and the resulting mixture was incubated at room temperature (1 min.). The crude blood preparation (1 µl) was spiked with a synthetic Ebola virus RNA target (1000 copies). Reactions were run in triplicate at 56° C. on a Roche LC480. Results are shown at FIG. 12.

In an additional experiment, the 1-step assay was able to distinguish between Zaire Ebolavirus Mayinga and Sudan Ebolavirus Boniface RNA molecules. Vero E6 cells were infected with Zaire Ebolavirus Mayinga or Sudan Ebolavi-

rus Boniface virus and viral RNAs were purified. Sets of reactions were run using purified RNA Zaire Ebolavirus Mayinga (683 copies) or Sudan Ebolavirus Boniface virus (650 copies). For each set, quadruplicate reactions (10 µl) were run on a Roche LC480. The assay detected Zaire Ebolavirus Mayinga RNA (FIG. 13; set of curves denoted A) and did not detect Sudan Ebolavirus Boniface RNA (FIG. 13; set of curves denoted B). Thus, the Zaire Ebola assay was specific for the detection of Zaire Ebola Mayinga.

An instrument comparison was run using various dilutions of Zaire Ebolavirus Mayinga RNA from about 10^1 - 10^7 copies of target RNA, including a no target control (NTC) sample. Instruments tested included the Roche Lightcycler 480 II, Axxin Detector, and Douglas Scientific Amplifire amplification and detection instruments. While some instrument variability was observed, all instruments could detect copies of EBOV RNA over a wide range (FIG. 14).

To determine a lower limit of detection for the 1-step EBOV assay, serially diluted samples containing 100, 50, 25, and 12 copies of Zaire Ebolavirus Mayinga RNA were tested. The 1-step reactions (10 µl) were run on the Roche LightCycler 480 using at least 10 technical replicates for each dilution. Twenty (20) technical replicates were run for the 100 and 50 copy reactions. Forty (40) technical replicates were run for the 25 copy reactions. A 100% (20/20) detection rate was observed for the detection of 100 and 50 copies per reaction (FIGS. 15A and 15B). A 95% (38/40) detection rate was observed for the detection of 25 copies per reaction (FIG. 15C). Thus, these results show the sensitivity and specificity of the EBOV assay, even when performed as a 1-step assay.

Example 4: Detection of Human Immunodeficiency Virus (HIV) in a Biological Sample

In one working example, human immunodeficiency virus (HIV) was detected in a 1-step RNABle® assay targeting a gag protein sequence. Purified HIV RNA (subtype C) was obtained (SeraCare), and known quantities of the HIV RNA, as quantified by COBAS TaqMan HIV-1 v2.0 test, were tested in the 1-step HIV RNABle® assay. The following primers and probe sequences were used:

Hgag (HIV gag target)		
Primer	Sequence	SEQ ID NO
Hgag.F2a	GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmSEQ ID NO: 6 AmGmAmAmG	
Hgag.F2b	GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmSEQ ID NO: 7 AmGmAmAmG	

-continued

Hgag (HIV gag target)		
Primer	Sequence	SEQ ID NO
Hgag.R1a	GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmSEQ CmAmC	ID NO: 8
Hgag.R1b	GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmSEQ CmAmC	ID NO: 9
Hgag.rt3.subC*	GCATCTAATTTTCGCC (external primer) SEQ	ID NO: 43
Hgag.probe.T	cgcaaggAGAGAGATGGGTGcttgcg	SEQ ID NO: 10

Primers: mN indicates methoxy base

Probe sequence: lowercase = stems, uppercase = recognition

*External primer sequence is specific to HIV subtype C (for the purified RNA sample used)

FIG. 16A is a map of the amplicon showing the locations of the sequences used. The sequence of the external primer was specific to HIV subtype C (for the purified RNA sample used). The 1-step HIV RNABle® assay was designed with two sets of forward and reverse primers to account for sequence variations in the population. In the sequences above, GAGTC is the nicking enzyme recognition site.

The 1-step reactions contained a final concentration of 9 nM forward primer (1:1 mix of Hgag.F2a+Hgag.F2b) and a final concentration of 91 nM reverse primer (1:1 mix of

20
25

Example 5: Detection of Dengue Virus Type 4 (DENV-4) in a Biological Sample

In one working example, dengue virus type 4 (DENV-4) was detected in a 1-step RNABle® assay targeting a 3' UTR sequence. Total RNA was isolated from cell culture, which included both viral and host cell RNA, and used in the 1-step DENV-4 RNABle® assay. Thus, total copy number was unknown. The following primers and probe sequences were used:

Den4 (Dengue type 4)		
Primer	Sequence	SEQ ID NO
Den4.F2	GACTCGATATCGAGTCAAAAACmAGCATATTmGmSEQ AmCmGmC	ID NO: 11
Den4.R1a	GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmSEQ TmGmG	ID NO: 12
Den4.R1b	GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmSEQ TmGmG	ID NO: 13
Den4.extRT1	TCTGTGCCTGGATTGAT (external primer) SEQ	ID NO: 44
Den4.probe.B	cgcatcTGGTCTTCCCAGCgatgcg	SEQ ID NO: 14

Primers: mN indicates methoxy base

Probe sequence: lowercase = stems, uppercase = recognition

Hgag.R1a+Hgag.R1b) in a primer ratio of about 1:10 forward to reverse primers. Final concentrations of 200 nM probe and 100 nM external primer were used. In addition, the 1 step reactions contained a final concentration of 1×Run Buffer, comprising Tris, K⁺, and Mg²⁺; Guanidinium thiocyanate (GITC); dNTPs; 0.4 U/μl BST polymerase; and 0.3 U/μl Nt.BSTnbi nicking enzyme. In addition to these components; the 1 step reactions contained 0.2 U/μl of AMV Reverse Transcriptase High Spec Activity XL (Life Sciences Advanced Technologies) and 0.5 U/μl of an RNase inhibitor (Superasin; Thermo Fisher). All water used was nuclease free.

Reactions were run using real-time detection of calflourescent 610 beacon signal (Abs 590 nm/Em 610 nm). 1-Step reactions were carried out at 56° C. for 20 minutes using 125, 250, 500, and 1000 copies of HIV RNA. Specific detection of HIV RNA at all copy numbers was demonstrated in the 1-step HIV RNABle® assay (FIG. 16B).

50
55

Primers: mN indicates methoxy base
Probe sequence: lowercase=stems, uppercase=recognition FIG. 17A is a map of the amplicon showing the locations of the sequences used. The 1-step DENV-4 RNABle® assay was designed with two sets of reverse primers to account for sequence variations in the population. In the sequences above, GAGTC is the nicking enzyme recognition site.

The 1-step reactions contained a final concentration of 83 nM forward primer and a final concentration of 17 nM reverse primer (1:1 mix of Den4.R1a+Den4.R1b) in a primer ratio of about 5:1 forward to reverse primers. Final concentrations of 200 nM probe and 100 nM external primer were used. In addition, the 1 step reactions contained a final concentration of 1× Run Buffer, comprising Tris, K⁺, and Mg²⁺; dNTPs; 0.4 U/μl BST polymerase; and 0.3 U/μl Nt.BSTnbi nicking enzyme. In addition to these components; the 1 step reactions contained 0.2 U/μl of AMV Reverse Transcriptase High Spec Activity XL (Life Sciences Advanced Technologies) and 0.5 U/μl of an RNase inhibitor (Superasin; Thermo Fisher). All water used was nuclease free.

60
65

53

Reactions were run using real-time detection of calflou red 610 beacon signal (Abs 590 nm/Em 610 nm). 1-Step reactions were carried out at 56° C. for 20 minutes using 20 pg total RNA. Specific detection of Dengue 4 RNA was demonstrated in the 1-step DENV-4 RNABl® assay (FIG. 17B).

Example 6: Detection of Influenza B in a Biological Sample

In one working example, influenza B was detected in a 1-step RNABl® assay targeting an influenza Segment 7 sequence. Total RNA was isolated from cell culture, which included both viral and host cell RNA, and used in the 1-step influenza B RNABl® assay. Thus, total copy number was unknown. The following primers and probe sequences were used:

FluB (influenza B)		
Primer	Sequence	SEQ ID NO
FluB.F2a	GACTCGATATCGAGTCAAATGCAmGATGGTCTCmA mGmCmTmA	SEQ ID NO: 15
FluB.F2b	GACTCGATATCGAGTCAAATGCAmAATGGTCTCmA mGmCmTmA	SEQ ID NO: 16
FluB.F2c	GACTCGATATCGAGTCAAATGCAmGATGGTTTCmA mGmCmTmA	SEQ ID NO: 17
FluB.R3a	GACTCGATATCGAGTCCTCCTTmTCCCATTCCAT mTmCmAmTmT	SEQ ID NO: 18
FluB.R3b	GACTCGATATCGAGTCCTCCCTTmTCCCATTCCAT mTmCmAmTmT	SEQ ID NO: 19
FluB.R3c	GACTCGATATCGAGTCCTCCTTmCCCCATTCCAT mTmCmAmTmT	SEQ ID NO: 20
FluB.extRT1a	TTTTGGACGTCTTCTCC (external primer)	SEQ ID NO: 45
FluB.extRT1b	TTTTGAACGTCTTCTCC (external primer)	SEQ ID NO: 46
FluB.probe.T	gccaaGCTATGAAACACAGCAAActggc	SEQ ID NO: 21

Primers: mN indicates methoxy base

Probe sequence: lowercase = stems, uppercase = recognition

FIG. 18A is a map of the amplicon showing the locations of the sequences used. The 1-step Influenza B RNABl® assay was designed with three sets of forward and reverse primers and two external primers to account for sequence variations in the population. In the sequences above, GAGTC is the nicking enzyme recognition site.

The 1-step reactions contained a final concentration of 9 nM forward primer (1:1:1 mix of FluB.F2a+FluB.F2b+FluB.F2c) and a final concentration of 91 nM reverse primer (1:1:1 mix of FluB.R3a+FluB.R3b+FluB.R3c) in a primer ratio of about 1:10 forward to reverse primers. Final concentrations of 200 nM probe and 100 nM external primer were used. In addition, the 1 step reactions contained a final

concentration of 1×Run Buffer, comprising Tris, K⁺, and Mg²⁺; dNTPs; 0.4 U/μl BST polymerase; and 0.3 U/μl Nt.BSTnbi nicking enzyme. In addition to these components; the 1 step reactions contained 0.2 U/μl of AMV Reverse Transcriptase High Spec Activity XL (Life Sciences Advanced Technologies) and 0.5 U/μl of an RNase inhibitor (Superasin; Thermo Fisher). All water used was nuclease free.

Reactions were run using real-time detection of calflou red 610 beacon signal (Abs 590 nm/Em 610 nm). 1-Step reactions were carried out at 56° C. for 20 minutes using total RNA from different isolates. Specific detection of influenza B in all isolates was demonstrated in the 1-step influenza B RNABl® assay (FIG. 18B).

54

Example 7: Detection of Bovine Viral Diarrhea Virus Genotype 1 (BVDV1) in a Biological Sample

In one working example, Bovine Viral Diarrhea Virus Genotype 1 (BVDV1) was detected in a 1-step RNABl® assay targeting an influenza Segment 7 sequence. Total RNA was isolated from cell culture, which included both viral and host cell RNA, and used in the 1-step BVDV1 RNABl® assay. Thus, total copy number was unknown. The following primers and probe sequences were used:

Bovine Viral Diarrhea Virus Type 1 (BVDV1)		
Primer	Sequence	SEQ ID NO
BVDV1.F1a	GACTCGATATCGAGTCGGCCACmTGTATTGCT mAmCmTmGmAmAmA	SEQ ID NO: 22
BVDV1.F1b	GACTCGATATCGAGTCGGCCACmTGCACTGCT mAmCmTmAmAmAmA	SEQ ID NO: 23
BVDV1.R1	GACTCGATATCGAGTCCTGTGATCmAACTCCmAm TmGmTmGmC	SEQ ID NO: 24
BVDV1.RT1v	TATGTTTGTATAAAAGTCATTG (external primer)	SEQ ID NO: 47
BVDV1.ProbeT	cgctacATCTCTGCTGTACATGgtagcg	SEQ ID NO: 25

Primers: mN indicates methoxy base

Probe sequence: lowercase = stems, uppercase = recognition

FIG. 19A is a map of the amplicon showing the locations of the sequences used. The 1-step BVDV1 RNABLE® assay was designed with two sets of forward primers to account for sequence variations in the population. In the sequences above, GAGTC is the nicking enzyme recognition site.

The 1-step reactions contained a final concentration of 9 nM forward primer (1:1 mix of BVDV1.F1a+BVDV1.F1b) and a final concentration of 91 nM reverse primer in a primer ratio of about 1:10 forward to reverse primers. Final concentrations of 200 nM probe and 100 nM external primer were used. In addition, the 1 step reactions contained a final concentration of 1×Run Buffer, comprising Tris, K⁺, and Mg²⁺; dNTPs; 0.4 U/μl BST polymerase; and 0.3 U/μl Nt.BSTnbi nicking enzyme. In addition to these components; the 1 step reactions contained 0.2 U/μl of AMV Reverse Transcriptase High Spec Activity XL (Life Sciences Advanced Technologies) and 0.5 U/μl of an RNase inhibitor (Superasin; Thermo Fisher). All water used was nuclease free.

Reactions were run using real-time detection of calflourescent red 610 beacon signal (Abs 590 nm/Em 610 nm). 1-Step reactions were carried out at 56° C. for 20 minutes using purified RNA (20 pg/technical replicate) from BVDV1 virus culture (mixed bovine host cell RNA and virus) and cell culture crude lysate (undiluted and 1:100 dilution). Specific

detection of BVDV1 virus in all samples was demonstrated in the 1-step BVDV1 RNABLE® assay (FIG. 19B).

Example 8: Molecular Beacon Recognition of Ebola Strains

Exemplary Beacon BLAST Alignment Output and Strains List:

5	<hr/> <p>Zaire ebolavirus isolate <i>H. sapiens</i>-tc/COD/1976/Yambuku-Ecran, complete genome Sequence ID: gb KM655246.1 Length: 18797 Number of Matches: 5 Range 1: 6513 to 6528 GenBank Graphics ▼ Next Match ▲ Previous Match</p> <hr/> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Score</th><th style="text-align: left;">Expect</th><th style="text-align: left;">Identities</th><th style="text-align: left;">Gaps</th><th style="text-align: left;">Strand</th></tr> <tr> <td>29.4 bits (14)</td><td>0.017</td><td>15/16 (94%)</td><td>0/16 (0%)</td><td>Plus/Plus</td></tr> </thead> <tbody> <tr> <td>Query</td><td>1</td><td>ACGACTTYYGCTGAAG</td><td></td><td>16</td></tr> <tr> <td>Sbjct</td><td>6513</td><td> </td><td>ACGACTTTCGCTGAAG</td><td>6528</td></tr> </tbody> </table> <hr/>	Score	Expect	Identities	Gaps	Strand	29.4 bits (14)	0.017	15/16 (94%)	0/16 (0%)	Plus/Plus	Query	1	ACGACTTYYGCTGAAG		16	Sbjct	6513		ACGACTTTCGCTGAAG	6528
Score	Expect	Identities	Gaps	Strand																	
29.4 bits (14)	0.017	15/16 (94%)	0/16 (0%)	Plus/Plus																	
Query	1	ACGACTTYYGCTGAAG		16																	
Sbjct	6513		ACGACTTTCGCTGAAG	6528																	

Query 1 (SEQ ID NO: 48)

Subject (SEQ ID NO: 49)

Zaire ebolavirus isolate <i>H. sapiens</i> -tc/COD/1976/Yambuku-Ecran, complete genome
29.4 89.2 100% 0.017 94% KM655246.1
Zaire ebolavirus isolate <i>H. sapiens</i> -wt/GIN/2014/Gueckedou-C05, complete genome
29.4 104 100% 0.017 94% KJ660348.2
Zaire ebolavirus isolate <i>H. sapiens</i> -wt/GIN/2014/Gueckedou-C07, complete genome
29.4 104 100% 0.017 94% KJ660347.2
Zaire ebolavirus isolate <i>H. sapiens</i> -wt/GIN/2014/Kissidougou-C15, complete genome
29.4 104 100% 0.017 94% KJ660346.2
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-NM042.3, partial genome
29.4 104 100% 0.017 94% KM233118.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-NM042.2, partial genome
29.4 104 100% 0.017 94% KM233117.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-NM042.1, partial genome
29.4 104 100% 0.017 94% KM233116.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3857, partial genome
29.4 104 100% 0.017 94% KM233115.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3856.3, partial genome
29.4 104 100% 0.017 94% KM233114.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3856.1, partial genome
29.4 104 100% 0.017 94% KM233113.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3851, partial genome
29.4 104 100% 0.017 94% KM233112.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3850, partial genome
29.4 104 100% 0.017 94% KM233111.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3848, partial genome
29.4 104 100% 0.017 94% KM233110.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3846, partial genome
29.4 104 100% 0.017 94% KM233109.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3841, partial genome
29.4 104 100% 0.017 94% KM233107.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3840, partial genome
29.4 104 100% 0.017 94% KM233106.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3838, partial genome
29.4 104 100% 0.017 94% KM233105.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3834, partial genome
29.4 104 100% 0.017 94% KM233104.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3831, partial genome
29.4 104 100% 0.017 94% KM233103.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3829, partial genome
29.4 104 100% 0.017 94% KM233102.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3827, partial genome
29.4 104 100% 0.017 94% KM233101.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3826, partial genome
29.4 104 100% 0.017 94% KM233100.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3825.2, partial genome
29.4 104 100% 0.017 94% KM233099.1
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3825.1, partial genome
29.4 104 100% 0.017 94% KM233098.1

-continued

-continued

Amplicon Similarity Analysis Across Ebola Strains Exemplary BLAST Alignment Output and Strains List:

Zaire ebolavirus *H.sapiens*-tc/COD/1976/Yambuku-Ecran, complete genome
Sequence ID: gb|KM655246.1| Length: 18797 Number of Matches: 1
Range 1: 6492 to 6547 GenBank Graphics ▼ Next Match ▲ Previous Match

Score		Strand
102 bits	Expect	Plus/
(112)	1e-23	Plus
	Identities	
	56/56 (100%)	
	Gaps	
	0/56 (0%)	

Query	1	TCCACAGTTATCTACCGAGGAACGACTTCTGCTGAAGGTGTCGTTGCATTCTGAT	56
Sbjct	6492	TCCACAGTTATCTACCGAGGAACGACTTCTGCTGAAGGTGTCGTTGCATTCTGAT	6547

(SEQ ID NO: 50)
Strains List:

15

Zaire ebolavirus isolate <i>H. sapiens</i> -tc/COD/1976/Yambuku-Ecran, complete genome					
102 102 100% 1e-23 100% KM655246.1					
Zaire ebolavirus isolate <i>H. sapiens</i> -wt/GIN/2014/Gueckedou-C05, complete genome					
102 102 100% 1e-23 100% KJ660348.2					
Zaire ebolavirus isolate <i>H. sapiens</i> -wt/GIN/2014/Gueckedou-C07, complete genome					
102 102 100% 1e-23 100% KJ660347.2					
Zaire ebolavirus isolate <i>H. sapiens</i> -wt/GIN/2014/Kissidougou-C15, complete genome					
102 102 100% 1e-23 100% KJ660346.2					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-NM042.3, partial genome					
102 102 100% 1e-23 100% KM233118.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-NM042.2, partial genome					
102 102 100% 1e-23 100% KM233117.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-NM042.1, partial genome					
102 102 100% 1e-23 100% KM233116.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3857, partial genome					
102 102 100% 1e-23 100% KM233115.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3856.3, partial genome					
102 102 100% 1e-23 100% KM233114.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3856.1, partial genome					
102 102 100% 1e-23 100% KM233113.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3851, partial genome					
102 102 100% 1e-23 100% KM233112.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3850, partial genome					
102 102 100% 1e-23 100% KM233111.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3848, partial genome					
102 102 100% 1e-23 100% KM233110.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3846, partial genome					
102 102 100% 1e-23 100% KM233109.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3841, partial genome					
102 102 100% 1e-23 100% KM233107.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3840, partial genome					
102 102 100% 1e-23 100% KM233106.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3838, partial genome					
102 102 100% 1e-23 100% KM233105.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3834, partial genome					
102 102 100% 1e-23 100% KM233104.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3831, partial genome					
102 102 100% 1e-23 100% KM233103.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3829, partial genome					
102 102 100% 1e-23 100% KM233102.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3827, partial genome					
102 102 100% 1e-23 100% KM233101.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3826, partial genome					
102 102 100% 1e-23 100% KM233100.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3825.2, partial genome					
102 102 100% 1e-23 100% KM233099.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3825.1, partial genome					
102 102 100% 1e-23 100% KM233098.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3823, partial genome					
102 102 100% 1e-23 100% KM233097.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3822, partial genome					
102 102 100% 1e-23 100% KM233096.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3821, partial genome					
102 102 100% 1e-23 100% KM233095.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3819, partial genome					
102 102 100% 1e-23 100% KM233093.1					
Zaire ebolavirus isolate Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3818, partial genome					
102 102 100% 1e-23 100% KM233092.1					

-continued

-continued

Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3713.2, partial genome			
102	102	100%	1e-23	100%
KM233050.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3707, partial genome			
102	102	100%	1e-23	100%
KM233049.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM124.4, partial genome			
102	102	100%	1e-23	100%
KM233048.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM124.3, partial genome			
102	102	100%	1e-23	100%
KM233047.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM124.2, partial genome			
102	102	100%	1e-23	100%
KM233046.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM124.1, partial genome			
102	102	100%	1e-23	100%
KM233045.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM121, partial genome			
102	102	100%	1e-23	100%
KM233044.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM120, partial genome			
102	102	100%	1e-23	100%
KM233043.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM119, partial genome			
102	102	100%	1e-23	100%
KM233042.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM115, partial genome			
102	102	100%	1e-23	100%
KM233041.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM113, partial genome			
102	102	100%	1e-23	100%
KM233040.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM112, partial genome			
102	102	100%	1e-23	100%
KM233039.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM111, partial genome			
102	102	100%	1e-23	100%
KM233038.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM110, partial genome			
102	102	100%	1e-23	100%
KM233037.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM106, partial genome			
102	102	100%	1e-23	100%
KM233036.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM104, partial genome			
102	102	100%	1e-23	100%
KM233035.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3687.1, partial genome			
102	102	100%	1e-23	100%
KM034563.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3686.1, partial genome			
102	102	100%	1e-23	100%
KM034562.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3683.1, partial genome			
102	102	100%	1e-23	100%
KM034561.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3682.1, partial genome			
102	102	100%	1e-23	100%
KM034560.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3680.1, partial genome			
102	102	100%	1e-23	100%
KM034559.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3679.1, partial genome			
102	102	100%	1e-23	100%
KM034558.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3677.2, partial genome			
102	102	100%	1e-23	100%
KM034557.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3677.1, partial genome			
102	102	100%	1e-23	100%
KM034556.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3676.2, partial genome			
102	102	100%	1e-23	100%
KM034555.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3676.1, partial genome			
102	102	100%	1e-23	100%
KM034554.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-G3670.1, partial genome			
102	102	100%	1e-23	100%
KM034553.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM098, partial genome			
102	102	100%	1e-23	100%
KM034552.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM096, partial genome			
102	102	100%	1e-23	100%
KM034551.1				
Zaire ebolavirus isolate	Ebola virus <i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM095, partial genome			
102	102	100%	1e-23	100%
KM034550.1				
Zaire ebolavirus isolate	<i>H. sapiens</i> -wt/SLE/2014/ManoRiver-EM095B, partial genome			
102	102	100%	1e-23	100%
KM034549.1				
Mutant Zaire ebolavirus, complete sequence				
102	102	100%	1e-23	100%

Other Embodiments

From the foregoing description, it will be apparent that variations and modifications may be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.

The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes

that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

This application may be related to International Patent Application No. PCT/US2013/035750, filed Apr. 9, 2013, which claims the benefit of U.S. Provisional Application No. 61/621,975, filed Apr. 9, 2012, the entire contents of which are incorporated herein by reference.

This application may be related to International Patent Application No. PCT/US2011/047049, filed Aug. 9, 2011, which claims the benefit of U.S. Provisional Application No. 61/373,695, filed Aug. 13, 2010, the entire contents of which are incorporated herein by reference.

All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.

SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 75

<210> SEQ ID NO 1
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<223> OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
      Synthetic primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (32)..(36)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 1

gactcgatat cgagtcgcctt ccacagttat cuaccg
```

36

```
<210> SEQ ID NO 2
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<223> OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
      Synthetic primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (29)..(33)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 2
```

```
gactcgatat cgagtcgaaa tgcaacgaca ccu
```

33

```
<210> SEQ ID NO 3
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      probe
```

```
<400> SEQUENCE: 3

gctacacgac ttttgtgaa ggttagc
```

26

```
<210> SEQ ID NO 4
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      probe
<220> FEATURE:
```

-continued

```

<223> OTHER INFORMATION: 5'-CALRed610nm-modified
<220> FEATURE:
<223> OTHER INFORMATION: 3'-BHQ2-modified

<400> SEQUENCE: 4
gctacacgac tttygctgaa ggttagc                                26

<210> SEQ ID NO 5
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      probe
<220> FEATURE:
<223> OTHER INFORMATION: 5'-FAM or FITC-modified
<220> FEATURE:
<223> OTHER INFORMATION: 3'-BHQ1-modified

<400> SEQUENCE: 5
gctacacgac tttygctgaa ggttagc                                26

<210> SEQ ID NO 6
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (30)..(36)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 6
gactcgatat cgagtctgac tagcggaggc tagaaag                                36

<210> SEQ ID NO 7
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (30)..(36)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 7
gactcgatat cgagtctgac tagcagaggc tagaaag                                36

<210> SEQ ID NO 8
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base

```

-continued

```

<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (28)..(33)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 8

gactcgatat cgagtctatt gacgctctcg cac                                33

<210> SEQ ID NO 9
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (28)..(33)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 9

gactcgatat cgagtctact gacgctctcg cac                                33

<210> SEQ ID NO 10
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      probe

<400> SEQUENCE: 10

cgcaaggggag agagatgggt gcttgcg                                27

<210> SEQ ID NO 11
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (32)..(36)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 11

gactcgatat cgagtccaaa aacagcatat tgacgc                                36

<210> SEQ ID NO 12
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (30)..(34)

```

-continued

<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 12

gactcgatat cgagtcagac agcaggatct ctgg

34

<210> SEQ ID NO 13

<211> LENGTH: 34

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (24)..(24)

<223> OTHER INFORMATION: Methoxy base

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (30)..(34)

<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 13

gactcgatat cgagtcagac agcaggatct gtgg

34

<210> SEQ ID NO 14

<211> LENGTH: 26

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic probe

<400> SEQUENCE: 14

cgcatctggc ctttcccagc gatgcg

26

<210> SEQ ID NO 15

<211> LENGTH: 37

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (24)..(24)

<223> OTHER INFORMATION: Methoxy base

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (33)..(37)

<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 15

gactcgatat cgagtcaaat gcagatggtc tcagcta

37

<210> SEQ ID NO 16

<211> LENGTH: 37

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (24)..(24)

<223> OTHER INFORMATION: Methoxy base

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (33)..(37)

<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 16

-continued

gactcgatat cgagtcaa at gcaa at ggtc tcagct a 37

```

<210> SEQ ID NO 17
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (33)..(37)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 17

```

gactcgatat cgagtcaa at gcagatggtt tcagct a 37

```

<210> SEQ ID NO 18
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24) ..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (35)..(39)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 18

```

gactcgatat cgagtcc ttttccatt ccattcatt 39

```

<210> SEQ ID NO 19
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (35)..(39)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 19

```

gactcgatat cgagtcc ttttccatt ccattcatt 39

```

<210> SEQ ID NO 20
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:

```

-continued

```

<221> NAME/KEY: modified_base
<222> LOCATION: (35)..(39)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 20
gactcgatat cgagtcctcc ttccccatt ccattcatt                                39

<210> SEQ ID NO 21
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      probe

<400> SEQUENCE: 21
gccaaagctat gaacacagca aacttggc                                28

<210> SEQ ID NO 22
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (33)..(39)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 22
gactcgatat cgagtcggcc cactgtattt ctactgaaa                                39

<210> SEQ ID NO 23
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (33)..(39)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 23
gactcgatat cgagtcggcc cactgcactg ctactaaaaa                                39

<210> SEQ ID NO 24
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (30)..(36)
<223> OTHER INFORMATION: Methoxy base

```

-continued

<400> SEQUENCE: 24

gactcgatat cgagtctgtg atcaactcca tgtgcc 36

<210> SEQ ID NO 25

<211> LENGTH: 28

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic probe

<400> SEQUENCE: 25

cgctacatct ctgctgtaca tggtagcg 28

<210> SEQ ID NO 26

<211> LENGTH: 18958

<212> TYPE: DNA

<213> ORGANISM: Zaire ebolavirus

<400> SEQUENCE: 26

cggcacacaca aaaagaaaaga agaattttta ggatctttt tggtgcgaata actatgagga 60

agattaataa ttttcctctc attgaaattt atatcggaat ttaaattgaa attgttactg 120

taatcacacc tggtttggg cagagccaca tcacaaagat agagaacacg ctaggtctcc 180

gaagggaaca agggcaccag tggctcagt tgaaaatccc ttgtcaacat ctaggtctta 240

tcacatcaca agttccaccc cagactctgc agggtgtatc aacaacccta atagaaaaat 300

tattgttaac ggacagcatt agttcacagt caaacaagca agattgagaa ttaaccttga 360

ttttgaacctt caacacccatg aggattggag attcaacaac cctaaaactt ggggtaaaac 420

attggaaata gttgaaagac aaattgctcg gaatcacaaa attccgagtg tggattctcg 480

tcctcagaaa gtctggatga cgccgagtct tactgaatct gacatggatt accacaagat 540

cttgacagca ggtctgtccg ttcaacaggg gattgttcgg caaagagtca tcccgagtgt 600

tcaagtaaac aatcttgagg aaatttgcca acttatcata caggccttg aagcagggt 660

tgatTTCAA gagagtgcgg acagtttctc tctcatgctt tgcgttcatc atgcgtacca 720

aggagatcac aaactttct tggaaagtgg tgcagtcaag tatttggaa ggcacgggt 780

ccgtttgaa gtcaagaaac gtgatgggtt gaagcgcctt gaggaattgc tgccagcagt 840

atcttagtgg aaaaacatca agagaacact tgcgtccatg ccggaaagagg agacgactga 900

agctaatgcc ggtcagtttc tctttttgc aagtcttcc cttccgaaat tggtagtagg 960

agaaaaggct tgccttgaga aagttcaaag gcaaattcaa gtacatgcag agcaaggact 1020

gataacaat ccaacagctt ggcaatcagt aggacacatg atggtgatc tccgtttgt 1080

gcgaacaaat ttttgatca aatttctcct aatacaccaa gggatgcaca tggttgcgg 1140

gcatgatgcc aacgatgctg tgatttcaaa ttcaatggctt caagctgtt tttcagggtt 1200

attgatgtc aaaacagtc ttgtatcata cctacaaaag acagaacgag gagttcgct 1260

ccatcccttc gcaaggactg ccaaggtaaa aaatgagggt aactccctta aggctgcact 1320

cagctccctg gccaaggatg gagagtatgc tccttcgccc cgactttga acctttctgg 1380

agtaaataat cttgagcatg gtctttccc tcaactatcg gcaattgcac tcggagtcgc 1440

cacagcacac gggagcaccc tcgcaggagt aaatgttggg gaacagtatc aacagctcg 1500

agaggctgcc actgaagctg agaagcaact ccaacaatat gcagaatctc gcgaaactgt 1560

ccatcttgg aattttttttt aattttttttt aattttttttt aattttttttt aattttttttt 1620

-continued

cggaaatcagc ttccagcaaa caaacgctat ggtaactcta agaaaagagc gcctggccaa	1680
gctgacagaa gctatcactg ctgcatactact gccccaaaaca agtggacccctt acgatgtatga	1740
tgacgacatt ccctttccag gaccatcaa tgatgacgac aatcctggcc atcaagatga	1800
tgatccgact gactcacagg atacgaccat tcccgtgtg gtgggttgc acgatgtatgg	1860
aagctacggc gaataccaga gttactcgga aaacggcatg aatgcaccag atgacttgg	1920
cctattcgtat ctagacgagg acgacgagg aactaagcca gtgcctaaca gattgaccaa	1980
gggtggacaa cagaaaaaaca gtcaaaaggcc acggcataca gagggcagac agacacaatc	2040
caggccaaact caaaatgtcc caggccctcg cagaacaatc caccacgcca gtgcctccact	2100
cacggacaac gacagaggaa atgaaccctc cggctcaacc acggccctcgca tgctgacacc	2160
aattaacgaa gaggcagacc cactggacga tgccgacgac gagacgtcta gtcttccgccc	2220
cttggagtca gacgatgaag aacaggacag ggacgaaact tccaaacogca caccactgt	2280
cgccccccacg gtcctccgtat acagagatca ctctgaaaag aaagaactcc cgcaagatga	2340
gcagcaagat caggaccaca ctcaagagggc caggaaccag gagagtgaca acacccagcc	2400
aagaacactct tttgaggaga tgtatcgcca cattctaaaga tcacaggacat catttgatgc	2460
tgttttgtat tatcatatga tgaaggatga gcctgttgtt ttcaactacta gtgtggcaa	2520
agagttacacg tatccggact cccttgaaga ggaatatccca ccatggotca ctgaaaaaga	2580
ggccatgaat gaagagaata gattgttac attggatggt caacaattttt attggccggt	2640
aatgaatcac aagaataaat tcatggcaat cctgcaacat catcagtgaa tgagaatggaa	2700
ataatggat gatthaaccg acaaataatgc aacattaaat agtcaagaaaa cgcaaacagg	2760
aagaattttt gatgtctaaag gtgtgaatta ttatcacaat aaaagtattt cttattttg	2820
aatttaaagc tagcttattta ttactagccg ttttcaaag ttcaatttga gtcttaatgc	2880
aaataggcgt taagccacag ttatagccat aattgttaact caatatctt gctagcgtt	2940
tatctaaattt aaattacatt atgcttttat aacttaccta ctgcctgcc caacattttac	3000
acatcgctt tataattaag aaaaaactaa tgatgaagat taaaaccttc atcatcctt	3060
cgtcaatttga attctcttagc actcgaagct tattgtcttc aatgtaaaag aaaagctgg	3120
ccaaacaagat gacaactaga acaaaggca gggccatata tggcgcacacg actcaaaacg	3180
acagaatgcc agggccctgag ctttcgggtt ggatctccga gcagctaatg accggaaagaa	3240
ttcctgttaag cgacatcttc tggatatttgc agaacaatcc aggattatgt tacgcatttt	3300
aaatgcacaa aacaaagcca aaccgcaga tgcgcaacag tcaaacccaa acggacccaa	3360
tttgcacatca tagttttgag gaggtgttgc aacacattggc ttcatggct actgtttgc	3420
aacaacaaac tatcgcatca gaatcatttgc aacaacgtat tacgagtctt gagaatggc	3480
taaagccagt ttatgtatgc gcaaaaacaa tctcctcattt gaacagggtt tggatgttgc	3540
tggttgcaaa atatgtatctt ctggatgtatgc caaccggctcg ggcaacagca accactgcgg	3600
caactgaggc ttattgggtt gaacatggc aaccaccacc tggaccatca ctttatggaa	3660
aaagtgcacaa tgggggttgc attgtatgc aacatggc tggatgtatgc ctggatgttgc	3720
aggcattcaa caatctagac agtaccactt cactaactga ggaaaattttt gggaaacactg	3780
acatccatcgaa aaggatggt agaaacattt tggatgtatgc ctggatgttgc tttggatgttgc	3840
ctttccacca attgtacaa tggatgtatgc aattggaaa agatagcaac tcattggata	3900
tcattcatgc tggatgtatgc gggccatata tggatgtatgc ctggatgttgc tttggatgttgc	3960

-continued

ttcaaattac aaaaagagtt ccaatcttcc aagatgctgc tccacctgtc atccacatcc	4020
gctctcgagg tgacattccc cgagcttgcg agaaaagctt ggcgtccagtc ccggccatcac	4080
ccaagattga tcgaggttgg gtatgtgtt tccagcttca agatggtaaa acacttgac	4140
tcaaaatttg agccaatctc ccttccctcc gaaagaggcg accaatagca gaggttcaa	4200
ctgctgaact acagggtacg ttacattaat gatacacttg tgagtatcag cccttagataa	4260
tataagtcaa tttaaacgacc aagccaaat tggccatatac ccgctagcag cttaaaatata	4320
aaatgaaata ggagctatac ctctgacagt attataatca attgttattta agtaacccaa	4380
acccaaaatg atgaagatta agaaaaacct acctcgactg agagagtgtt tttccatcaa	4440
ccttcatctt gtaaacggtt agccaaattt tgacgaatat gaggcgggtt atattgccta	4500
ctgctccctcc tgaatatacg gaggccatatac accctgtcag gtcaaattca acaattgcta	4560
gggggtggcaa caacaataca ggcttcctga caccggagtc agtcaatgga gacactccat	4620
cgaatccact caggccaaatt gctgtatgaca ccatcgacca tgctagccac acaccaggca	4680
gtgtgtcatc agcattcatc cttgaagctt tggtgaatgt catatcgccccc aaaggatgc	4740
taatgaagca aattccaaatt tggccatctt taggtgtcgc tgatcaaaag acctacagct	4800
ttgactcaac tacggccgccc atcatgcttgc cttcatatac tatcaccat ttcggcaagg	4860
caaccaatcc acttgtcaga gtcaatcgcc tgggtcctgg aatccccggat cacccttcata	4920
ggctccctgcg aattggaaac caggccctcc tccaggagtt cgttcttccg ccagtccaaac	4980
taccccgatc tttcacctt gatttgacag cactcaaact gatcacccaa ccactgctg	5040
ctgcaacatcg gaccgtatgc actccaaacag gatcaatgg agcgctgcgt ccaggaaattt	5100
cgtttcatcc aaaacttcgc cccattcttt tacctaaca aagtggaaag aagggaaaca	5160
gtgccgatct aacatctcca gagaaaatcc aagcaataat gacttcactc caggacttta	5220
agatcggtcc aattgtatcca accaaaaata tcatgggtat cgaagtgcga gaaactctgg	5280
tccacaagct gaccggtaag aagggtactt ctaaaaatgg acaaccatc atccctgttc	5340
ttttgc当地 gtagatgggg tgggacccgg tgggtccagg agacctcacc atggtaatca	5400
cacaggatttgc tgacacgtgt cattctcttgc caagtcttcc agctgtgatt gagaagtaat	5460
tgcaataatt gactcagatc cagtttaca gaatcttctc agggatagtg ataacatcta	5520
ttagtataatc cgtctattatc aggagatact tttatgtatcaatataacta aagggtcttt	5580
acaccattgt ctttttctc tcctaaatgt agaacttaac aaaagactca caatataactt	5640
gtcttaaaga gattgtatgc tgaaagatca tgactaataa cattacaat aatctacta	5700
taatcaatac ggtgattcaa atattaatct ttcttaattgc acatactctc tgccctatc	5760
ctcaaattgc ctacatgcct acatctgagg atagccatgt tgacttggat tggagatgt	5820
ggaaagaaat cggaaaccat ctccagggttgc ttcacaatcc aagcacagac atcgcccttc	5880
taatataaaga aaaatccggcg atgaagatca agccgacatg gacgcgcaatc ttccatcttc	5940
ttagattatt tttttccatc agtaggggtc atcaggcttccatc ataaaccaaaa	6000
taaaacttcac tagaaggata ttgtgaggca acaacacaat gggtattaca ggaatattgc	6060
agttacctcg tgatcgattc aagaggacat cattcttctt ttgggtattt atccctttcc	6120
aaagaacatt ttccatccca cttggaggatca tccacaatag cacattacaat gtttagtgc	6180
tcgacaaactt agttgtcgatc gacaaactgtt catccacaaa tcaattgaga tcaatggac	6240
tgaatctcg aaggaaatggg gttggcaactg acgtgcacatc tgcaactaaa agatgggct	6300
tcaggccgg tggccatccca aagggtgtca attatgaagc tgggtatgg gctgaaaact	6360

-continued

gctacaatct tgaaatcaa aaacctgacg ggagttagtg tctaccagca gcgccagacg 6420
 ggattcgggg cttccccgg tgccgttatg tgcacaaagt atcaggaaacg ggaccgttg 6480
 ccggagactt tgccttccac aaagagggtg ctttcttct gtatgatcga cttgcttcca 6540
 cagttatcta ccgaggaacg actttcgctg aaggtagtcgt tgcattctg atactgcccc 6600
 aagctaagaa ggacttcttc agctcacacc cttgagaga gccggtaat gcaacggagg 6660
 acccgtccag tggctactat tctaccacaa ttagatata ggctaccggg tttggAACCA 6720
 atgagacgga gtacttgttc gaggttgaca atttgaccta cgtccaaactt gaatcaagat 6780
 tcacgccaca gttttgttc cagctgaatg agacaatata tgcaagtggg aaaaggagca 6840
 acaccacggg aaaactaatt tggaaggta accccgaaat tgatacaaca atcggggagt 6900
 gggccttctg ggaaactaaa aaaacctcac tagaaaaatt cgcaagtgaag agttgtctt 6960
 cacagctgta tcaaacggag ccaaagacat cagtggtcag agtccggcgc gaacttctc 7020
 cgaccacagag acctacacaa caactgaaga ccacaaaattt atggcttcag aaaattctc 7080
 tgoaatggtt caagtgcaca atcaaggaag ggaagctgca gtgtcgcatc tgataaccct 7140
 tgccacaatc tccacgagtc ctcaatcccc tacaacccaa ccaggtcagg acaacagcac 7200
 ccataataca cccgtgtata aacttgacat ctctgaggca actcaagttt aacaacatca 7260
 tgcgagaaca gacaacgaca gcacagccctc cgacactccc cccgcccacga ccgcagccgg 7320
 acocccaaaaa gcagagaaca tcaacacgag caagagcgct gactccctgg accccgcccc 7380
 cacgacaagt ccccaaaact acagcagacac cgctggcaac aacaacactc atcacaaga 7440
 taccggagaa gagagtgcgg gcagcgggaa gctgggctt attgccaata ctattgctgg 7500
 agtcgcaggg ctgatcacag gccccggaaaag aactcgaaga gaagcaattt tcaatgctca 7560
 accccaaatgc aaccccaatc tacattactg gactactcag gatgaagggtg ctgcaatcg 7620
 attggcctgg ataccatatt tcgggcccagc agecgaggaa atttacacag aggggctaat 7680
 gcacaatcaa gatggttaa tctgtggatt gaggcagctg gccaatgaga cgactcaagc 7740
 ttctcaactg ttccctgagag ccacaactga gctacgcacc ttttcaatcc tcaaccgtaa 7800
 ggcatttatgat ttcttgctgc agcgatgggg cggcacatgc cacatgggg gaccggactg 7860
 ctgtatcgaa ccacatgatt ggaccaagaa cataacagac aaaattgttc agattatca 7920
 tgatttgtt gataaaaccc ttccggacca gggggacaat gacaatttggg ggactggatg 7980
 gagacaatgg ataccggcag gtattggagt tacaggcgatc ataattgcag ttattgctt 8040
 attctgtata tgcaaatttg tcttttagtt tttttcaga ttgcttcatg gcaaagctca 8100
 gcctcaaatc aatgagatta ggatattt atatggatca cttgaatcta agattactg 8160
 acaaataatgata atataataca ctggagcttt aaatatacgcc aatgtgatcc taactccctt 8220
 aaactcacaat ttaatcataa acaagggttt acatcaatct agtttatatct ttgagaatga 8280
 taaaacttgat gaagattaag aaaaaggtaa tctttcgatt atcttttagtc ttcatccctt 8340
 attctacaat catgacagtt gtcttttagtg acaaggggaaa gaagccttt tagtaagttg 8400
 taataatcg atctgcgaac cggttagagtt taattgcac ctaacacaca taaaggattt 8460
 gtcaaaaagt caatagaaat ttaaacagtg agtggagaca actttcaat ggaagctcca 8520
 tacgagagag gacgccccgg agctgccaga cagcattcaa gggatggaca cgaccatcat 8580
 gttcgagcac gatcatcatc cagagagaat tatcgaggtt agtaccgtca atcaaggagc 8640
 gcctcacaag tgccgttcc tactgttattt cataagagga gagttgaacc attaacagtt 8700

-continued

cctccagcac ctaaaagacat atgtccgacc ttggaaaaag gattttgtg tgacagtagt	8760
tttgcaaaa aagatcacca gttggaaagt ttaactgata ggaaattact cctactaatc	8820
gcccgtaga a cttgtggatc agtagaacaa caattaaata taactgcacc caaggactcg	8880
cgcttagcaa atccaacggc t gatgattc cagcaagagg aaggtc当地 aattaccttg	8940
ttgacactga tcaagacggc agaacactgg gcgagacaag acatcaggac cacagaggat	9000
tcaaaattaa gaggattgtt gactctatgt gctgtgatc cgaggaaatt ctcaaaatcc	9060
cagctgagtc ttttatgtga gacacacctg aggccgagg ggcttggca agatcaggca	9120
gaacctccgtc tcgaagtata tcaacgatta cacagtata aaggaggcag tttcgaagct	9180
gcactatggc aacaatggg tcgacaatcc ctaattatgt ttatcactgc attcttgaat	9240
atcgctctcc agttaccgtg tgaaaggctt gctgtcgat tttcagggtt aagaacattg	9300
gttcctcaat cagataatga ggaagcttca accaaccggg ggacatgctc atggctgtat	9360
gatggtagccc cttataaagg ctgactaaaa cactatataa ctttctactt gatcacaata	9420
ctccgtatac ctatcatcat atattcaatc aagacggat cttttaaaac ttattcagta	9480
ctataatcac tctcgatcc aattaataag atatgcataa ttgc当地 atatgaagag	9540
gtatgatatac accctaatacg t gatcaaaga aaatcataat ctcttacgc tcgtaatata	9600
acctgccaag cataccttgc gcacaaaggatg attcttgcata acaaataatg ttttactcta	9660
caggaggttag caacgatcca tcccatcaaa aaataaggat tttatgactt actaatgatc	9720
tcttaaaata ttaagaaaaa ctgacggAAC acaaattctt tctgcttca gttgtggagg	9780
aggtctttgg tattggctat tgatattataa caatcaataa caagctgtt aaaaatattgt	9840
tcttgatcc aagggtagat t gatgacgg aacgctaaac taatgatgaa gattaatgcg	9900
gagggtctgtat aagaataaac cttattatc agattaggcc ccaaggcata ttcttcatct	9960
ccttttagca aagtactatt tcagggtatg ccaattatgt acacgtctt tagctgtata	10020
tcagtcgcccc ctgagatacg ccacaaaagg gtctctaagc taaattggc t gatcacatc	10080
tcatacattt gattagggc aataatatct aattgaaactt agccgtttaa aatttagtgc	10140
ataaacctgg gctaactcca ccaggatcaac tccattggct gaaaagaagc ccacccatcaa	10200
cgaacatcac tttgagcgc cttacaatta aaaaatagga acgtcgatcc aacaatttgc	10260
cgcaagggtt caaggtgaa ctgagatgc ctaaacacca aaatatcgat aattcagaca	10320
ccaagcaaga cctgagaagg aaccatggct aaagctacgg gacgatacaa tctaatacg	10380
cccaaaaaagg acctggagaa aggggttgc ttaagcgacc tctgtaactt cctagttgt	10440
caaactattt aagggtggaa ggtctattgg gctggatgg agtttgc当地 gactcaca	10500
ggaatggccc tattgcatac actgaaaact aatgactttt cccctgc当地 gtc当地	10560
aggaatctat ttccctatattt aattcaaaaat ccgaattcca caattgatgc accactgtgg	10620
gcattgagag tcatcctgc agcagggtta caggaccagg tgatggatc gtcttgc当地	10680
gaacccttag caggagccct tggctgatc tctgatggc tgctaaacaa caacactaac	10740
catttcaaca tgc当地 acgtgttgc gaaatgtt gcttggaaat gctgtcgat	10800
attcgatcca atattctcaa gtttattaaac caattggatc ctctacatgt cgtactac	10860
aacgggttgc tgagcactat tgaaatttgc actcaaaatc atacaatcat tataactcg	10920
actaacatgg gtttttgtt ggatccaa gaacctggaca aatcgccatc gaacctggca	10980
aaggcctggc cggc当地 aatttgc当地 catgatccca cactgaaagc aatttgc当地	11040
gggtccctcga cacgatgc当地 aagtttgc当地 cttgatccaa atagctctt gatc当地	11100

-continued

ttaagatgga atacttcata ttgagctaac tcataatatgc tgactcaata gttatcttga 11160
catctctgt ttcataatca gataatataag cataataaaat aaataactcat atttcttgat 11220
aatttggta accacagata aatcctaact gtaagccage ttccaagttg acacccttac 11280
aaaaaccagg actcagaatc cctcaaataa gagattccaa gacaacatca tagaattgct 11340
ttattatatg aataagcatg ttatcaccag aaatccaata tactaaatag ttaattgtaa 11400
ctgaacccgc aggtcacgtg tgtaggttt cacagattat atatattact aactccatc 11460
ccgttaattaa cattagataa gtagattaag aaaaacgctt gaggaagatt aagaaaaact 11520
gcttattggg tctttccgtg tttagatga agcagttgac attcttcctc ttgatattaa 11580
atggctacac aacataccca ataccagac gccaggttat catcaccaat tgtattggac 11640
caatgtgacc tagtcaactag agcttgcggg ttatattcat catactccct taatccgca 11700
ctacgcaact gtaaactccc gaaacatato taccgtttaa aatatgtatgt aactgttacc 11760
aagttcttaa gtgatgtacc agtggcgaca ttgccaatag atttcatagt cccattctt 11820
ctcaaggcac tgcaggcaa tgggttctgt cctgttgagc cgccgtgtca acagttctt 11880
gatgaaatca ttaagtacac aatgoaagat gctctttcc tggaaatattt tctcaaaaat 11940
gtgggtgctc aagaggactg tgtagtgcact cacttcaag agaaaatctt atcttcaatt 12000
cagggcataatg aatttttaca tcaaattgttc ttctggatg acctggctat tttgactcga 12060
aggggttagat taaatcgagg aaactctaga tcaacatggg ttgttcatga tgatttaata 12120
gacatcttag gctatgggg aatgttttt tggaaatgc caatttcaat gttaccctg 12180
aacacacaag gaatccccca tgctgctatg gatgggtatc aggcatacg attcaaagaa 12240
gcgggttcaag ggcatacaca cattgtttct gttctactg ccgacgtctt gataatgtgc 12300
aaagatttaa ttacatgtcg attcaacaca actctaattt caaatgc agaggtttag 12360
gatccagttt gttctgatta tcccgatttt aagattgtt ctatgttta ccagagccg 12420
gattactac tctccatatt agggtctgtat gggataaaaa ttattaaatgtt cctcgaaat 12480
ttgtgcttgg caaaaattca attatgtca aagtacaccg agaggaaggg ccgattctt 12540
acacaaatgc atttagctgt aaatcacacc ctggaaagaaa ttacagaaat gcgtgcacta 12600
aaggcctcac aggatcaaaa gatccgtaa ttccatagaa cattgataag gctggagatg 12660
acgccacaac aactttgtga gctattttcc attcaaaaac actgggggca tcctgtgtca 12720
catatgtaaa cagcaatcca aaaagttaaa aaacatgcca cgggtctaaa agcattacgc 12780
cctatagtga ttttcgagac atattgtt tttaaatata gtattgcaaa acattattt 12840
gatagtcaag gatcttggta cagtgttact tcagatagga atttaacgcc aggtcttatt 12900
tcttataatca aagaaatca attccccccg ttgccaatga ttaaagaact actatggaa 12960
tttaccacc ttgaccatcc tccacttttc tcaacaaaaa ttattagtga cttaagtatt 13020
tttataaaag acagagctac cgcaatggaa aggacatgct gggatgcagt attcgagcct 13080
aatgttctag gatataatcc acctcacaaa ttcaatgtacta aacgtgtacc agaacaattt 13140
tttagagcaag aaaacttttc tattgagaat gttcttcctt acgcgcaaaa actcgagttat 13200
ctactaccac aataccggaa ttttcttcc tcattgaaag agaaagaggtaa gaatgttagt 13260
agaactttcg gaaaattgcc ttatccgact cgcaatgttca aacactttg tgaagctctg 13320
tttagctgtatg gtcttgcata agcatttcctt agcaatgttca ggttagtgcac agagcgtgag 13380
caaaaagaaa gcttattgca tcaagcatca tggcaccaca caagtgtatga ttttggttag 13440

-continued

catgccacag ttagagggag tagctttgta actgatttag agaaatacaa tcttcattt 13500
agatatgagt ttacagcacc ttttatagaa tattgttaacc gttgctatgg tggttagaat 13560
gttttaatt ggatgcatta tacaatcccc cagtgttata tgcattgtcag tgattattat 13620
aatccaccgc ataacctcac tctggaaaat cgagacaacc ccccccgaagg gcccagttca 13680
tacagaggtc atatgggagg gattgaagga ctgcaacaaa aactctggac aagtatttca 13740
tgtgctcaa tttctttagt tgaaataaaag actggttta agttacgcctc agctgtgatg 13800
ggtgacaatc agtgcattac cgtttatca gtcttccct tagagactga cgccagacgag 13860
caggaacaga gcgcgaaga caatgcagecg agggtggccg ccagcctagc aaaagttaca 13920
agtgcctgtg gaatctttt aaaaacctgtat gaaacatttgc tacattcagg ttttatctat 13980
tttggaaaaa aacaatattt gaatggggtc caattgcctc agtcccttaa aacggctaca 14040
agaatggcac cattgtctga tgcaattttt gatgatcttc aaggggaccct ggctagtata 14100
ggcactgctt ttgaacgatc catctctgag acacgcacata tcttccttg caggataacc 14160
gcagcttcc atacgtttt ttccgggtgaga atcttgcacatc atcatcacct cgggttcaat 14220
aagggttttgc accttggaca gttgacactt ggcaaaaccc tcggatttcgg aacaatatca 14280
ttggcacttag cggtaccgcgca ggtgcttggaa gggttattctt tcttgaatcc tgagaaatgt 14340
ttctaccgga atttaggaga tccagttacc tcaggcttat tccagttaaa aacttatttc 14400
cgaatgatttgc agatggatga tttattctta cctttatgtt cgaagaaccc tgggaactgc 14460
actgccatttgc acctttgtctt aaatccttgcgca ggattaaatg tccccgggtc gcaagactta 14520
acttcatttc tgcgcagat tgcgttgcggacttccatc taagtgcgaa aaacaaactt 14580
attaataactt tatttcatgc gtcagctgac ttcaagacg aaatggtttgc taaatggcta 14640
ttatcatcaa ctccctgttat gagtcgtttt gcggccgata tcttttcacg cacgcccagt 14700
gggaagcgat tgcaaaattctt aggataccgtt gaaggaacac gcacattatt agcctctaag 14760
atcatcaaca ataatacaga aacaccgggtt ttggacagacg tgagggaaat aacattgca 14820
aggtggagtc tatggtttag ttatcttgcgat cattgtgata atatcctggc agaggctta 14880
acccaaataa cttgcacagt tgatttagca cagatctgtt gggaaatatttcttgcacat 14940
attttagagg ggagacctctt tattggagcc acacttccat gtatgattga gcaattcaaa 15000
gtgggttggc tgaaacccctt cgaacaatgtt ccgcgtgtt ccaaatgcggaaaccccttgcgtt 15060
gggaaaccat tcgtgtcagt ggcagtcaag aaacatatttgc ttagtgcattt gccgaacgca 15120
tccccgaataa gctggactat cggggatggaa atccccatataa ttggatcaag gacagaagat 15180
aagataggac aacctgttat taaacccaaaa tgccttcgg cagccttaag agaggccattt 15240
gaactggcgat cccgtttaac atgggttactt caaggcgtt cgaacagtgc tttgttataa 15300
aaaccatattt tggaaagcactt agttaatttgc ttagtgcattt gcaattcaaa 15360
tcacattactt caggaaatatttgc ttttttttttgc ttttttttttgc ttttttttttgc 15420
atggccaatc gtatgatgttgc ttcagcgacttgc cgttgcatttgc ttttttttttgc 15480
gagtttttcag gaggtggccat ttttttttttgc ttttttttttgc ttttttttttgc 15540
aattatgcgtt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 15600
tataatcgat ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 15660
ttaacatataa catctacatttgc ttttttttttgc ttttttttttgc ttttttttttgc 15720
tatgacaataa atcctcttgc ttttttttttgc ttttttttttgc ttttttttttgc 15780
ttccaaaggta aacggctaaa cattatagaa gatgatcttgc ttttttttttgc ttttttttttgc 15840

-continued

ggatggagc tagccaagac catcatgaa tcaattttt cagatagaa caattcgct 15900
acagacccaa ttagcagtgg agaaacaaga tcattcaactt cccattttt aacttatccc 15960
aagataggac ttctgtacag ttttgggcc tttataagtt attatcttgg caatacaatt 16020
cttcggacta agaaaattaac acttgacaat tttttatattt acttaactac ccaaattcat 16080
aatctaccac atcgctcatt gcgaaatctt aagccaaatc tcaaacatgc aagcgttatg 16140
tcacggtaa tgagttatgaa tcctcattttt tctatttaca taggcgggtgc ggcagggtgac 16200
agaggactct cagatcgccg cagggttattt ttgagaacgt ccatttcattt ttttcttgc 16260
tttataaaag agtggataat taatcgccga acaattgtcc ctatggat agtataatccg 16320
ctagagggtc aaaacccaac acctgttaat aatttcccttcc atcagatcgta agaactgctg 16380
gtgcattgtt catcaagaca acaggctttt aaaactacca taagtgtatca tgtacatcct 16440
cacgacaatc ttgttttacac atgtaagagt acagccagca atttcttcca tgcgttattg 16500
gcgtactgga gaagcaggca cagaaacagc aatcgaaaat acttggcaag agacttca 16560
actggatcaa gcacaaacaa cagtgtatggt catattgaga gaagtcaga acaaaccacc 16620
agagatcccc atgatggcac tgaacggaaat ctatgttccaa aatgagccaa tgaaataaaa 16680
agaacgacaa ttccacaaga aagcacgcac cagggtccgt cgttccagtc atttctaagt 16740
gactctgtt gtggtaacagc aaatccaaaa ctaaatttgc atagatcgag acataatgt 16800
aaatctcagg atcataactc ggcatccaaag agggaaaggc atcaaataat ctcacaccgt 16860
ctagtccctac ctttcttac attgtctcaa gggacgcgc aattaacgctc atccaatgag 16920
tcacaaaccc aagacgagat atcaaagtttac ttacggcaat tgagatccgt cattgatacc 16980
acagtttttattt gtaggtttac cggtatagtc tcgtccatgc attacaaaact ttagtgggtc 17040
ctttggaaaa tagagagttt taagtcggct gtgacgctag cagagggaga aggtgtgg 17100
gccttactat tgattcagaa ataccaagttt aagaccttattt tttcaacac gctagctact 17160
gagtcctagta tagagtccaga aatagttatca ggaacgacta ctccttaggt gcttctac 17220
gttatgtcaa aattccatata tgaccaaattt gagattttc ttaacaattt ggcacaccaa 17280
ataacagaca taacaaatcc tactgggttca aaagacccaa gagcaaggctt acctaggcaa 17340
gtcgagggtta taaccatgga tgcagagacg acagaaaata taaacagatc gaaatttgtac 17400
gaagctgtat ataaatttgtat cttacaccat attgtatccca gcttattgaa agcagtggtc 17460
cttaaagtct ttcttaagtgt tactggggat atgttatggc taaatgataa ttttagcccc 17520
tttttgccca ctggttatattt aattaagccaa ataacgtcaa gtgctagatc tagtgagtgg 17580
tatctttgtc tgacgaaactt cttatcaactt acacgttacaaga tgccacacca aaaccatctc 17640
agttgtaaac aggtataact tacggcattt caactgcaaa ttcaacggag cccatactgg 17700
ctaagtctttaactcagta tgctgactgc gatttacattt taagttatattt ccgccttgg 17760
tttccatcat tagagaaagt actataaccac aggtataacc tctgtcgattc aaaaagaggt 17820
ccacttagtct ctatcactca gcacttggca catcttagag cagagattcg agaatttgact 17880
aatgattata atcaacagcg acaaaggctgg actcaaaatc atcactttt tcgtactgc 17940
aaaggacgaa tcacaaaactt agtcaatgtat tattttttat tttttcttgc tttgtgc 18000
ttaaaacata atgggacatg gcaagctgg tttttaagaaat taccagagttt gatttagtgc 18060
tgcaataggt ttatcatat tagagattgc aattgtgaag aacgtttttt agttcaaaacc 18120
ttatcatatc atagaatgca ggattctgaa gttaaagctt tgcggatggctt gacagggttt 18180

-continued

```

ctgagttat tcccgatgg tcttacagg ttgttggaa ttaccgtgca tagtatccctg 18240
atacttgtga aggttggata tcaacgtaca gattataaaa aactcacaaa ttgcctctcat 18300
acatcatatt gatcgatatt caataaataa ctattnaat aacgaaagaa gtccttat 18360
tatacactat atttagcctc tctccctcg tgataatcaa aaaattcaca atgcagcatg 18420
tgtgacatat tacttcccgcg atgaatctaa cgcaacataa taaactctgc actctttata 18480
attaagctt aacaaaaggt ctgggctcat attgttattt atataataat gttgtatcaa 18540
tacccgtca gatggatag tggtttgggt gataacacga cttcttaaaa caaaattgtat 18600
cttcaagatt aagttttta taattatcat tactttaattt tgtcgattttaaaaatggta 18660
tagccttaat ctttgttaa aataagagat taggtgtat aactttaaca ttttgcttag 18720
taagctacta tttcatacag aatgataaaa taaaagaaaa aggcatgact gtaaaatcag 18780
aaataacctc tttacaatatacag aatgataaaa taaaagaaaa aggcatgact gtaaaatcag 18840
acattgacca cgctcatcag gaggctcgcc aggataaacg ttgcaaaaag gattcctgga 18900
aaaaatggtcg cacacaaaaa tttaaaaata aatctatttc ttcttttttg tgggtccaa 18958

```

<210> SEQ ID NO 27
<211> LENGTH: 341
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 27

```

ataggcgga gggaaagctca tcagtggggc cacgagctga gtgcgtccctg tcactccact 60
ccccatgtccc ttgggaaggt ctgagactag ggccagaggc ggccctaaca gggctctccc 120
tgagcttcgg ggaggtgagt tcccagagaa cggggctccg cgcgagggtca gactggcag 180
gagatgcgtt ggaccccgcc ctteccccggag gggcccgccg gatgcctctt tgccggagc 240
ttggAACAGA ctcacggcca gcgaagttagt ttcaatggct gaggtgaggt accccgcagg 300
ggacctcata acccaattca gactactctc ctccgccccat t 341

```

<210> SEQ ID NO 28
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (6)..(12)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 28

gagtcnnnnn nn 12

<210> SEQ ID NO 29
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (6)..(10)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 29

ggatcnnnnn 10

-continued

```

<210> SEQ ID NO 30
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (6)..(10)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 30

gagtcnnnnn

```

10

```

<210> SEQ ID NO 31
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (6)..(7)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 31

gactcnngag tc

```

12

```

<210> SEQ ID NO 32
<211> LENGTH: 14
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (6)..(9)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 32

gactcnnnng agtc

```

14

```

<210> SEQ ID NO 33
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (6)..(11)
<223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 33

gactcnnnnn ngagtc

```

16

```

<210> SEQ ID NO 34
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: modified_base

```

-continued

<222> LOCATION: (1)..(4)
 <223> OTHER INFORMATION: a, c, t, g, unknown or other
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (10)..(15)
 <223> OTHER INFORMATION: a, c, t, g, unknown or other
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (21)..(24)
 <223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 34

nnnnngactcn nnnnngagtc nnnn

24

<210> SEQ ID NO 35
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (1)..(4)
 <223> OTHER INFORMATION: a, c, t, g, unknown or other
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (10)..(13)
 <223> OTHER INFORMATION: a, c, t, g, unknown or other
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (19)..(22)
 <223> OTHER INFORMATION: a, c, t, g, unknown or other

<400> SEQUENCE: 35

nnnnngactcn nnngagtcnn nn

22

<210> SEQ ID NO 36
 <211> LENGTH: 23
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 36

cttcttagct tggggcagta tca

23

<210> SEQ ID NO 37
 <211> LENGTH: 500
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide

<400> SEQUENCE: 37

aagatgactg caggagtcaa tgccgcgttg gtcccgccag accaggcgaa cattaccgaa	60
ttttacaaca agtcccttac atcctacaag gagaatgagg agaacatcca gtgtgggag	120
aacttcatgg acatggagtg ctcatgatt ctgaacccca gtcagcagct ggcaattgcc	180
gtcttgctc tcacactggg caccttcaca gttctggaga acttgcgtgt gctgtgtgtc	240
accacagttt tctaccgagg aacgactttc gctgaagggtg tcgttgcatt tctgattcct	300
tcaactccgc agccctcgct gccggccctc ttaccacttc atcattagcc tggccgtggc	360
cgcacccctg gggagtgta tttttgtcta cagcttgcgt gactttcatg tggccacccg	420
caaggacagc cccaaacgtct ttctttcaaa attgggtggg gtcacccgcct cttcacggc	480

-continued

ctctgttaggc agcctttcc	500
<210> SEQ ID NO 38	
<211> LENGTH: 89	
<212> TYPE: RNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide	
<400> SEQUENCE: 38	
gacugcagga gucugcugcu uccacaguua ucuaccgagg aacgacuuuc gcugaaggug	60
ucguugcauu ucugauuccu ucacucccg	89
<210> SEQ ID NO 39	
<211> LENGTH: 36	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer	
<220> FEATURE:	
<223> OTHER INFORMATION: Description of Combined DNA/RNA Molecule: Synthetic primer	
<220> FEATURE:	
<221> NAME/KEY: modified_base	
<222> LOCATION: (24)..(24)	
<223> OTHER INFORMATION: Methoxy base	
<220> FEATURE:	
<221> NAME/KEY: modified_base	
<222> LOCATION: (31)..(36)	
<223> OTHER INFORMATION: Methoxy base	
<400> SEQUENCE: 39	
gactcgatat cgagtccacg agcugagtg guccug	36
<210> SEQ ID NO 40	
<211> LENGTH: 35	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer	
<220> FEATURE:	
<223> OTHER INFORMATION: Description of Combined DNA/RNA Molecule: Synthetic primer	
<220> FEATURE:	
<221> NAME/KEY: modified_base	
<222> LOCATION: (24)..(24)	
<223> OTHER INFORMATION: Methoxy base	
<220> FEATURE:	
<221> NAME/KEY: modified_base	
<222> LOCATION: (31)..(35)	
<223> OTHER INFORMATION: Methoxy base	
<400> SEQUENCE: 40	
gactcgatat cgagtccagac cttcccaagg gacau	35
<210> SEQ ID NO 41	
<211> LENGTH: 27	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic probe	
<400> SEQUENCE: 41	
ccacgcctgt cactccactc cgcgtgg	27

-continued

<210> SEQ ID NO 42
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 42

cctctggccc tagtctcag

19

<210> SEQ ID NO 43
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 43

gcatctaatt tttcgcc

17

<210> SEQ ID NO 44
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 44

tctgtgcctg gattgat

17

<210> SEQ ID NO 45
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 45

tttggacgt cttctcc

17

<210> SEQ ID NO 46
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 46

ttttgaacgt cttctcc

17

<210> SEQ ID NO 47
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 47

tatgttttgt ataaaagttc atttg

25

-continued

```

<210> SEQ ID NO 48
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Zaire ebolavirus

<400> SEQUENCE: 48
acgactttag ctgaag                                16

<210> SEQ ID NO 49
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Zaire ebolavirus

<400> SEQUENCE: 49
acgactttcg ctgaag                                16

<210> SEQ ID NO 50
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Zaire ebolavirus

<400> SEQUENCE: 50
tccacagtta tctaccgagg aacgacttgc gctgaagggtc tcgttgatt tctgat      56

<210> SEQ ID NO 51
<211> LENGTH: 59
<212> TYPE: DNA
<213> ORGANISM: Zaire ebolavirus

<400> SEQUENCE: 51
ttccacacgtt atctaccgag gaacgacttt cgttgcatt ttctgatac      59

<210> SEQ ID NO 52
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
probe
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (14)...(14)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 52
gctacacgac tttggctgaa ggttagc                                26

<210> SEQ ID NO 53
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
probe

<400> SEQUENCE: 53
gctacacctca gcraaagtgc gtagc                                25

<210> SEQ ID NO 54
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer
<220> FEATURE:
<221> NAME/KEY: modified_base

```

-continued

<222> LOCATION: (24)..(24)
 <223> OTHER INFORMATION: Methoxy base
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (32)..(36)
 <223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 54

gactcgatat cgagtccttc cacagtttac taccga

36

<210> SEQ ID NO 55
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (24)..(24)
 <223> OTHER INFORMATION: Methoxy base
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (32)..(36)
 <223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 55

gactcgatat cgagtcgctt ccacagttat ctaccg

36

<210> SEQ ID NO 56
 <211> LENGTH: 36
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (24)..(24)
 <223> OTHER INFORMATION: Methoxy base
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (32)..(36)
 <223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 56

gactcgatat cgagtcacag ttatctaccg aggaac

36

<210> SEQ ID NO 57
 <211> LENGTH: 33
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (24)..(24)
 <223> OTHER INFORMATION: Methoxy base
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (29)..(33)
 <223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 57

gactcgatat cgagtcaaat gcaacgacac ctt

33

<210> SEQ ID NO 58
 <211> LENGTH: 33
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence

-continued

```

<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (29)..(33)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 58

```

gactcgatat cgagtcgaaa tgcaacgaca cct

33

```

<210> SEQ ID NO 59
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (29)..(33)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 59

```

gactcgatat cgagtcagaa atgcaacgac acc

33

```

<210> SEQ ID NO 60
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (32)..(36)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 60

```

gactcgcgcg cgagtcacag ttatctaccg aggaac

36

```

<210> SEQ ID NO 61
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (32)..(36)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 61

```

gactcgcgcg cgagtcacaca gttatctacc gagaa

36

-continued

<210> SEQ ID NO 62
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (32)..(36)
<223> OTHER INFORMATION: Methoxy base
<400> SEQUENCE: 62

gactcgcgcg cgagtcac agttatctac cgagga

36

<210> SEQ ID NO 63
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (29)..(33)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 63

gactcgcgcg cgagtcaaat gcaacgacac ctt

33

<210> SEQ ID NO 64
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (29)..(33)
<223> OTHER INFORMATION: Methoxy base

<400> SEQUENCE: 64

gactcgcgcg cgagtgcggaa tgcaacgaca cct

33

<210> SEQ ID NO 65
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Methoxy base
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (29)..(33)
<223> OTHER INFORMATION: Methoxy base

-continued

<400> SEQUENCE: 65

gactcgcg cgagtcagaa atgcaacgac acc 33

<210> SEQ ID NO 66

<211> LENGTH: 55

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 66

ccacagttat ctaccgagga acgacttgc ctgaagggtg cgttgcatatt ctgat 55

<210> SEQ ID NO 67

<211> LENGTH: 71

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 67

tgactagcgg aggctagaag gagagagatg ggtgcgagag cgtcaatatt aagaggcgaa 60

aaatttagatg c 71

<210> SEQ ID NO 68

<211> LENGTH: 48

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 68

tgactagcag aggctagaag gagagagatg ggtgcgagag cgtcagta 48

<210> SEQ ID NO 69

<211> LENGTH: 71

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 69

caaaaacagc atattgacgc tggaaagac cacagatcct gctgtctctr caacatcaat 60

ccaggcagc a 71

<210> SEQ ID NO 70

<211> LENGTH: 47

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 70

caaaaacagc atattgacgc tggaaagac cacagatcct gctgtct 47

<210> SEQ ID NO 71

<211> LENGTH: 73

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 71

```
aatgcagat ggtctcagct atgaacacag caaaaacaat gaatggaatg ggaaaaggag      60
aagacgtcca aaa                                         73
```

<210> SEQ ID NO 72
 <211> LENGTH: 73
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 72

```
aatgcaaat ggtctcagct atgaacacag caaagacaat gaatggaatg ggaaaggag      60
aagacgttca aaa                                         73
```

<210> SEQ ID NO 73
 <211> LENGTH: 60
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 73

```
aatgcagat ggtttcagct atgaacacag caaaagcaat gaatggaatg gggaaaggag      60
```

<210> SEQ ID NO 74
 <211> LENGTH: 81
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 74

```
ggcccaactgt attgctactg aaaatctctg ctgtacatgg cacatggagt tgatcacaaa      60
tgaactttta tacaaaacat a                                         81
```

<210> SEQ ID NO 75
 <211> LENGTH: 58
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 75

```
ggcccaactgc actgctacta aaaatctctg ctgtacatgg cacatggagt tgatcaca      58
```

What is claimed is:

1. A method of amplifying a target RNA molecule in a reverse transcriptase and nicking amplification reaction, the 60 method comprising:

(a) contacting a target RNA molecule in a crude sample with a reverse transcriptase primer in the presence of a reverse transcriptase and dNTPs under conditions permissive for cDNA synthesis, thereby generating a cDNA;

(b) contacting the cDNA with

- (i) forward and reverse primers, wherein each primer comprises at least one nicking enzyme recognition sequence and a 3'-terminal recognition region which specifically binds the cDNA in the presence of a nicking enzyme, and one or more 2' modified nucleotides in the recognition region,
- (ii) dNTPs, and
- (iii) a strand-displacement polymerase under conditions permissive for the isothermal amplification of the cDNA, thereby generating amplicons.

117

2. The method of claim 1, wherein the polynucleotide molecule is an Ebola virus (EBOV), human immunodeficiency virus (HIV), dengue virus, influenza B virus, or bovine diarrhea virus polynucleotide.

3. The method of claim 1, wherein the method comprises a one-step reaction where the reverse transcriptase and strand-displacement polymerase are included in a single reaction and steps (a) and (b) are carried out at the same time.

4. The method of claim 1, wherein the reverse transcriptase enzyme and the strand-displacement DNA polymerase are the same or different enzymes.

5. The method of claim 1, wherein the method is carried out in about 5, 7, 10, 15, 20, 25, or 30 minutes.

6. The method of claim 1, wherein the primer used in step (a) has the same sequence as a primer used in step (b).

7. The method of claim 1, wherein the crude sample is a biological sample or an environmental sample.

8. The method of claim 7, wherein the biological sample is a swab of a mucosal membrane selected from the group consisting of buccal, nasal, eye, rectal, and vaginal or skin.

9. The method of claim 7, wherein the biological sample is a tissue sample obtained from a subject, necropsy, or culture media.

10. The method of claim 1, wherein the strand-displacement DNA polymerase is a 5'-exo-derivative selected from the group consisting of Bst DNA polymerase I, Gst DNA polymerase I, Gka DNA polymerase I, Gca DNA polymerase I, Gan DNA polymerase I, Gbo DNA polymerase I, Gsp70 DNA polymerase I, GspT3 DNA polymerase I, Gsp52 DNA polymerase I and/or fragments thereof.

11. The method of claim 1, wherein the nicking enzyme is one or more of Nt.BstNBI, Nt.BspD6I, Nt.BspQI, Nt.B-smAI, Nt.AlwI, N.Bst9I, or N.BstSEI.

12. The method of claim 1, wherein the reverse transcriptase is M-MLV RT, AMV RT, or RSV RT.

13. The method of claim 2, wherein the forward and reverse primers each comprise a nucleotide with a methoxy modification;

wherein the forward and reverse primers for detection of EBOV comprise primers selected from the group consisting of:

Forward primer:

(SEQ ID NO: 1)
GACTCGATATCGAGTCGCTTCCAmCAGTTATCmUmAmCmG,
and

Reverse Primer:

(SEQ ID NO: 2)
GACTCGATATCGAGTCGAAATGCmAACGAmCmAmCmU;

wherein the forward and reverse primers for detection of HIV comprise primers selected from the group consisting of:

Forward primers:

(SEQ ID NO: 6)
GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmAmG,
and

(SEQ ID NO: 7)
GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmAmG,
and

Reverse Primers:

(SEQ ID NO: 8)
GACTCGATATCGAGTCTATTGACmGCTmCmGmCmAmC,

118

-continued

(SEQ ID NO: 9)
GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC;

wherein the forward and reverse primers for detection of dengue virus comprise primers selected from the group consisting of:

Forward primer:

(SEQ ID NO: 11)
GACTCGATATCGAGTCCAAAACmAGCATATTmGmAmCmGmC,
and

Reverse Primer:

(SEQ ID NO: 12)
GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG,
and

(SEQ ID NO: 13)
GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG;

wherein the forward and reverse primers for detection of influenza B virus comprise primers selected from the group consisting of:

Forward primers:

(SEQ ID NO: 15)
GACTCGATATCGAGTCAAATGCmGATGGTCTCmAmGmCmTmA,
(SEQ ID NO: 16)

GACTCGATATCGAGTCAAATGCmAATGGTCTCmAmGmCmTmA,
and

(SEQ ID NO: 17)
GACTCGATATCGAGTCAAATGCmGATGGTTTCmAmGmCmTmA,
and

Reverse Primers:

(SEQ ID NO: 18)
GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT,

(SEQ ID NO: 19)
GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmT,
and

(SEQ ID NO: 20)
GACTCGATATCGAGTCCTCCCTTmCCCCATTCCATmTmCmAmTmT,
or

wherein the forward and reverse primers for detection of bovine diarrhea virus comprise primers selected from the group consisting of:

Forward primers:

(SEQ ID NO: 22)
GACTCGATATCGAGTCGGCCCACmTGTATTGCTmAmCmTmGmAmAmA,
and

(SEQ ID NO: 23)
GACTCGATATCGAGTCGGCCCACmTGCACTGCTmAmCmTmAmAmAmA,
and

Reverse Primer:

(SEQ ID NO: 24)
GACTCGATATCGAGTCGTGATCmAACTCCmAmTmGmTmGmCmC,

wherein mN indicates that the base N is a methoxy base.

14. The method of claim 13, wherein the modified nucleotide is one or more of 2'-O-methyl, 2'-methoxyethoxy, 2'-fluoro, 2'-hydroxyl, 2'-alkyl, 2'-allyl, 2'-O-[2-(methylamino)-2-oxoethyl], 4'-CH₂—O-2'-bridge, 4'-(CH₂) 2-O-2'-bridge, 2'-LNA, and 2'-O—(N-methylcarbamate).

119

15. A kit for amplifying a polynucleotide molecule in a reverse transcriptase and nicking amplification reaction, the kit comprising:

a) forward and reverse primers each comprising a nucleotide with a methoxy modification;

wherein the forward and reverse primers are for the detection of EBOV and comprise primers selected from the group consisting of:

Forward primer:

(SEQ ID NO: 1)
GACTCGATATCGAGTCGCTTCCAmCAGTTATCmUmAmCmCmG,
and

Reverse Primer:

(SEQ ID NO: 2)
GACTCGATATCGAGTCGAATGCmAACGAmCmAmCmCmU;

wherein the forward and reverse primers for detection of HIV comprise primers selected from the group consisting of:

Forward primers:

(SEQ ID NO: 6)
GACTCGATATCGAGTCTGACTAGmCGGAGGmCmTmAmGmAmAmG,
and

(SEQ ID NO: 7)
GACTCGATATCGAGTCTGACTAGmCAGAGGmCmTmAmGmAmAmG,
and

Reverse Primers:

(SEQ ID NO: 8)
GACTCGATATCGAGTCTATTGACmGCTCmTmCmGmCmAmC,
and

(SEQ ID NO: 9)
GACTCGATATCGAGTCTACTGACmGCTCmTmCmGmCmAmC;

wherein the forward and reverse primers for detection of dengue virus comprise primers selected from the group consisting of:

Forward primer:

(SEQ ID NO: 11)
GACTCGATATCGAGTCCAAAAACmAGCATATTmGmAmCmGmC,
and

Reverse Primer:

(SEQ ID NO: 12)
GACTCGATATCGAGTCAGACAGCmAGGATCmTmCmTmGmG,
and

5

10

20

25

30

35

40

45

120

-continued

(SEQ ID NO: 13)
GACTCGATATCGAGTCAGACAGCmAGGATCmTmGmTmGmG;

wherein the forward and reverse primers for detection of influenza B virus comprise primers selected from the group consisting of:

Forward primers:

(SEQ ID NO: 15)
GACTCGATATCGAGTCAAATGCmGATGGTCTCmAmGmCmTmA,

(SEQ ID NO: 16)
GACTCGATATCGAGTCAAATGCmAATGGTCTCmAmGmCmTmA,
and

(SEQ ID NO: 17)
GACTCGATATCGAGTCAAATGCmGATGGTTTCmAmGmCmTmA,
and

Reverse Primers:

(SEQ ID NO: 18)
GACTCGATATCGAGTCCTCCTTmTCCCATTCCATmTmCmAmTmA,

(SEQ ID NO: 19)
GACTCGATATCGAGTCCTCCCTTmTCCCATTCCATmTmCmAmTmA,
and

(SEQ ID NO: 20)
GACTCGATATCGAGTCCTCCTTmCCCCATTCCATmTmCmAmTmA;
or

wherein the forward and reverse primers for detection of bovine diarrhea virus comprise primers selected from the group consisting of:

Forward primers:

(SEQ ID NO: 22)
GACTCGATATCGAGTCGGCCCACmTGTATTGCTmAmCmTmGmAmAmA,
and

(SEQ ID NO: 23)
GACTCGATATCGAGTCGGCCCACmTGCAC TGCTmAmCmTmAmAmAmA,
and

Reverse Primer:

(SEQ ID NO: 24)
GACTCGATATCGAGTCTGTGATCmAACTCCmAmTmGmTmGmCmC,

wherein mN indicates that the base N is a methoxy base;

- b) a reverse transcriptase enzyme;
- c) a nicking enzyme;
- d) a strand-displacement polymerase; and
- e) directions for use of the aforementioned primers and enzymes for amplifying a polynucleotide molecule.

* * * * *